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INVESTIGATION OF THE IN VITRO AND IN VIVO EFFECTS OF SOME HERBAL PREPARATIONS ON 





Several herbal preparations (Folium pyrrosiae, Desmodium styracifolium, Hylocereus trigonus, 
Phyllanthus niruri, Orthosiphon stamineus and Cystone®) were investigated as potential 
therapeutic and prophylactic agents for kidney stone disease.  These studies were executed in the 
context of the existence of a virtually stone-free (black) and a stone-prone (white) population group 
in South Africa, with a view of establishing whether their respective renal responses are different.  
 
The independent in vitro effects of six plant extracts were tested on the crystallization 
characteristics of calcium oxalate (CaOx), the predominant stone-forming salt in urine. These 
investigations were performed in synthetic urine and real urine collected from healthy black and 
white South African males and the following parameters were assessed: urine composition; CaOx 
metastable limit; particle size-volume distribution; 
14
[C]-oxalate deposition kinetics; CaOx crystal 
nucleation, aggregation and growth kinetics; examination of crystalluria by scanning electron 
microscopy and calculation of various physicochemical risk indices (Bonn Risk Index, Tiselius 
Risk Index and the relative urinary supersaturation of several stone-forming salts). All plant 
extracts inhibited one or more of the crystallization processes.  
 
Furthermore, crystal-cell binding, another risk factor for stone formation, was investigated in the 
presence of plant extracts. Madin-Darby canine kidney (MDCK)-I cells were used for this 
experiment. Crystals (inorganic and urinary) were bound to cells incubated in both aqueous media 
and real urine. Results showed that plant extracts reduced crystal binding under some but not all 
conditions. One of the extracts (Folium pyrrosiae) was administered to healthy South African black 
(n=9) and white (n=9) males in a double-blind placebo-controlled study. No significant effects on 
urine chemistry were found and there were no significant differences between the race groups post-
treatment. Compounds from this herb were isolated and purified by the use of sequential liquid-
liquid extractions and gel-permeation chromatography. A novel compound, 5-(3-(5,5-dihydroxy-3-
oxopentyl)phenoxy)-2-hydroxy-5H-indene-6-carboxylic acid, was identified using mass 
spectrometry and nuclear magnetic resonance imaging spectroscopy. 
 
The findings in this thesis have contributed to the body of knowledge about kidney stone disease. It 
has been demonstrated that some herbal preparations may be potentially useful in treating and 

















BRI  Bonn Risk Index 
BU  Urine from black subjects 
BuOH  Butanol 
BUP1  Black urine pool 1 
BUP2  Black urine pool 2 
CaOx  Calcium oxalate 
COD  Calcium oxalate dihydrate 
COM  Calcium oxalate monohydrate 
CYS  Cystone ® 
DS  Desmodium styracifolium 
EtOAc  Ethyl acetate 
FP  Folium pyrrosiae 
GAGs  Glycoaminoglycans 
GC  Gas chromatography 
HCl  Hydrochloric acid 
HPLC  High-performance liquid chromatography 
HT  Hylocerus trigonus 
iCOM  Inorganic calcium oxalate monohydrate 
l   liter(s) 
M  Molarity 
mM  Milli molar 
mL  milliliter  
MS  Mass spectrometry 
MSL  Metastable limit 
MSMPR Mixed suspension mixed product removal 
NaOH  Sodium hydroxide 
Na2Ox  Sodium oxalate 
NMR  Nuclear magnetic resonance 
OD  Optical density 
OS  Orthosiphon stamineus 
PBS  Phosphate buffer saline 














ppm  Parts per million 
PSD  Particle size distribution 
RS  Relative supersaturation 
SE  Standard error 
SEM  Scanning electron microscopy 
SS  Supersaturation 
SU  Synthetic urine 
TLC  Thin-layer chromatography 
TRI  Tiselius Risk Index 
uCaOx  Urinary calcium oxalate 
WU  Urine from white subjects 
WUP1  White urine pool 1 
WUP2  White urine pool 2 
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Urolithiasis, the formation of calculi in the urinary tract, has been well-established as one of the 
oldest and most painful diseases of mankind through different archaeological findings (cited in: 
Lopez and Hoppe 2010).  Early recordings of stones have been found in Papyrus Ebers, the main 
origin of traditional Egyptian medicine, dating back to 1500 BC (cited in: Eknoyan 2004). 
Furthermore, in 1901, English archeologist E. Smith found a 5000 year old stone in an Egyptian 
mummy (cited in: Lopez and Hoppe 2010). During the same era, various treatments to expel or 
dissolve stones were identified in Mesopotamia. Saltpeter (potassium nitrate) and turpentine oil 
(distilled product of resin from pine trees) were known for their diuretic action, and pulverized 
egg shells (calcium carbonate) were ingested to complex with potential stone forming species 
(cited in: Dardioto et al. 1997, Shah and Whitfield 2002). Uroscopy (a historic medical practice 
of examining urine for symptoms of disease) was mentioned in the Hippocratic Collection five 
centuries BC (cited in: Dardioto et al. 1997, Sachs 2003). And three centuries BC, Ammonius 
introduced lithotrity to break up bladder stones so that they could be passed-out in urine (cited in: 
Shah and Whitfield 2002). Despite these revolutionary advances in combatting stone disease, 
surgical procedure only became popular two centuries later.  
 
In the first century BC, ancient Greek Medicine had become popular in the Roman Empire and 
one of the foremost physicians of the time, Aulus Cornelius Celsus, introduced lithotomy (a 
surgical procedure for stone removal). However due to the absence of anesthetics, catastrophic 
side effects such as excruciating pain and even death ensued as a result of infection. This 
procedure, known as the Celsic method, was employed up until the eighteenth century (cited in: 
Shah and Whitfield 2002, Sach 2003, Lopez and Hoppe 2010).  
 
Kidney stone disease continues to be a common modern-day medical disorder in industrialized 
and developing countries. However there have been several developments in understanding its 















The disease has also shown a greater incidence in males (12%) than in females (5%) (Blacklock 
1982, Hesse et al. 2003, Parmar 2004). The pathogenesis of urinary stones is multi-factorial in 
nature (Blacklock 1982, Li et al. 1985, Ljunghall et al. 1985, Kohri et al. 1988, Smith 1989, 
Curhan et al. 2004b, Holmes and Assimos 1999, Goldfarb 2005, Moe and Bonny 2005, Stoller 
and Rubenstein 2005). However idiopathic stone formation, indicating the absence of a medical 
cause of the disease is also common.  
 
Studies have shown that 70-80% of urinary stones are composed predominantly of calcium 
oxalate (CaOx) (Marangella et al, 1999, Aggarval et al. 2000, Coe et al. 2005, Khan 2006, 
Heilberg and Schor 2006). Consequently, the factors that govern CaOx precipitation have been a 
target of research over the years. 
 
In this general introduction, four main aspects of kidney stone disease will be presented: 
epidemiological factors, mechanisms of stone formation and composition of stones, 















1.1 Epidemiological factors 
 
The prevalence of urolithiasis (defined as the history of stone disease) varies according to 
climate and geography, ethnicity, age, gender, occupation and diet (Scott 1985, Beukes et al. 
1987, Sakhaee et al. 1987, Ramello et al. 2000, Curhan 2011). The incidence of kidney stones 
(defined as the first stone event) also varies in different parts of the world (Robertson et al. 1975) 
due to differences in lifestyle, diet, climate and daily water intake (Curhan et al. 1993, Trinchieri 
2006, Hesse et al. 1993). In addition, other studies have related these variations in stone 
prevalence and incidence to co-morbidities such as diabetes, obesity and hypertension (Daudon 
et al. 2004, Leiske et al. 2006, Cupisti et al. 2007, Sakhee et al. 2011).  
 
1.1.1 Climate and geography 
 
There are some areas of Europe, South East United States (South Eastern “stone belt”) and 
Africa where the incidence of stone formation is notably higher than the Western world average 
(Blacklock 1982, Ramello et al. 2000, López and Hoppe 2010, Romero et al. 2010). In these 
developed countries, the risk of urinary stone incidence was reported to be 13% in North 
America, 12% in Canada, and between 5-9% in Europe (Ramello et al. 2000) with the highest 
risk existing in Saudi Arabia, namely 20% (Robertson and Hughes 1994, Alsuwaida et al. 2010). 
It is postulated that the extremely hot climatic conditions in these areas (in addition to dietary 
factors) contribute to increased perspiration and dehydration leading to decreased urinary output. 
Hence increased concentrations of various stone forming salts and relative supersaturations 
thereof, all of which are known to increase the risk of stone formation (Al-Dabbagh and Fahadi 
1977, Schwille and Herman 1992). Another effect of prolonged exposure of the skin to UV 
radiation is the conversion of 7-dehydrocholesterol to vitamin D3. This vitamin and its 





 levels resulting in an increase in intestinal calcium absorption thereby 
increasing the potential of stone formation (Robertson and Peacock 1983, Broadus et al. 1984, 
















1.1.2 Gender and race 
 
With respect to gender, males have a higher stone incidence than females (12% vs 5%) 
(Blacklock 1982, Hesse et al. 2003, Parmar 2004) and a higher average urinary oxalate 
concentration than women (Curhan 1999, Miller et al. 1977). These differences have been 
attributed to hormones in the respective sexes. Estrogen has been shown to give immunity to 
women by lowering the urinary supersaturation of stone-forming salts (Heller et al. 2002, Ferrari 
et al. 2004) whereas the increased risk in men may be due to testosterone increasing urinary 
oxalate levels (Lee et al. 1996, Yoshihara et al. 1999). 
 
Worldwide, there has been a higher incidence of idiopathic stone formation reported in the white 
population relative to their black counterparts irrespective of other epidemiological factors 
(Muskat 1951, Modlin 1967, Robertson et al. 1980, Soucie et al. 1994, Whalley et al. 1998, 
Ramello et al. 2000, Maloney et al. 2005, Taylor and Curhan 2007). Similarly, a lower incidence 
of stones has also been found in ethnic groups like the Inuits, Australian Aborigines, American 
blacks and South African blacks (Modlin 1967, Bateson 1977, Whalley et al. 1998, Akoudada et 
al. 2010). The rarity of stones in the black population of South Africa is of great interest in the 
context of this thesis and will be discussed in greater detail later in the chapter.  
 
1.1.3 Occupation  
 
Another factor affecting susceptibility to urolithiasis is that of occupation. The prevalence of 
stone formation is found to be greater in people with sedentary work e.g. aviation pilots and 
truck drivers (Blacklock 1969, Borghi et al. 1993, Zheng et al. 2002). A possible explanation for 
the higher risk in truck drivers is that infrequent voiding increases the urinary concentration of 
the various stone forming salts. Stone disease was also found to be five times higher in outdoor 
workers than those who worked indoors, suggesting chronic dehydration to be a contributory 
factor (Pin et al. 1992) which is also the likely cause of a higher incidence rate in machinists who 
















1.1.4 Diet  
 
The association of dietary factors on urine composition has been verified by many studies over 
the past several years (Trinchieri et al. 1991, Curhan 1993a, Curhan 1993b, Massey et al. 1993, 
Curhan et al. 1996, Rodgers and Lewandowski 2002, Siener and Hesse 2002, Massey 2003, 
Taylor and Curhan 2004, Goldfarb 2005, Massey et al. 2005, Borghi et al. 2006, Siener 2006, 
Kynast-Gales and Massey 2007, Karagǘlle et al. 2007, Thomas et al. 2008, Meschi et al. 2011). 
Nutrition plays and important role in stone formation as it alters urinary composition and 
supersaturation. Certain foodstuffs are considered lithogenic (increases the risk of stone 
formation) whereas others are anti-lithogenic (decreases the risk of stone formation). Specific 
dietary factors implicated in stone disease include: calcium, oxalate, citrate, magnesium, animal 
protein, carbohydrate, sodium, phytate and fluid intake.  
 
Calcium  
Although a restriction of calcium intake was previously considered to be anti-lithogenic 
(Robertson et al. 1981, Breslau 1994, Heller et al. 2003), several studies have stated that the 
contrary is true (Bataille et al. 1983, Messa et al. 1991, Messa et al. 1997, Curhan 1999). While 
the initial hypothesis was largely based on the finding that most recurrent stone formers have 
hypercaliuria (Pak 1998), calcium restriction is no longer recommended as decreased calcium 
intake could induce a potential risk of hyperoxaluria (Bataille et al. 1983, Jaegaer et al. 1994) 
and bone loss which could lead to osteoporosis (Coe et al. 1982, Curhan et al. 1993a, Curhan et 
al. 1996).  
 
Curhan et al. (1993) showed an inverse correlation between stone formation and intake of dietary 
calcium. A plausible explanation for this finding could be that by reducing the intake of dietary 
calcium, the binding of calcium to oxalate in the gut decreases thereby allowing more oxalate to 
be absorbed in the blood stream and excreted in the urine (Curhan et al. 1993a). For kidney stone 
patients, a recommended calcium intake of 800-1200 mg/day should be maintained rather than 

















Dietary oxalate is a crucial risk factor for calcium oxalate stone formation as it influences the 
concentration of urinary oxalate (Hess et al. 1993, Holmes et al. 1995, Holmes et al. 1998, 
Holmes and Kennedy 2000, Pak et al. 2004a, Coe et al. 2005). Oxalate complexes with calcium 
in urine to form CaOx which is the most common stone forming precipitate. Hence stone formers 
are advised to minimize consumption of foodstuffs containing high levels of oxalate such as: 
spinach, rhubarb, beetroot, peanuts, chocolates, strawberries and tea (Hesse et al. 1993, Massey 
et al. 1993, Holmes and Kennedy 2000). Estimates of normal dietary oxalate intake are in the 
range of 50-200 mg/day (Holmes et al. 1995, Siener and Hesse 2002, Taylor and Curhan 2007a). 
 
Urinary oxalate is derived both exogenously and endogenously. Exogenous oxalate is absorbed 
from the gastrointestinal tract (Holmes et al. 1999) and contributes 10-40% of urinary oxalate 
but some variation in this figure has been reported (Finch et al. 1981, Williams and Smith 1983, 
Holmes et al. 1999). Factors that influence the absorption of exogenous oxalate are not clearly 
known but are likely to include other dietary factors (e.g. calcium), genetic factors and intestinal 
flora. The remaining oxalate is derived endogenously as an end-product of ascorbate metabolism 
and a by-product of the metabolic reaction involving glyoxalic acid (Massey et al. 1993, 
Robertson 1999).  
 
Researchers have investigated the influence of dietary calcium on urinary oxalate and the results 
show that as dietary oxalate increases, urinary oxalate increases only when calcium intake is 
minimized (Marshal et al. 1972, Breslau et al. 1988, Hess et al. 1996, Heilberg 2000, Curhan 
2004, Krieg 2005). 
 
Citrate  
The effect of citrate and several citrate-containing supplements as a therapeutic agent in treating 
and managing urolithiasis has been extensively investigated and reviewed (Pak 1987, Pak 1991, 
Pak 1994, Lemann et al. 1989, Rumenapf and Schwille 1987, Whalley et al. 1998, Allie-















These studies have been carried out by means of (1) in vitro crystallization experiments (Ryall et 
al. 1981, Kok et al. 1987, Tiselius 1993, Bek-Jensen et al. 1996), (2) measurement of baseline 
urinary citrate in healthy and CaOx stone forming subjects (Nicar et al. 1983, Pak et al. 1985, 
Laminski et al. 1990, Cupisti et al. 1992), and (3) clinical trials involving kidney stone patients 
whose urinary risk factors (Allie-Hamdulay et al. 2005) and stone recurrence rates were 
measured pre- and post-treatment with citrate-containing preparations (Pak et al. 1994, Barcelo 
et al. 1993, Whalley et al. 1996).  
 
Citrate has been found to consistently increase urinary pH (acts as an alkalinizer) and induces an 
increase in the dissociation of uric acid (Schwille et al. 1985, Schwille et al. 1987, Berg et al. 
1990, Abdulhadi et al. 1993, Hofbauer et al. 1994, Ogawa 1994, Heilberg and Schor 2006). 
Furthermore, its inhibitory potency lies in its ability to form soluble complexes with calcium 
thereby reducing urinary supersaturation of CaOx and CaP and retards nucleation, aggregation 
and growth of crystals thereof (Pak and Fuller 1986, Ettinger et al. 1997, Laube et al. 2002, 
Grohe et al. 2011). A recent study also showed that citrate binds specifically to the large flat 
surface of COM crystals which contributes to its inhibition of COM crystal growth and 
aggregation (Grohe et al. 2011). 
 
Magnesium  
Dietary magnesium is considered to be a prophylaxis in the management of urolithiasis as it 
binds free oxalate in the gastrointestinal tract thereby reducing its excretion in urine (Barilla et 
al. 1978, Berg et al. 1986, Pearle et al. 2008). Magnesium oxalate is more water-soluble than 
CaOx. In this way it can decrease the supersaturation of CaOx (Lindberg et al. 1990) thereby 
decreasing the risk of stone formation. Lower urinary magnesium excretion has been reported in 
stone formers compared to healthy controls (Tiselius et al. 1978). Some studies have shown that 
an increase in the oral intake of magnesium leads to an increased excretion of urinary 
magnesium (Fetner et al. 1978, Johanson et al. 1980a), but no effect was seen in others (Fetner et 
al. 1978, Ettinger et al. 1984) and gastrointestinal disorders were produced in some (Johansson 
et al. 1980b). Magnesium has also demonstrated inhibition of nucleation, aggregation and 
growth of CaOx and calcium phosphate crystals (Li et al. 1985, Achilles and Ulshöfer 1985) in 














High fluid intake  
The main determinant of urine volume is fluid intake. It is routinely recommended that stone 
forming patients increase their fluid intake to between 2.5-3 litres per day in order to decrease 
the likelihood of stone recurrence (Pak et al. 1984, Coe et al. 1992, Rodgers 1999, Borghi et al. 
1996, Borghi et al. 1999, Meschi et al. 2004). Dehydration elevates the saturation of stone 
forming salts and decreases urinary pH, both of which are risk factors for stone formation.  
 
Therefore, theoretically a high volume of fluid intake may decrease risk as it would dilute the 
urine thereby decreasing the concentration of stone forming constituents and lowering urinary 
saturation (Goldfarb 1990, Goldfarb 1994). However concern has been expressed that diluting 
urine would also decrease the concentration of inhibitors which may counter the effect of 
reduced saturation. Pak et al. (1980) conducted studies to clarify these conflicting theories and 
concluded that urinary dilution decreases crystallization of calcium salts and lowers the level of 
supersaturation. Hence a greater intake volume is considered to have a protective effect against 
stone formation (Pak et al. 1980). Increased urine dilution might also exert its antilithogenic 
effect by reducing the renal intratubular transit time thereby favoring the expulsion calcium 
precipitates (Pak et al. 1980).   
 
Stone formers are advised to consume sufficient fluid to obtain a minimum urinary output of 2 
litres per day (Goldfarb 1990). Mineral water containing solutes like calcium and magnesium 
have demonstrated prophylactic effects on stone formers. In a study carried out by Rodgers 
(1998) on male stone formers, 9 risk factors changed favourably upon consumption of mineral 
water rich in magnesium and calcium (Rodgers 1998).  
 
Other beverages have shown adverse effects on stone formation e.g. coffee (Goldfarb et al. 
2005),  herbal teas (Hesse et al. 1993), cranberry juice (McHarg et al. 2003), apple juice 
(Vahlensieck 1986, Curhan et al. 1996) and lemonade (Seltzer et al. 1996, Kang et al. 2007, 
Penniston et al. 2007, Aras et al. 2008). However, the effect of these beverages is due to their 
composition i.e. the presence caffeine in tea and coffee (Goldfarb et al. 2005), and citrate in fruit 
juices such as lemonade. Beverages with a high oxalate content namely cola (Rodgers 1999) and 














Animal protein intake 
Another important dietary factor with respect to effect on stone disease is that of animal protein 
intake and a strong correlation exists (Robertson et al. 1979, Robertson et al. 1981, Brockis et al. 
1982, Yoshida and Okada 1990, Curhan 1993, Hesse et al. 2003, Pak 2004, Siener 2006). 
Biochemically, a diet high in animal protein causes an increase in the urinary excretion of 
calcium, oxalate and uric acid and a decrease in citrate excretion.  All of which are well-known 
risk factors for idiopathic stone formation (Curhan 1993, Trinchieri et al. 1991, Nguyen et al. 
2001).  
 
Nguyen et al. (2001) postulated that in approximately one third of idiopathic calcium oxalate 
stone formers, urinary oxalate increases after an animal protein load (Nguyen et al. 2001). A 
proposed mechanism for the increased calcium excretion is that dietary protein increases 
endogenous acid production. Elevated levels of acid stimulate an increase in calcium 
reabsorption of bone hence increased urinary calcium excretion (Brockis et al. 1982). Another 
hypothesis for the increased urinary calcium is that sulphur-containing amino acids (predominant 
in animal protein) complex with calcium, preventing its reabsorption by renal tubules thereby 
increasing its urinary excretion (Schulette et al. 1980). A high animal protein load increases 
urinary uric acid due to its high content of purine, a substrate for urate synthesis, (Coe et al. 
1976, Krieg 2005) resulting in transient acidosis thereby increasing tubular reabsorption of 
citrate and lowering urinary citrate (Fellström et al. 1984, Siener and Hesse 2002).  
 
Carbohydrate  
Some researchers claim that the higher incidence of stones in wealthier countries is due to 
increased refined sugar intake (Robertson et al. 1978a, Robertson et al. 1978b, Thorn et al. 1981, 
Robertson et al. 1987). A correlation has been observed between an increased carbohydrate 
intake and an increased excretion of urinary calcium in both healthy subjects and CaOx stone 
formers (Wood and Allen 1983, Iguchi et al. 1993, Coe and Parks 1994b, Leman et al. 1989, 
Taylor and Curhan 2004) although this increase was more prominent in the latter group. 
Furthermore, refined sugars also stimulate endogenous synthesis of oxalate which is eventually 
excreted in urine (Lekcharoensuk et al. 2001). High urinary concentrations of calcium and 


















A high dietary sodium intake is a risk factor for stone formation due to its calciuric action 
independent of calcium intake (Kok et al. 1990, Sakhaee et al. 1993, Pak et al. 2004). It has been 
reported that a 100 mmol increase in daily sodium intake is associated with an approximate 
increase of 1 mmol in urinary calcium excretion (Nordin et al. 1993, Lemann et al. 1999). This 
effect is probably due to the inhibition of sodium and calcium reabsorption in the proximal 
tubule and along the loop of Henle (Curhan 2004). Other studies have found that increasing 
dietary sodium caused a decrease in urinary citrate (Kok et al. 1990, Sakhaee et al. 1993). 
Hypercalciuria and hypocitraturia are important lithogenic consequences of an excessive intake 
of dietary salt, thereby increasing the risk of CaOx stone formation. 
 
Phytate 
Phytic acid (inositol 1,2,3,4,5,6-hexakisphosphate) is a natural sugar present in most seeds and 
cereals. The compound contains six phosphate groups, each with two hydroxyl moieties. In its 









, to form insoluble complexes (Ryall 2011). Several studies have reported 
that phytate is one of the most powerful inhibitors of CaP and CaOx crystallization (Grases and 
March 1989, Graf and Eaton 1990, Grases et al. 1994, Grases et al. 2000a, Grases et al. 2000b). 
The concentration of phytate in normal human urine has been reported to be 2.5 mg/L which is 
significantly higher than that of stone formers (1.5 mg/L) (March et al. 1998, Grases et al. 
1999). There is an important positive correlation between dietary intake and urinary excretion of 
phytate (Taylor and Curhan 2004). A clinical study conducted by Conte et al. (1989) on CaOx 
stone formers showed that even low consumption of phytate significantly reduced the risk of 
developing stones (Conte et al. 1989c). The potency of phytate in reducing risk of stone 

















1.2  Physicochemical mechanisms of stone formation and composition of kidney stones  
 
Stones in the urinary tract are predominantly crystalline with the rare exception of matrix stones 
and there are several important physiochemical mechanisms involved in stone formation which 
include CaOx supersaturation and CaOx crystal nucleation, growth and aggregation (Finlayson 
1978, Rose 1982, Coe et al. 1992, Hess and Kok 1996, Coe and Parks 1997, Kavanagh 2006a, 




Supersaturation, the fundamental driving force for the change of phase from solution to solid (i.e. 
when crystallization occurs), is the first and most essential step in the process of stone formation. 
It is an expression of the excess of free energy (ΔG) between two phases, i.e. the difference in 
chemical potential of the solution (μsoln) and the chemical potential of the crystalline phase at 
equilibrium (μcryst). A positive change in the chemical potential (μsoln - μcryst) favours 
crystallization whereas a negative chemical potential favours dissolution. Chemical potential can 
be expressed in terms of the gas constant (R), the absolute temperature (T), the activity of the 
unionized salt in the supersaturated solution (A) and the activity of the solution at equilibrium 




The supersaturation ratio (A/Aeq) is referred to as the relative supersaturation (RS). When         
RS < 1, the solution is undersaturated and stone forming species remain in solution. A solution 
for which RS = 1, is said to be saturated and an equilibrium exists between the salts that have 
crystallized out and those in solution. When RS > 1, the solution is said to be supersaturated in 
which case crystals can grow (Finlayson 1978, Hess and Kok 1996, Coe et al. 2005). It has been 
reported that urine from stone formers tend to be more supersaturated than those of healthy 
individuals (Robertson et al. 1968, Marangella et al. 1985, Coe and Favus 1986). However other 
researchers have reported the contrary, namely that people who have never passed a stone in 
their life sometimes pass highly saturated urine (Ryall 1993, Hess and Kok 1996, Kavanagh 















2006a). Therefore supersaturation of urine is not a pathological problem as long as crystalline 
particles pass freely through the urinary tract. A pathological scenario arises when crystals are 




The first kinetic step in stone formation is nucleation i.e. the phase transformation from liquid 
into solid in a supersaturated solution. When this process occurs, stone forming salts in solution 
form loose clusters which can increase in size due to the addition of new clusters. These clusters 
form the substrate upon which growth and aggregation can occur (Finlayson 1978, Brown and 
Purich 1992, Kok and Khan 1994).  
 
Urine lying between the solubility product (S<1) and the formation product (S>1) is referred to 
being in a zone of metastability or metastable (Nordin et al. 1993). When urine surpasses the 
upper limit of metastability, the solution becomes unstable and crystals form prolifically 
(Robertson et al. 1981). This spontaneous formation of crystals is known as homogenous 
nucleation which actually very rarely occurs in urine due to the presence of other foreign 
nucleating material (e.g. cell debris, urinary macromolecules and crystalline material of other 
stone forming salts). Heterogeneous nucleation is more likely as most stones are a mixture of 
more than one crystal type and different proteins (Hess and Kok 1996). There are two 
phenomena closely associated with heterogeneous nucleation i.e. secondary nucleation and 
epitaxy. The former describes the nucleation of crystals on pre-existing surfaces of the same 
material. Epitaxy refers to the compatibility of one crystalline material precipitating upon the 
surface of another whose lattice dimensions match (Hess and Kok 1996).  
 
Urinary supersaturation can be calculated using the computer program, EQUIL. This program 
takes into account the chemical analysis of 23 urinary components and the calculation of 103 
complexes (Werness et al. 1985, Brown et al. 1993). More recently, another chemical speciation 
program Joint Expert Speciation System (JESS), has been used to determine speciation and 
saturation index (SI) values (Rodgers et al. 2007). JESS has a large database comprising over   














entropy, Gibbs free energy, solubility products and redox potential and can be used to model 
chemical speciation under any specific conditions (May and Murray 1991a, May and Murray 
1991b).  
 
1.2.3 Crystal growth  
 
Crystal growth is the addition of new crystal components onto an existing crystal nucleus i.e. the 
incorporation of solute into the crystal lattice (Hess and Kok 1996). The kinetics of crystal 




where S = supersaturation, t = time, P = precipitation, k = reaction rate constant, A = surface 
area for crystallization, n = order of the reaction. For CaOx, n = 2. Therefore after integration, 




where So = initial supersaturation. Therefore by keeping the surface area constant in metastable 
supersaturated solutions, the rate constant (k) can be derived. This can be utilized in the 
Langmuir adsorption isotherm to compare inhibitory activities of added substances (Gill et al. 
1984). In whole urine, calcium oxalate crystallization can be directly measured by adding 
specific quantities of oxalate seed crystals and measuring changes of 
14
C in the supernatant 
fraction (Gill et al. 1984). 
 
While nucleation is undoubtedly a crucial first step in crystallization, it is crystal growth that 
induces a pathological situation. The transit time of urine through the kidney in healthy 
individuals is not sufficiently long enough to allow crystals to grow to a size range which will 
allow them to be trapped in the renal tubules (Finlayson et al. 1984, Hess and Kok 1996). 
However if crystals grow too big and become trapped in the renal tubule, they disturb the flow of 
- (dS/dt) = (dP/dt) = kAS
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urine and provide a substrate to which newly formed urinary crystals attach and further increase 




Crystal aggregation is the process whereby crystalline particles in solution stick together to form 
a larger particle. It is a natural process which is energetically favoured and can occur in all states 
of saturation (Kok and Khan 1994, Hess and Kok 1996). Aggregation of crystals is achieved 
through several electrostatic interactions, namely van der Waals forces, viscous binding and solid 
bridges. Attractive van der Waals forces favour particle aggregation and increases strongly as the 
distance between particles decreases. Viscous binding refers to the sticky properties of foreign 
molecules, such as macromolecules, which stick to crystal surfaces and encourage aggregation. 
Solid bridges refer to crystalline material connecting two particles which stabilizes an aggregate 
(Hess and Kok 1996).  
  
A force which has opposing effects i.e. can promote both aggregation and disaggregation, is the 
shear force arising from stirring crystalline solutions or by solvent currents in tubular fluids. This 
dual force can favour aggregation by increasing the collisions between particles but it can also 
have a counter effect by disrupting particles (Hess and Kok 1996). 
 
The zeta potential is the electrical potential at the interface between the solid particle and the 
surrounding solution. In the field of urolithiasis, zeta potential has been used to study the 
mechanism of aggregation where an increase in the negative charge of the zeta potential is 
interpreted as an increase in inhibition of aggregation (Finlayson et al. 1984, Scurr et al. 1986, 
Hess et al. 1989, Cao et al. 1996).  
 
Several studies have reported that aggregation is the most important step in stone formation. 
Evidence in support of this is that the short transit time of the urinary system is insufficient for 
CaOx crystals to grow into a significant size to be problematic whereas aggregation can occur 
within seconds. Furthermore, microscopic and ultrastructural studies of kidney stones show that 














1.2.5 Urinary inhibitors 
 
As mentioned previously that under normal conditions urine is supersaturated and sometimes 
even CaOx crystallization occurs. However, stones do not form in all cases due to the presence 
of inhibitors that retard the processes of stone genesis (Boyce et al. 1968, Fleisch 1978, Rose et 
al. 1982, Hess and Kok 1996b, Worcester 1996, Ryall 1997, Khan and Hackett 1993, Khan and 
Kok 2004, Ryall 2004). Inhibitors may function by preventing nucleation, or if crystals do form, 
they may hinder enlargement by growth and aggregation. Furthermore, they can affect crystal-
cell binding interactions or induce dissolution of endocytosed precipitates (Ryall 2011).   
 
Inhibitors are classified into 2 categories, namely macro- and small chemical species. 
Macromolecular inhibitors generally refer to glycosaminoglycans (GAGS) and proteins, while 
the smaller inhibitors include citrate, magnesium, pyrophosphate and phytate. 
 
Glycosyaminoglycans are unbranched polysaccharides made up of repeating dissacharide units. 
Each unit consists of an N-acetyl-hexosamine (amino sugar) and a hexose or hexuronic acid 
which are linked together by a glycoside bond. The molecular weight of GAGS vary from 18-48 
kDa (Nishio et al. 1985, Roberts and Resnick 1986). Examples of urinary GAGS are chondroitin 
sulfate (CS), heparan sulphate (HS), keratan sulphate (KS), dermatan sulphate (DS) and non-
sulphated hyaluronic acid (HA) (Khan and Kok 2004). In various studies, these macromolecules 
have been reported to inhibit nucleation, aggregation and growth of CaOx crystals (Koide et al. 
1981, Sallis et al. 1981, Ryall and Marshall 1984, Breslau et al. 1994, Khan and Kok 2004) 
however unequivocal proof of their mode of action has yet to be established (Ryall 2011).  
 
Osteopontin is a phosphoprotein with a molecular weight of between 44 to 75 kDa (Malyankar 
et al. 1997). OPN has been reported to be an inhibitor of nucleation, growth and aggregation of 
CaOx crystals (Asplin et al. 1998, Wang et al. 2008, Mo et al. 2007). In addition to its inhibitory 
activity, OPN demonstrated the ability to promote crystallization of COD (calcium oxalate 
dihydrate) in preference to COM (calcium oxalate monohydrate). COD is known to have a lower 
affinity for adhesion to renal epithelial cells (Wesson et al. 1998) hence minimizing the risk of 














Tamm-Horsfall protein has been classified as the most abundant protein in human urine with a 
molecular weight of 80-100 kDa (Ryall 1997). THP is known to exist in monomeric and 
polymeric states and its inhibitory effect depends on its state of aggregation as the monomeric 
state considered to be a more potent inhibitor (Hess et al. 1989). There have been some 
conflicting theories on function of THP as it has been reported to inhibit and promote CaOx 
crystallization depending on the experimental conditions (Hess 1994, Grover et al. 1998), 
however it has been shown to strongly inhibit COM aggregation (Viswanathan et al. 2011).  
 
Albumin is found in great quantities in urine, urinary stones and crystal matrix (Atmani et al. 
1998, Fraij 1989). In some experiments it has been reported to promote CaOx nucleation but 
inhibits CaOx crystal aggregation (Grover et al. 1998, Worcester 1996, Khan and Kok 2004). 
 
Urinary prothrombin fragment-1 is found more abundantly in the kidneys of stone formers 
(Doyle et al. 1991, Doyle et al. 1995). The protein has a molecular weight of 31 kDa and 
contains approximately 154 amino acids of which 23% are glutamic and aspartic acids. In 
addition, 10 of the carbonic acids are γ-carboxylated. The presence of γ-carboxyglutamate (Gla) 
residues imparts inhibitory activity to UPTF1 due to its ability to bind calcium (Doyle et al. 
1991, Grover and Ryall 2002, Webber et al. 2002, Cook et al. 2008). Despite the intense interest 
in the inhibitory functions of this molecule, conclusive evidence of its impact on stone formation 
has not yet been elucidated (Ryall 2011).   
 
Bikunin is a complex plasma protease inhibitor that belongs to a family of inter-α-inhibitor 
proteins (Salier et al. 1996). It has been reported to be an inhibitor of CaOx crystallization and 
inhibits the binding of CaOx to renal epithelial cells (Ebusino et al. 1999a, Yang et al. 2005). 
But as with all urinary inhibitors, there is some uncertainty with respect to its mode of action 















1.2.6 Composition of kidney stones  
 
The chemical compositions of stones vary depending on the ionic imbalance in the urine at the 
time of crystal nucleation and growth (Coe et al. 2005, Moe 2006). There are four main stone 
types: calcium (~80%), uric acid (9%), magnesium ammonium phosphate (10%) and cystine 
(1%) (Finlayson 1978). 
 
CaOx stones 
COM (whewellite) and COD (weddelite) stones occur more frequently than calcium oxalate 
trihydrate (COT) stones (Herring 1962, Streit et al. 1998, Grases et al. 1998, Bithelis et al. 2004, 
El-Shall et al. 2004). The vast majority of CaOx stone formers suffer from no systemic disease 
(Coe et al. 2010). Hypercalciuria (greater than 10 mM per 24 hour urine) is the most common 
cause of calcium stone production but stone formation may also occur as a result of primary 
hyperparathyroidism (elevated parathyroid hormone levels) or disorders of calcium metabolism 
(Coe et al. 2005). Stones can be pure or mixed with calcium phosphate, uric acid or ammonium 
urate (Trinchieri et al. 2005). 
 
Calcium phosphate stones 
In the majority of kidney stones, CaOx is the main constituent and CaP is present in amounts 
ranging from 1%-90% (Mandel and Mandel 1989). When stones are made up of more than 50% 
calcium phosphate, they are referred to as CaP stones (Coe et al. 2005). CaP stones exist in 
various forms such as apatite (calcium hydroxyl phosphate) and brushite (calcium hydrogen 
phosphate) (Parks et al. 2004, Worcester and Coe 2008). It usually occurs in patients with 
hormonal disorders such as hyperparathyroidism or metabolic disorders such as renal tubular 
acidosis (a condition whereby the kidneys are unable to excrete acid) (Hess and Jaeger 1993). 
High urinary pH and low urinary citrate are the driving forces for the formation of CaP stones 


















Uric acid stones 
Uric acid is the end product of purine metabolism and approximately 3% of stone-formers form 
this type of stone (Nordin and Hodgkinson 1967). Low urinary pH (below 5.5) is dominant 
factor leading to the formation of uric acid stones. Other contributing factors of uric acid stone 
formation are urate/uric acid renal handling, hyperuricosuria (high levels of urinary uric acid) 
and excess dietary protein (William-Larson 1990, Shekarriz and Stoller 2002, (Coe et al. 2005)).  
 
Magnesium ammonium phosphate stones 
Magnesium ammonium phosphate (struvite) stones are formed as a result of urinary tract 
infections which are caused by micro-organisms (e.g. Proteus, Providencia, Klebsiella, 
Pseudomonas and Enterococci) (Bruyeni et al. 2008, Gόmez-Nùňez et al. 2009). These bacteria 
produce the enzyme urease which degrades urea to ammonia and carbon dioxide thereby raising 
urinary pH and favouring the formation of struvite. The typical morphology of struvite stones are 
„staghorn‟ calculi (Ramello et al. 2000).  
 
Cystine stones 
Cystine stones represent only a small percentage (1-2 %) of urinary calculi (Ramello et al. 2000, 
Coe et al. 2005). These stones form as a consequence of cystinuria i.e. an inherited genetic defect 
that causes an abnormal transport of the amino acids cystine in the kidney and gastrointestinal 
system (Coe et al. 2005). This type of stone is commonly found in children and young adults. 















1.2.7  Pathways of stone formation 
 
As mentioned previously, supersaturation is the driving force of uric acid and cystine stones, and 
infection stones form as a result of bacterial metabolism (Moe 2006). However there is no simple 
theory to explain the mechanisms of the crystallization processes that lead to the formation of 
calcium containing calculi, the most common type (Coe et al. 2010, Knoll 2010). A significant 
component of this process is particle retention which allows the calculus to develop (Finlayson 
and Reid 1978a, Coe et al. 2005, Coe et al. 2010, Evan et al. 2010, Knoll 2010, Tiselius 2011). 
By use of human tissue biopsies and intra-operative imaging, 3 pathways that lead to stone 
formation have been identified namely (1) overgrowth on interstitial apatite, (2) crystal deposits 
in renal tubules and (3) free solution crystallization (Coe et al. 2010).  
 
Overgrowth on interstitial apatite 
More than seventy years ago, Randall discovered calcifications within the renal papilla in 20% of 
1000 random cadaveric renal units (Randall 1940). These calcium salt deposits (plaques), which 
manifest as irregular whitish legions on the tip of the renal papillae, were interstitial 
(intercellular), composed of apatite (mineral phase found in bone) and were not observed in the 
tubular lumen. He proposed that the plaques were precursors of urinary stones (Randall 1940). 
Randall‟s hypothesis had not progressed for decades until Evan et al. (2003, 2005, 2006) were 
able to show that such CaP plaques are present in all idiopathic stone formers (Evan et al. 2003, 
Kim et al. 2005, Matlaga et al. 2007); however plaque formation is not limited to stone formers 
only (Evan et al. 2003).  
 
Detailed examination of human tissue has shown that plaque forms at the basement membranes 
of the thin limbs of the loop of Henle and serves as the attachment site for stones (Matlaga et al. 
2007, Gambaro et al. 2009, Coe et al. 2010, Evan et al. 2010). Matlaga et al. (2005) cited a 
positive correlation of the frequency of stone recurrence and the surface area of papillae covered 
by plaques (Kim et al. 2005) suggesting that plaque favours CaOx overgrowth (Coe et al. 2005). 
Kuo et al. (2003) found independent correlations between plaque surface area and urinary 














parameter (citrate, oxalate and phosphate) was found to have a significant effect of plaque (Kuo 
et al. 2003).   
Although the site of stone formation has been identified, the cascade of events of crystallization 
following thereafter still remains unclear (Coe et al. 2010, Evan et al. 2010, Knoll 2010, Tiselius 
2011). It is suggested that urinary supersaturation is the driving force which allows 
crystallization to extend beyond the matrix (Coe et al. 2005, Coe et al. 2010). This pathway is 
primarily associated with idiopathic CaOx stone formers but has also been found in brushite 
stone formers and patients with primary hyperparathyroidism, ileostomy and bowel resection 
(Coe et al. 2010).  
 
Crystal deposits in renal tubules (Intratubular crystallization) 
Apart from idiopathic CaOx stone formers, all other type of stone formers are known to form 
crystals in their renal tubules which may lead to stone formation (Coe et al. 2010). These crystals 
project into the urinary space leading to dilation of the ducts, interstitial fibrosis and crystal 
mediated cellular injury (Matlaga et al. 2005, Coe et al. 2010). 
 
Although caliceal (final) urine and urine in the distal region of the collecting duct is highly 
supersaturation with respect to CaOx, there is no driving force for CaOx precipitation at nephron 
levels above the above the collecting duct (Kok and Khan 1994, Kok and Khan 1995, Hojgaard 
et al. 1996, Tiselius and Hojgaard 1999,). However, a high level of CaP supersaturation is found 
in the ascending loop of Henle and distal region of the distal tubule (Deganello et al. 1990, 
Hojgaard et al. 1996, Tiselius and Hojgaard 1999, Evan et al. 2003) and microscopic 
examination have confirmed the presence of crystals in these nephron segments (Resnick et al. 
1978, Asplin et al. 1991, Asplin et al. 1996, Evan et al. 2007). Although these particles have not 
been identified by means of chemical composition analysis, study of its morphology strongly 
suggests CaP nuclei (Smith et al. 1983, Hering et al. 1988). There are two possible subsequent 
pathways that have been identified for precipitated CaP crystals nephron i.e. the interstitial route 
where precipitates are internalized by tubular cells or the intratubular route where crystal 
deposits are transported down the urinary stream towards the collecting duct and caliceal space 















Internalization or endocytosis (interstitial route) is proposed to be a defense mechanism whereby 
cells in the nephron eliminate intratubular precipitates to prevent obstruction of tubules (Vervaet 
et al. 2010). Dissolution of crystals may be brought about by lysosomes and macrophages (Smith 
et al. 1983). Alternatively, CaP crystals move down the nephron at a slower rate (Khan and 
Hackett 1991, Khan 1995, Yuen et al. 2010) which allows time for aggregation to occur. If these 
aggregates are too large to be handled by the cells it remains intratubular. It has been suggested 
that these crystals are translocated to the basement membrane/interstitial tissue through cells or 
between cells (Evan et al. 2007, Coe et al. 2010, Tiselius 2011).  
 
Free solution crystallization 
The most common stones formed via this pathway are composed of cystine. Cystine is poorly 
soluble and highly supersaturates urine in the ducts of Bellini which leads to stone formation. 
These stones are always found free and unattached in the renal pelvis (Coe et al. 2010). Even 
though it is an uncontroversial pathway, it‟s still of great importance as it illustrates how the 

















1.3 Urinary risk factors  
  
As mentioned, various epidemiological factors affect the risk of stone formation. These 
parameters influence one or more of six urinary risk factors (Robertson and Peacock 1983) and 
are considered to be the main determinants of CaOx crystallization (Robertson et al. 1978, 
Finlayson et al. 1984, Hess et al, 1996). Robertson and Peacock (1983) identified these risk 
factors to be hypercalciuria, hyperoxaluria, hyperuricosuria, elevated pH, decreased volume and 
decreased excretion of urinary inhibitors (i.e. magnesium, citrate, phosphate and pyrophosphate) 
(Robertson and Peacock 1983).  
 
1.3.1 Urinary calcium 
 
It is well-known that abnormally high calcium levels (hypercalciuria) is a risk factor for recurrent 
stone formation as it contributes to the supersaturation of both CaOx and CaP stones (Goldfarb 
1994, Borghi et al. 1996). Many studies have found a notably higher incidence of idiopathic 
hypercalciuria in stone formers than in healthy subjects (Coe et al. 1982, Pak 1998, Heilberg 
2000, Curhan et al. 2001). Researchers have reported the normal urinary calcium excretion upper 
limit to be 7.5 mmol per 24 hours in men and 6.25 mmol in women. A 24 hour urinary calcium 
excretion reaching 10 mmol poses the threat of stone formation (Robertson et al. 1978, Monk 
1996, Bihl and Meyers 2001). 
 
Hypercalciuria presents itself in stone formers in one of three ways, namely: idiopathic 
(absorptive), resorptive and renal.  
 
Idiopathic (absorptive) hypercalciuria is the most prevalent type (30 – 50% of patients) and is 
caused by an overproduction of 1,25-dihydroxy-vitamin D3. This molecule is responsible for the 
transportation of calcium ions through the intestinal cells. Therefore patients with this condition 
absorb far more calcium from foodstuffs than healthy subjects which leads to elevated serum 
calcium levels resulting in high urinary calcium excretion (Jaegar 1998, Parmar 2004, Bushinsky 














Resorptive hypercalciuria is a consequence of increased bone resorption which occurs as a result 
of primary hyperparathyroidism i.e. an excessive secretion of parathyroid hormone, PTH. The 
principal functions of PTH are to mobilize calcium from bone, conserve calcium in the kidney 
and indirectly increase gastrointestinal calcium absorption. This abnormality is only reported in 
5% of patients with recurrent stones (Mollerup et al. 2002, Parmar 2004). 
 
Renal hypercalciuria is an outcome of impaired renal tubular absorption of calcium (Parmar 
2004; Coe et al. 2005). This condition exists in about 2% of patients with recurrent stone 
formation. 
 
Various studies have also established that a high intake of sodium can also lead to elevated 
urinary calcium excretion as calcium and sodium have similar renal handling mechanisms (Hesse 
et al. 1993, Sakhaee et al. 1993, Martini et al. 1998). Another contributing factor to 
hypercalciuria is a high intake of dietary calcium (Broadus et al. 1978, Massey and Kynast-Gales 
1998, Messa et al. 1997). 
 
1.3.2 Urinary oxalate 
 
Oxalate is a dicarboxylate anion and when complexed with calcium in urine forms an insoluble 
salt. At neutral pH, CaOx has a solubility of 0.67 mg/L in water, however urine is often 
supersaturated with respect to this salt, therefore crystallization can occur. Excessive oxalate in 
the urine (hyperoxaluria) is reported to be the cause of 30% of calcium stones (Bihl and Meyers 
2001). There have been conflicting reports on differences in urinary oxalate between healthy 
subjects and stone formers. Several studies have reported a higher concentration of urinary 
oxalate in the latter group (Robertson et al. 1978, Schwille et al. 1989, Wilson et al. 1989) while 
others have reported no differences between the two groups (Tiselius 1997, Holmes et al. 1998).  
 
The amount of oxalate excreted in urine is mainly dependent on one of four factors: (1) dietary 
intake, (2) intestinal absorption and renal tubular secretion, (3) the rate of endogenous synthesis 
and (4) a deficiency in oxalate-degrading bacteria, Oxalobacter formigenes (Robertson 1999, 














oxalate for absorption (Robertson 1999). (2) Intestinal absorption is an important determinant in 
oxalate excretion and one of the factors that promote it is malabsorption which is the inability of 
the intestinal tract to absorb fatty acids and other nutrients properly. It may cause calcium to bind 
unabsorbed fat instead of oxalate resulting in excess oxalate being absorbed in the digestive tract 
and eliminated through the kidneys (Earnest et al. 1974). (3) The rate of endogenous synthesis is 
not considered to be a likely cause of elevated levels of urinary oxalate in idiopathic stone 
formers (Massey et al. 1993). (4) A deficiency in Oxalobacter formigenes, a colonic anaerobe 
which constitutes the normal component of human microflora, can cause an increase in the risk 
of hyperoxaluria and stone formation. By utilizing oxalate in the digestive tract, these oxalate-
degrading bacteria maintain a homeostatic oxalate balance and prevent excessive enteric oxalate 
absorption (Allison et al. 1986, Sidhu et al. 1999).  
 
Hyperoxaluria is considered to be the most critical determinant of renal stone formation 
compared to other risk factors like hypercalciuria, hyperuricosuria (a high urinary uric acid 
concentration) and hypocitraturia (low urinary citrate excretion) (Robertson 1999). 
 
1.3.3 Urinary magnesium 
 
Magnesium has been well-established as an inhibitor of CaOx crystallization as it readily forms 
highly soluble complexes with oxalate thereby reducing free oxalate in the urine (Rushton and 
Spector 1982, Trinchieri et al. 1992). This is highly favourable as oxalate plays a greater role in 
CaOx stone formation than calcium. Apart from ability to chelate to oxalate, magnesium has 
been found to decrease the nucleation and growth rates of CaOx crystals in vitro as well as lower 
urinary supersaturation of CaOx (Ryall et al. 1981, Li et al. 1985, Lindberg et al. 1990).  
 
There have been conflicting reports on the relative levels of urinary magnesium concentration in 
healthy subjects and stone formers. Some studies have reported no major differences between the 
groups (Robertson et al. 1968, Welshman et al. 1975) while others have found urinary 
magnesium levels to be lower in stone formers than healthy subjects (Trinchieri et al. 1991, 















1.3.4 Urinary citrate 
 
The association of hypocitraturia and stone disease has been well-documented (Pak et al. 1985, 
Laminski et al. 1990, Cupisti et al. 1992). Citrate complexes with ionic calcium thereby lowering 
its concentration and reducing the potential for the formation calcium precipitates. Calcium 
citrate complexes are also highly water soluble. Apart from this function, in vitro studies have 
demonstrated citrate to be an effective inhibitor of CaOx nucleation, aggregation and of crystal 
growth (Tiselius et al. 1990, Bek-Jansen and Tiselius 1991, Schwille et al. 1999). It is also 
known to bind to CaOx crystals surface thus influencing aggregation and growth (Ryall 1997).  
In view of these findings, low urinary citrate excretion is considered to be an important risk 
factor for renal stone formation and alkali therapy is often recommended to patients (Parks and 
Coe 1986, Conte et al. 1989a).  
 
1.3.5 Urinary uric acid 
 
Hyperuricosuria is another significant risk factor for renal stone formation (Robertson et al. 
1978, Coe 1983, Griffith et al. 1986). Uric acid stones may be dissolved by increasing the pH to 
approximately 6.5 (Hesse et al. 1997). It has been reported that one third of patients with CaOx 
stones have high uric acid excretion. There are two possible causes of this namely an endogenous 
overproduction of uric acid (70% of cases) or a high intake of dietary protein (30% of cases) 
(Coe 1978). Uric acid is an end-product of purine (animal protein) metabolism. Therefore 
recurrent stone formers are advised to restrict their intake of foods rich in protein, such as: meat 
and fish (Coe 1978, Scheinman 2000). Allopurinol therapy has been reported to be very effective 
in decreasing urinary uric acid and recurrent stone formation by blocking uric acid production 
(Ettinger 1991) and purine reabsorption (Pak et al. 1978).  
 
1.3.6 Urinary phosphate 
 
The concentration of urinary phosphate is directly dependent on the dietary intake of phosphate 
rich foods and is therefore subject to huge variations. It has a great influence on establishing the 














phosphate is 35 mmol per twenty four hours (Hesse et al. 1997). Elevated levels of urinary 
phosphate can pose a risk for CaP crystallization especially if hypercalciuria is present. Urinary 
phosphate can also serve as an inhibitor of CaOx crystallization as it can complex with ionic 
calcium thereby reducing the availability of calcium to bind oxalate (Schwille 1989, Baumann et 
al. 2000).  
 
1.3.7 Urinary pyrophosphate   
 
Pyrophosphate has been reported to inhibit nucleation (Grases et al. 1989a, Ryall 1997), growth 
(Grases et al. 1989b, Conte et al. 1989b) and aggregation of CaOx crystals (Robertson et al. 
1973, Robertson et al. 1974). The inhibitory activity of pyrophosphate is due to its capacity to 
selectively and irreversibly bind to the surfaces of COM crystals and not to COD crystals 
(Wikström et al. 1983, Wesson et al. 1998). This attribute is of great pathological significance as 
COD crystals are less likely to adhere to renal epithelial cells and crystal-cell binding is a critical 
step in stone formation (Wesson et al. 1998).   
 
1.3.8  Urinary pH 
 
Urinary pH is crucial in determining the ion-product activity of CaP and CaOx and hence their 
risk of precipitation (Pak 1994). At high urinary pH (> 7.0), more phosphate and citrate ions are 
dissociated which minimizes the risk of CaOx crystallization, as calcium and citrate ions are able 
to complex (Tiselius et al. 1978, Pak 1994, Højgaard et al. 1999). However, this inadvertently 
raises the risk of calcium phosphate crystallization. This was shown in a study where calcium 
phosphate crystals precipitated at a pH of 6.45 but no CaOx crystals formed (Højgaard et al. 
1999) however CaOx crystallization is known to occur at pH < 6.25 (Ahlstrand et al. 1984). Low 
urinary pH (< 6.0) has been associated with excessive uric acid crystallization and subsequent 
stone formation (Hess 2006). Magnesium ammonium phosphate stones are reported to form at 
urinary pH > 7.0 due to the presence of urease producing bacteria (Hesse et al. 2002). 
Ammonium urate stones, which are also caused by infection, occur at pH 6.5 and 7.0 (Hesse et 














minimize the risk of CaOx, CaP and uric acid stone formation (Ahlstrand et al. 1984, Tiselius 
2003).   
 
1.3.9  Urinary volume 
 
Urinary volume is another crucial factor affecting renal stone formation. A high fluid intake is 
the first line of treatment recommended for stone formers as it reduces the relative 
supersaturation of crystal components in urine. A high urinary volume also aids in flushing out 
the renal system of any crystals that may have formed thereby reducing the risk of crystal-cell 
adhesion (Curhan et al. 1993, Borghi et al. 1996, Pearle et al. 2008). Although diluting the urine 
is advantageous, excessively high intake of fluids is not advised as it could decrease the 
concentration of inhibitors and counter its positive effects (Pak et al. 1980).  
 
In studies by Borghi et al. (1996, 1999) the clinical significance of a high fluid intake was 
demonstrated. When the fluid intake was increased to achieve an output of 2 liters, both urinary 
calcium and urinary oxalate concentrations decreased significantly, and a reduction in stone 
recurrence from 27% to 12% was noted. They also reported a decrease in CaOx supersaturation 
but no substantial change in CaOx MSL was found. A urinary volume of 2 litres also did not 
affect the inhibitory properties of macromolecules on CaOx crystallization (Borghi et al. 1996, 
1999). The overall conclusion is that a low urine volume is a risk factor of stone formation as it 
















1.4 Conservative treatment and management of idiopathic CaOx urolithiasis  
 
1.4.1 General  
 
It is common knowledge that stone patients are very likely to have recurrent episodes, ranging 
from 40% within 3 years, 74% within 10 years to 98% within 25 years (Sutherland et al. 1985, 
Milliner 1995, Robertson 1999, Atmani et al. 2000, Johri et al. 2010). Despite years of medical 
research, there is no ideal drug to cure renal stone disease. Patients tend to be treated with the 
same medicines for long periods of time and efficacy of the medicines and side-effects may 
sometimes become problematic (Koide et al. 1995, Atmani et al. 2000, Glover et al. 2011, 
Navaneethan et al. 2011). 
 
The single most common factor that initiates stone formation is insufficient fluid intake (Hall 
1995, Moe 2006), therefore increased hydration is the first line of therapeutic defence. Thiazide 
diuretics (hydrochlorothiazide or chlorthalidone) have been reported to be effective in managing 
kidney stones (Yendt and Cohanim 1978, Ramsay 1999, Pearle et al. 2008, Eisner 2009, 
Goldfarb 2009, Vigen 2010). Thiazides act by blocking the reabsorption of sodium in the distal 
tubules of the kidney hence the laminar fluid is more concentrated (Coe 1977).  
 
Since diet significantly affects urine composition, certain foods and dietary supplements are used 
as anti-lithogenic agents (Lewandowski et al. 2001, Lewandowski and Rodgers 2004, Meschi et 
al. 2010). While most physicians agree that dietary interventions should be encouraged after the 
development of a stone, consensus on the specifics of these changes have been lacking, with the 
exception of increasing hydration (Harvey et al. 1985, Curhan et al. 1993, Curhan et al. 1997a, 
Messa et al. 1997, Lemann 2002, Heller et al. 2003). Several different kinds of citrate-containing 
compounds have been used in the treatment of urolithiasis (Pak et al. 1985, Pak et al. 1986a, Pak 
et al. 1992a, Barcelo et al. 1993, Ogawa 1994 Sakhaee et al. 1994, Whalley et al. 1996, Schwille 
















With adequate hydration, stones with a diameter < 5 mm will be spontaneously expelled from the 
renal system in ~ 90% of patients. However as the size of the stone increases, the likelihood of 
passage decreases and stones with a diameter of 1 cm have a 10% chance of being passed out 
without surgical intervention. Open surgical removal of stones is still an option for some patients 
(< 1%) (Matlaga and Assimos 2002). However over the years minimally invasive techniques, 
such as percutaneous nephrolithotomy (PCNL), Nephro-ureteroscopy (URS) and extracorporeal 
shockwave lithotripsy (ESWL) have revolutionized the management of urolithiasis. PCNL is the 
procedure where stones are removed through a small puncture made through the skin. URS is the 
removal of stones by fiberoptic nephron-ureteroscopes. ESWL is the most common of the 
aforementioned techniques and involves the use of mechanical shock waves to shatter stones into 
smaller fragments which are subsequently passed out of the body (Bataille et al. 2000, Coe et al. 
2005, Samplaski et al. 2009, Buchholz et al. 2011, Cortes et al. 2011).  
 
Even though highly effective, these surgical techniques also risk compromising renal function in 
some way. Complications that could arise include injury to renal blood vessels, infection, 
interstitial inflammation, severe hematuria, cellular damage and persistent renal fragments that 
may serve as a nidus for new stone formation (Schmidt et al. 2001, Pais and Assimos 2005, 
Samplaski et al. 2009). 
 
The health care costs associated with the treatment of renal stone disease has risen considerably 
over the years (Trinchieri 2006). In the USA, this figure was estimated to be 2.5 – 3 billion 
dollars per annum (Chandoke 2005). Furthermore, it was reported that each new stone incidence 
in the UK costs the local health care system approximately £2000 (Robertson 2006). 
 
Urolithiasis is becoming more prevalent and although pathogenesis is not completely understood, 
the risk of heat and climate has been well established, as mentioned in section 1.1.1. Recent 
estimates from computer models have predicted up to a 10% rise in the prevalence rate in the 
forthcoming half century due to the secondary effects of global warming, coinciding with a 25% 
increase in health-care expenditures (Romero et al. 2010, Fakheri and Goldfarb 2011). Taking 
into consideration the high frequency of stone recurrence, more cost-effective alternate methods 














In recent years, herbal remedies have been found to be useful in the treatment of urinary stone 
disease with fewer side-effects than contemporary Western medicine (Koide et al. 1995, Mok 
and Chau 2006, Butterweck et al. 2009). There remedies may therefore be suitable for long-term 
treatment. There are different schools of herbal medicines such as traditional Chinese medicine 
(TCM) and Ayurvedic medicine and these will be discussed in the following section.  
 
1.4.2  Traditional Chinese Medicine (TCM) 
 
The use of herbal treatment for kidney stone disease has been practiced in China and Hong Kong 
long before the introduction of Western medicine. This medicinal system has renewed popularity 
around the world due to its effectiveness in preventing many diseases and imbalances in the 
body.  In 1999, the Chinese medicine ordinance implemented a regulation which allows the use, 
manufacture and trading of Chinese medicines in Hong Kong and China (cited by: Gohel et al. 
2006) and today TCM practitioners are active in many Western countries.
 
 
This therapeutic system employs the use of different herbal preparations in various mixtures. The 
selected blend is dependent upon the patient‟s particular ailment. In contrast to western 
medicine, TCM does not give names to diseases but instead diagnoses the imbalance in the 
patient i.e. the deviation from a healthy balance (Ikegami et al. 2004, Qin et al. 2004, Jiang 
2005). After physical examination, the symptoms of a patient are interpreted according to the 
ancient theories of 4 diseased states. The diagnosis is based significantly on intuition, experience 
and observational skills of the practitioner. Based on this, a combination of herbs is prescribed 
which is intended to assist the patient to return to a balanced state. Although the efficacy of TCM 
is suggested by years of clinical observations, there is little scientific evidence on their 
pharmacodynamics (Koide et al. 1995, Yasui et al. 1999, Ikegami et al. 2003, Miyaoka and 
Monga 2009).  
 
Various herbs and combinations thereof have been successfully used in the treatment and 
prevention of urinary stone disease. This method of treatment covers the whole urinary system, 
including balancing of mineral electrolytes and the endocrine system (Qin et al. 2004). Herbal 














urinary system in order to prevent retention which can lead to further growth (Gohel et al, 2006). 
Herbal anti-lithics also induce diuresis to flush out crystalline deposits from the kidneys. An in 
vitro study of a herbal blend containing the traditional herbs Takusya (Alismatis Rizoma), Chorei 
(Polyporous), Bukuryo (Hoelen), Kasseki (Talcum Crystallium), Kinsensou (Desmodii Herba) 
and Kagosou (Purunellae Spica) revealed inhibitory effects on CaOx crystallization (Koide et al. 
1995).
 
The results of the study showed that with increasing concentrations of these 6 herbal 
extracts, the size of the calcium oxalate crystals formed, decreased (Koide et al. 1995). 
 
In another in vitro study, the effects of 16 herbal extracts (including the 6 mentioned above) on 
calcium oxalate formation were tested.
 
The two extracts showing the greatest potential for 
calcium oxalate crystallization inhibition, namely Takushya and Kagosou, were tested using an 
in vivo rat model. Of the two, Takushya showed a more significant inhibitory effect on CaOx 
crystallization (Koide et al. 1995). In addition to the aforementioned inhibitory effect, the 
administration of Takushya in rats induced a decrease in the expression of osteopontin, a stone 
matrix protein (Yasui et al. 1999). Osteopontin is strongly expressed in the kidneys of stone 
formers therefore down regulation of the expression of osteopontin is considered to be anti-
lithogenic (Kohri et al. 1990). Chorei-to, a herbal mixture containing Takushya, Chorei, 
Bukuryo, Akyoh and Kasseki were tested in a rat model and exhibited stone prophylaxis (Yasui 
et al. 1999). In a clinical trial involving human subjects, Chorei-to was administered orally to 
patients who suffered from lower urinary tract problems. A total efficacy rate of 76% was 
achieved and no side-effects were observed (Horii et al. 1988). 
 
Further in vitro studies have been carried out by Gohel et al. (2006) on the effect of Folium 
pyrrosiae, Desmodium styracifolium, Pyrrosia Sheareri, Dong Kui Zi and Siaoniaotong pills on 
calcium oxalate crystallization. These studies showed that all 5 plant extracts promote nucleation 
while inhibiting growth. Therefore they may be suitable for prophylaxis of urinary stones (Gohel 
et al. 2006). It is important to note that an increase in crystal nucleation is regarded as a 
favourable effect in the context of stone formation because it decreases urinary supersaturation 
(Kavanagh 1992). Thus small crystals are formed and expelled prior to them undergoing growth 















1.4.3  Ayurvedic medicine  
 
Ayurveda is a Sankrit term meaning „the knowledge of life span‟. It is an ancient medicinal 
system from India that originated thousands of years ago. The fundamental principles of 
Ayurvedic medicine can be traced to the Vedas, the oldest books of Indian knowledge. It is 
considered to be a form of alternative medicine in the West and encompasses different methods 
of treatment such as the use of herbs, massage, meditation and yoga (Mitra et al. 1998, 
Tomlinson 2002, Kieley et al. 2008, Patwardhan et al. 2009). Ayurvedic medicine is also based 
on the maintenance of health through the balance of the three essential humors (bodily fluids): 
wind, gall and mucus. Imbalances in these humors, also referred to as dosas, manifest themselves 
as diseases in the body. Treatment is based on restoring homeostasis of these factors (Kieley et 
al. 2008). As with TCM, herbs are prescribed in blends as they work synergistically. Most 
medicines for urinary calculi disease have a wide range of action, including: analgesic, anti-
inflammatory, anti-microbial, diuretic, antispasmodic properties, and anticalcifying activities. 
Some of the most popular and effective Ayurvedic herbs for treating renal calculi are: Tribulus 
terrestris (Gokshura), Arctostaphylos (Bearberry Uva-Ursi), Phyllanthus niruri (Bahupatra), 
Orthosiphon stamineus (Java Tea) and Orthosiphon grandiflorus (Joshi et al. 2005, Kieley et al. 
2008). Phyllanthus niruri and Orthosiphon stamineus are herbs that will be investigated in this 
thesis.  
 
Tribulus terrestris is one of the most commonly administered Ayurvedic medicines for renal 
problems. Its primary use is as a diuretic (Joshi et al. 2005).  In vitro studies in which COM 
crystals were grown by a double diffusion gel growth technique, showed a significant inhibition 
of crystal growth brought about by an aqueous extract of Tribulus terrestris (Joshi et al. 2005). 
Using a rat-model, the mechanism by which Tribulus terrestris prevents nephrolithiasis was 
found to be by decreasing the excretion of urinary oxalate by inducing changes in hepatic oxalate 
synthesizing enzymes: glycolate oxidase (GAO) and glycolate dehydrogenase (GAD) (Joshi et 
al. 2005). Suppression of these two enzymes as well as renal lactate dehydrogenase (LDH), a 
promoter of high urinary oxalate levels, was noted in sodium glycolate-fed rats that were 















1.5.4 Herbal remedies for urolithiasis 
 
As mentioned, herbal remedies are increasingly being considered as a suitable long-term 
treatment for renal dysfunction due to a reduced likelihood of side-effects and no known toxicity 
(Atmani et al. 2000, Gohel et al. 2006). There are not many published papers describing these 
effects however strong anecdotal evidence exists in support of their existence. Hence rigorous 
scientific analyses of these anecdotal observations are warranted. A few plants which are 
indigenous to different parts of the world purported to be effective in the treatment of 
urolithiasis, have been selected for investigation in the present project. These plants are 
introduced below.  
 
Folium Pyrrosiae (Shi Wei) 
Folium pyrrosiae, an evergreen plant that grows throughout China, is the principal plant of 
interest in this thesis and is most prominently recommended by TCM practioners for the 
treatment of urinary stone disease. According to the principles of TCM, the leaves of Folium 
pyrrosiae have bitter, sweet and mildly cold properties and are used in treating lung and bladder 
disorders (Gohel et al. 2006). Its main functions are to clear damp (one of the 6 influences 
causing disharmony to the body) and expel phlegm from the body (Ma et al. 2003). In relation to 
urinary stone disorders, Folium pyrrosiae acts as a diuretic and antibacterial. It relieves strangury 
(painful drop by drop release of urine) and has demonstrated its potential as being a prophylaxis 
of stones by promoting nucleation of CaOx crystals and inhibiting crystal aggregation and 
growth in vitro in synthetic urine (Gohel et al. 2006). The main chemical ingredients in the 
leaves of the plant are tannins, saponins, anthraquinones and chlorogenic acid (Li and Tong 
1992).  
 
Desmodium styracifolium (Jin Qian Cao) 
The Desmodium genus grows widely in the tropical and sub-tropical regions of China. 
Desmodium styracifolium is another important TCM plant used in the treatment of urinary stone 
disease (Gohel et al. 2006). It reduces heat and swelling and induces diuresis and acidification of 
urine (Gohel et al. 2006). In vitro studies on Desmodium styracifolium have shown a significant 














decreases the probability of stone formation. The chemically active ingredients in Desmodium 
styracifolium are polysaccharides, triterpenoids and flavonoids (Ming et al. 2007). 
 
Hylocereus trigonus (Odyvato) 
Hylocereus trigonus belongs to the cacti family. It grows prominently in equatorial regions, 
especially in the Carribean and Puerto Rico but is also found in Madagascar. It is a well-known 
folk medicine and is commonly called Odyvato. The dried aerial parts of the plant are brewed as 
a drink and it is used to treat kidney stone ailments. Even though Odyvato is administered to 
stone patients routinely in Madagascar, there is no published data to support its mechanisms of 
action again kidney stone disease (Private communication: Professor Philippe Rasoanaivo, 
Institut Malgache de Recherches Appliquées, Madagascar).  
 
Phyllanthus niruri  
Phyllanthus niruri belongs to the family of Phyllanthaceae and grows worldwide in tropical and 
subtropical regions. It has been used in Ayurvedic and Brazilian folk medicine for the treatment 
of urolithiasis to control pain and eliminate stones. Several studies, including in vitro and in vivo 
(human and rat model), have been carried out on Phyllanthus niruri and its potency has been 
demonstrated in its ability to inhibit CaOx aggregation and growth (Freitas et al. 2002, Barros et 
al. 2003, Barros et al. 2006). Furthermore its ability to normalize elevated urinary calcium levels 
in calcium stone forming patients has been demonstrated (Micali et al. 2005). This herb is 
commercially available as Uriston
®
 in western countries. Regular treatment with Phyllanthus 
niruri post ESWL in stone patients was found to significantly decrease stone recurrence (Micali 
et al. 2005). Many chemical components of Phyllanthus niruri have been identified such as 
alkaloids, tannins, lignans, phenols, steroids, flavanoids and triterpenes (Barros et al. 2003). 
 
Orthosiphon stamineus  
Also known as Java tea and „Cat‟s Whiskers‟, Orthosiphon stamineus is a native plant of South 
Asia and belongs to the family Lamiaceae. It is a well-known traditional Indonesian and 
Ayurvedic medicine that is used in the treatment of kidney stone disease and urinary tract 
infections (Hirayama et al. 1993, Adam et al. 2009). Arafat et al. (2008) demonstrated the 














model. Dharmaraj et al. (2008) reported the inhibitory effect of Orthosiphon stamineus on CaOx 
crystal growth by conducting in vitro studies on a 50% methanol extract of the plant material. It 
is also known to act as a diuretic and to reduce inflammation (Dharmaraj et al. 2006). The plant 
has been widely studied and the leaf extract has revealed the following constituents: terpenoids, 
polyphenols, sterols and caffeic acid derivates (Dharmaraj et al. 2006, Arafat et al. 2008).  
 
Cystone® 
Cystone® is a polyherbal Ayurvedic preparation produced by the Himalaya Drug Company. This 
herbal formulation is used in the treatment of urolithiasis. Its constituent plants are: 
Didymocarpus pedicellata, Saxifraga ligulata, Rubia cordifolia, Cyperus scariosus, Achyranthes 
aspera, Onosma bracteatum, Vernonea cinerea and Tribulus terrestris (Jethi et al. 1983, Mitra et 
al. 1998, Erickson et al. 2011). In vitro studies by Jethi et al. (1983) showed demineralization 
(i.e. dissolution) of the crystal matrix and inhibition of deposition of calcium and phosphate ions. 
Cystone® also induced a reduction in cisplatin induced renal-and nephrotoxicity as shown by rat 
models (Rao and Rao 1998, Rao et al. 1999). In another study, Cystone demonstrated the ability 
to aid expulsion of stones in patients (Kumaran and Patki 2011). Didymocarpus pedicellata, the 
main component of Cystone® tablets, posseses a high concentration of polyphenolics and 














1.5 Urolithiasis in South Africa 
 
As stated previously, in South Africa the occurrence of stones amongst the black population is 
extremely rare (< 1%) while in the white population stone occurrence is similar to the incidence 
rate in the Western world (~ 15%) (Modlin 1967, Beukes et al. 1987, Meyers 1994, Whalley et 
al. 1998).  
 
Studies of the urine composition of these two population groups have revealed interesting results. 
It has been reported that blacks actually have a lower urinary citrate and higher urinary oxalate 
concentrations which would cause them to be more susceptible to stone formation (Modlin 1967, 
Whalley et al. 1998, Lewandowski and Rodgers 2004). However, this does not happen and is 
somewhat perplexing. On the other hand, urinary calcium and phosphate excretions have been 
found to be significantly lower in black subjects compared to white (Modlin 1967, Whalley et al. 
1998, Lewandowski et al. 2001, Lewandowski and Rodgers 2002). Further interesting results 
were obtained from studies on urinary pH where this parameter was found to be lower in black 
subjects (Modlin 1967, Lewandowski et al. 2001, Rodgers et al. 2005).  However all these 
values lie within the normal range. Thus although the lower excretions of these two parameters 
may explain the lower incidence in the black population, it cannot account for its near absence in 
the black group. Therefore urine composition alone cannot account for the rarity of stones in the 
black population.  
 
In order to elucidate the differences in stone frequency in the two race groups, several studies 
have been undertaken by the Kidney Stone Research Laboratory (KSRL) at the University of 
Cape Town where the renal handling of different dietary and supplemental challenges have been 
investigated.  
 
Lewandowski and Rodgers (2004a) investigated individual effects of 5 different dietary or 
supplemental challenges (high dietary calcium; calcium, vitamin B6, L-glutamine and L-cysteine 
supplementation) on urinary risk factors of CaOx kidney stone formation. None of these 
protocols altered any biochemical of physiochemical factors in black subjects, however the 














potassium and decreased relative supersaturation of brushite; supplemental calcium decreased 
the Tiselius Risk Index; vitamin B6 decreased urinary calcium, urinary phosphate and relative 
supersaturation of brushite; L-glutamine decreased the relative supersaturation of CaOx; and L-
cysteine decreased urinary calcium and TRI. Since none of these factors was detected in blacks, 
these workers speculated that renal or gastrointestinal homeostatic adjustment occurs in this 
group (Lewandowski and Rodgers 2004a). 
 
In another supplementation study, evening primrose oil was administered to black and white 
subjects and the effects of urinary risk factors were investigated. The principal ingredient in this 
supplement is γ-linolenic acid, an ω-6 polyunsaturated fatty acid. Urinary citrate increased in 
both groups and urinary calcium and TRI decreased in both groups. A decrease in urinary oxalate 
was detected in the black group but not in the white group indicating the sensitivity of the former 
group to this supplementation (Rodgers et al. 2009a). 
 
Further investigations have been carried out on carbohydrate (glucose, sorbitol and xylitol) and 
oxalate-containing dietary agents (rhubarb, spinach and an aqueous solution of sodium oxalate) 
(Rodgers et al. 2009b). These agents were selected as dietary surveys revealed that the 
consumption of these potentially lithogenic substances were higher in the black population 
group. The results showed that these agents initiated more significant urinary changes in black 
subjects compared to whites. The only changes measured in white subjects was upon 
consumption of sorbitol which induced an increase in urinary oxalate and a decrease in urinary 
phosphate. However in black subjects, the following urinary changes were detected: an intake of 
glucose resulted in a decrease in phosphate, an intake of sorbitol also resulted in a decrease of 
phosphate, whereas an intake of xylitol resulted in an increase of oxalate. It has been proposed 
that decreases in urinary phosphate are a consequence of reduced renal filtered load of phosphate 
due to entry of phosphate into cells after glucose or sorbitol ingestion. Whereas increased urinary 
oxalate following sorbitol and xylitol occurs via metabolic pathways which are governed by 
certain enzymes that convert the two sugars into oxalate.  The activity of the enzyme aldolase 















Furthermore, the black population is able to handle dietary oxalate in a more efficacious way 
compared to their white counterparts (Lewandowski et al. 2001).  In additional studies, it was 
found that even when black subjects consumed a greater amount of dietary oxalate than white 
subjects, urinary oxalate levels were not significantly different. In addition, these studies have 
revealed that black subjects also have significantly more oxalate-degrading bacteria that have 
greater capabilities than those isolated from white subjects (Lewandowski et al. 2001, Rodgers et 
al. 2002, Lewandowski et al. 2004, Lewandowski et al. 2005).  
 
These studies have shown that the renal response and therefore renal handling mechanisms in the 
subjects from the two groups is different and it is the handling of supplemental challenges that is 
of interest in the present study.  
 
Investigation of the role of urinary proteins in the two population groups was another attempt at 
trying to understand the anomaly of stone incidence that exists between South Africa‟s black and 
white population groups. Analysis of THM and UPTF1 (explained in section 1.2.5), has 
suggested the urine composition in black subjects enhances a superior inhibitory activity of these 
proteins (Craig et al. 1999, Webber et al. 2002). The N-linked glycans on UPTF1 isolated from 
black subjects was found to have a significantly greater proportion of disialylated fragments 
compared to those found in white subjects (Webber et al. 2004).  Bikunin, a plasma protease 
inhibitor, isolated from matrix extract proteins was found in greater quantities black subjects 
compared to that in white subjects. In further studies, OPN isolated from the urine of black 
subjects has demonstrated greater inhibition of CaOx aggregation and deposition, and decreased 
promotion of nucleation than OPN derived from the urine of the whites (Deppa et al. 2005). 
Whereas urinary albumin isolated from the two race groups was found to have different 
molecular and structural differences, hence different activity (Rodgers et al. 2006b). These 
observed inhibitory properties of proteins in the black population group may be key role-players 
in their immunity to stone disease. 
 
Although many studies have been performed at the University of Cape Town, no single 
explanation has emerged regarding the difference in stone prevalence between blacks and whites, 














1.6       Objectives 
 
There is minimal evidence that any herbal remedy is actually effective in preventing stone 
recurrence. Furthermore, in those few cases where a remedy has been effective, there is no 
scientific evidence as to how it may work. Although it could be via an alteration in the 
crystallization processes or crystal-cell binding, the role of these phenomena is still uncertain. It 
is equally likely that herbal remedies might work via completely different mechanisms, such as 
the formation of Randall‟s plaque. Thus a scientific study that investigates the possible efficacy 
of herbal remedies and the mechanisms by which they act is warranted. The present thesis aims 
to address some of these. 
 
The first principal objective of the project described in this thesis was to develop and establish a 
model for the in vitro and in vivo investigation of traditional herbal preparations which have been 
previously advocated for the possible treatment of urolithiasis and to implement the model in the 
investigation of several such preparations.  
 
The second principal objective was to investigate the renal response of subjects from South 
Africa‟s black and white population groups to the administration of a herbal preparation which 
has been widely used for the treatment of kidney stone disease in the Tradition Chinese 
Medicinal system, with a view of gaining insights into understanding why the incidence of this 
disease in the former group is extremely rare.  
 
In order to achieve these main objectives, the following specific aims were defined:  
 
(i) Investigate the independent in vitro effects of several traditional herbal preparations 
on CaOx crystallization characteristics in a synthetic urine 
(ii) Investigate the independent in vitro effects of several traditional herbal preparations 
on CaOx crystallization characteristics in real urine derived from healthy black and 
white South Africa subjects 
(iii) Investigate the independent in vitro effects of several traditional herbal preparations 














(iv) Investigate the in vivo renal response with respect to urinary composition and 
supersaturation, to the administration of Folium pyrrosiae in black and white South 
African subjects 
(v) Characterize the chemical composition and structure of Folium pyrrosiae with a view 
to identifying the active ingredient and, in so doing, establish a protocol for 


















This chapter provides details on the general laboratory procedures which were used to achieve 
the objectives of this thesis. It begins by giving details of how the plant extracts under 
investigation were obtained, followed by descriptions of the preparation of synthetic urine (SU) 
and the collection and treatment of 24 hour urine samples. Details on the measurement of the 
CaOx metastable limit (MSL) are given. Thereafter, experiments to determine: particle size-
volume distribution (PSD); 
14
C-oxalate deposition kinetics; and inhibition kinetics of crystal 
nucleation, aggregation and growth are described. Details on examination of crystalluria by 
scanning electron microscopy (SEM) and calculation of the various physicochemical risk indices 
are also presented.  
 
2.1 Origin of plant extracts 
 
Folium pyrrosiae and Desmodium styracifolium were purchased individually under the brand 
name Nong’s Powder, from PuraPharm pharmaceutical company, Hong Kong. Hylocerus 
trigonus was obtained from the Institut Malgache de Recherches Alliquées, Madagascar. It is 
commercially available in Madagascar as Masy Odivato. Phyllanthus niruri (a product of Peru) 
was purchased from Raintree Nutrition, Nevada, USA. Orthosiphon stamineus was purchased as 
Java Tea from Midas Herbs, Indonesia. Cystone®, manufactured by the Himalaya Drug 
Company, was obtained from an Ayurvedic practitioner, Dr Rajen Coopan (Durban, South 
Africa).  
 
2.2 Preparation of synthetic urine 
 
SU was prepared according to the method of Walton et al. (2005) for in vitro crystallization 
experiments. A 1 litre solution was constituted by the addition of the following salts at the given 
concentrations: 0.320 M NaCl (Orion Chemicals), 0.050 M NaH2PO4 (Merck), 0.00652 M 
MgCl2 (Riedel-de Haën), 0.164 M KCl (Merck), 0.00434 M K3Citrate (Merck), 0.0438 M 
(NH4)2SO4 (Merck) and 0.007 M NH4Cl (Merck). During preparation of SU, salts were added in 














next. The pH of the mixture was adjusted to 6.0 by the addition of 5 M NaOH. The solutions 
were stored at 4 ˚C for a maximum of 4 days after preparation and filtered (0.22 μm) 
immediately before use to remove any particulate matter. Solutions of 0.005 M NaOx (Chemical 
Enterprises) and 0.120 M CaCl2 (Merck) were prepared separately and the following volumes 
were added per liter SU: 2.86 mL NaOx and 17.8 mL CaCl2. 
 
2.3 Urine collection and treatment   
 
For experiments in real urine, 24 hour samples were collected in plastic bottles without 
preservative. Extensive details concerning aspects of urine collection in the various experiments 
are described for those studies elsewhere in this thesis, in sections which have been dedicated. 
Black and white male subjects aged between 18 and 32 years old, with no prior history of kidney 
stone disease, were recruited from the cohort of students from the University of Cape Town. 
Subjects were asked to restrict their diet with respect to oxalate rich foods. Urine collections that 
tested positive for the presence of haematuria or nitrites using urinalysis test strips (Boehringer 
Mannheim, Germany) were excluded from the study. Urine was pre-filtered through a 0.75 m 
filter followed by 0.45 m nitrocellulose filter paper before use to remove cellular debris.   
 
Biochemical urine measurements 
An aliquot of each urine sample was retained for urinalysis. Urinary pH and volume were 
routinely measured (pH meter 211, Hanna Instruments, USA). Sodium, potassium, calcium and 
magnesium were analyzed by atomic absorption spectroscopy (Varian 1275, Australia) (Willis 
1961, Trudeau and Freier 1967, Fernandez and Kahn 1971). Oxalate and citrate concentrations 
were determined by enzymatic assays. Analytical kits were employed in the measurement of 
oxalate (Trinity Biotech, Ireland) (Chiriboga 1963) and citrate (Boehringer Mannheim, 
Germany) (Gruber and Mollering 1966). Inorganic phosphate was measured using ammonium 
molybdate (Dryer and Routh 1963), creatinine was measured using picric acid (Rock et al. 1986) 
and uric acid was measured using uricase (Fossati et al. 1980). Chloride determination was 















2.4 CaOx metastable limit (MSL) 
 
CaOx MSL is a measure of the ability of urine to resist spontaneous nucleation and hence 
crystallization. This method described by Ryall et al. (1985, 1995) was followed. Urine samples 
were prepared by successively filtering through a 0.75 μm pre-filter (Macherey-Nagel, Germany) 
followed by a 0.45 μm nitrocellulose membrane (Sartorius AG, Germany). Aliquots of 10 mL of 
filtered urine were pipetted into Coulter cups and incubated at 37 ˚C in a circulating water bath at 
100 rpm (Labcon, Johannesburg). To each aliquot, 100 μL of progressively increasing 
concentrations of sodium oxalate (Na2Ox; 15 mmol/L to 195 mmol/L) were added. Dosing was 
performed at 2 minute intervals. After incubation for a total of 30 minutes for each sample, 
particle numbers and volumes were measured using a Coulter Multisizer II (Coulter Electronics 
Ltd., England) fitted with a 140 μm orifice (2.8 – 90.0 μm particle size range). The MSL 
corresponds to the minimum Na2Ox concentration needed to induce spontaneous crystallization 
(denoted by the pink dot). It is determined by plotting particle size vs Na2Ox concentration as 






























































2.5 CaOx particle size-volume distribution  
 
CaOx particle size-volume distributions were determined according to the method described by 
Ryall et al. (1995). Each urine sample (30 mL) was incubated at 37 ˚C in a shaking water bath at 
100 rpm (Labcon, Johannesburg). Once the temperature of the urine had equilibrated, an aliquot 
of 10% (v/v) Na2Ox corresponding to 30 mmol/L above the MSL, was added to induce 
crystallization.  
 
After a 2 hour incubation period, the total volume of the particles precipitated and mean particle 
size were determined using a Coulter Multisizer II (Coulter Electronics Ltd., England). Graphs 
of particle volume vs particle size were plotted. The mode of the curve, determined using 
Software R (Azzalini and Capitanio 1999), is a representation of the average size of precipitated 
particles, whereas the total volume is calculated by integration of the curve. A typical volume vs 
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2.6 Scanning electron microscopy (SEM) 
 
Urine samples were prepared as described in the CaOx particle size-volume experiment. After 
the 2 hour incubation period, 2 mL of the dosed urine was filtered (0.22 μm) and the filter paper 
was dried at room temperature. Once dried, the filter paper was mounted on aluminium stubs 
using Sticky Tabs (ProSciTech, Thailand). Crystals were viewed using a Leica S440 scanning 
electron microscope (Leica Cambridge Ltd., England) operating at an accelerating voltage of 10 
kV, a working distance of 10-15 mm and a probe current of 20-30 pA. The magnification at 
which stubs were viewed varied for different studies. However micrographs for a particular 




C-oxalate deposition kinetics 
 
There are known limitations of the Coulter Counter in determining the volume of particles i.e. 
the inability to recognize crystal aggregates and to measure crystal sizes outside a specific range. 
Therefore, to determine particle-volume as an accurate reflection of an increase in crystal mass, 
14
C-oxalate was used in experiments where a decrease in soluble radioactivity correlates to 
precipitation of CaOx (Ryall et al. 1995).   
 
The method described by Ryall et al. 1995 was used for this experiment. Urine (30 mL) was 
pipetted into soda-lime flasks (to prevent crystals from sticking to the sides) and incubated in a 
shaking water bath (100 rpm) at 37 ˚C. At equilibrium, 3.125 μCi 
14
C-oxalic acid (NEN, Boston, 
USA) per 100 mL of urine was added. Crystallization was then induced by the addition of Na2Ox 
(10 % v/v) at a concentration of 30 mmol/L above the previously determined MSL and the total 
incubation time was 120 minutes. At 30 minutes intervals, starting with the first reading at 0 
minutes, a 2.5 mL aliquot was removed and filtered into concentrated hydrochloric acid (10 % 
v/v) in order to quench the reaction so that no further crystallization could occur. 1 mL of this 
acidified urine was added to two aliquots of 10 mL scintillation fluid (Zinsser Analytic, 
Frankfurt). 
14
C was counted using a scintillation counter (Beckmann LS 5000TD Scintillation 















The percentage of precipitated 
14
C-oxalate was determined using the following equation (Doyle 




Graphs of percentage precipitated 
14
C-oxalate were then plotted as a function of time. The 
following experimental systems were investigated: (1) filtered human urine, and (2) filtered 
human urine dosed with plant extracts. The activity of the plant extracts in filtered human urine 
were monitored by comparison with the control (undosed filtered human urine). 
 
 
2.8 Crystallization experiments 
 
2.8.1 Preparation and characterization of COM crystals 
 
Pure COM crystals were prepared for the crystal growth kinetics assay (section 2.8.3). The 
method described by Pak et al. (1975) was followed. Using two line feeds, equal volumes of 
0.010 M NaOx and 0.010 M CaCl2 were mixed at a constant rate of 1 mL/min using a peristaltic 
pump with stirring. The mixture was allowed to stir for 7 days at 4 ˚C after which the crystals 
were collected by filtration (0.22 μm). The crystals were dried in an oven at 37 ˚C for 
approximately 1 hour. X-ray powder diffraction (XRD) analysis, described below, was used to 
confirm the presence of COM.  
 
X-Ray powder diffraction 
The x-ray powder diffraction pattern was determined using a Phillips PW1050/25 goniometer 
with a nickel filtered Cu-K α radiation source (λ = 1.5418 Å) produced at 40 kV and 25 mA. The 
crystals were ground with a mortar and pestle to produce a homogenous powder of constant 
particle size. The sample was placed in an aluminium holder. The intensity of the reflected x-
rays as a function of the Bragg angle (2θ) was recorded between 12-40˚ for each sample. The x-
ray diffraction pattern obtained for CaOx crystals is shown in Figure 2.3. The angles 
corresponding to the maximum peaks of the scan were converted to their equivalent d-spacings 
% of precipitated 
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using a standard table for Cu-K α radiation based on the Bragg Equation (Parrish and Mack 
1963). These d-spacings were then compared with standard reference values for COM crystals 












Figure 2.3:  XRD pattern of CaOx crystals prepared by the method of Pak et al. (1975) 
 
 
















Standard values for COM Present study 
d-spacing (Å) Relative intensity d-spacing (Å) 
5.93 100 5.98 
5.79 25  
4.64 7  
4.52 6  
3.78   
3.76 13  
3.65 100 3.67 
3.00 10  
2.97 46 2.98 
2.91 12 2.96 
2.89 10  
2.84 14 2.83 
2.51 2  
2.48 30 2.49 
2.41 5  
2.37 2  
























2.8.2 Simultaneous measurement of CaOx crystal nucleation and aggregation kinetics 
 
The spectroscopic method developed by Hess et al. (1995) was used to simultaneously determine 
the inhibition kinetics of CaOx nucleation and aggregation. This simple batch (discontinuous) 
system is widely used in crystallization research. It involves the mixing of two solutions 
(calcium and oxalate) which when combined produce a metastable supersaturated solution of 
CaOx. Once crystallization is induced, supersaturation will reduce as calcium and oxalate are 
removed from the solution. The decay of supersaturation or change in turbidity is followed 
continuously.  
 
A graph of absorbance vs time is plotted and the gradient of this graph represents an increase in 
the rate of particle number i.e. crystal nucleation. When equilibrium (saturation) is reached, 
crystals can neither nucleate nor grow. A progressive decrease in turbidity is observed reflecting 
the rate of decrease in particle number due to aggregation then occurs (Hess et al. 1995, Hess 
and Kok 1996).  
 
Stock solutions of 8.5 mmol/L calcium chloride (CaCl2) (containing 200 mmol/L sodium 
chloride and 10 mmol/L sodium acetate) and 1.0 mmol/L Na2Ox (containing 200 mmol/L 
sodium chloride and 10 mmol/L sodium acetate), were prepared. The pH was adjusted to 5.7 and 
the solutions were filtered through a 0.22 μm membrane.  
 
The stock solutions of CaCl2 and Na2Ox were allowed to equilibrate to 37 ˚C in a shaking water 
bath at 100 rpm (Labcon, Johannesburg). To a glass cuvette, 1 mL CaCl2 solution was added, 
and placed in a spectrometer (Specord 40, Analytikjena, Germany). Thereafter, 1 mL Na2Ox was 
added give final assay concentrations of 4.25 mmol/L calcium and 0.5 mmol/L oxalate. The 
temperature in the cuvette was maintained at 37 ˚C and stirred at 500 rpm (Analytikjena, 
Germany) throughout the experiment. The absorbance at 620 nm was measured every 0.5 second 
for 60 minutes. The maximum increasing slope of OD620nm vs time is measure of crystal 
nucleation kinetics, termed SN. Once equilibrium was achieved, the decrease in the slope of 
OD620nm vs time represents crystal aggregation kinetics, termed SA. A typical nucleation plot is 

































The following experimental systems were investigated: (1) SU, (2) SU dosed with plant extracts, 
(3) filtered human urine, and (4) filtered human urine dosed with plant extracts.   
 
Percentage inhibition of nucleation and aggregation were calculated using the following 



















Figure 2.4:  A typical plot of absorbance vs. time for the simultaneous determination of CaOx nucleation 
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SA: Aggregation slope 
percentage inhibition of nucleation (% IN) = 100(1 – Ts/Tc) 
 
percentage inhibition of aggregation (% IA) = 100(1 – Ts/Tc) 
 
SN: Nucleation slope 















2.8.3 CaOx crystal growth kinetics 
 
Crystal growth kinetics were determined according to the method adapted by Webber et al. 
(2007). This is an example of a seeded batch system and is performed by setting up a metastable 
saturated solution and introducing seed crystals which then grow. When equilibrium is reached, 
crystal growth will be represented by the kinetics of supersaturation decay and in this case, by 
the change in turbidity.  
 
A seed crystal slurry was prepared by suspending COM crystals (prepared as described 
previously) in Tris buffer at a concentration of 16 mg/mL. The slurry was allowed to equilibrate 
overnight with fast stirring. Tris buffer was prepared by mixing 10 mM Tris-(hydroxymethyl)-
aminomethane with 90 mM NaCl. The pH of the solution was adjusted to 7.2 and the buffer was 
filtered (0.22 μm) prior to use. 
 
A metastable solution of CaOx, consisting of CaCl2 (0.5 mM) and Na2Ox (0.5 mM), was made 
up in Tris buffer. The metastable CaOx solution was maintained at room temperature with fast 
stirring. Care was taken to ensure that the solution did not turn cloudy while being stirred during 
the experimental period. In cases where cloudiness appeared, fresh solutions were made up. A 2 
mL aliquot of the metastable CaOx solution was transferred to a quartz cuvette and placed in a 
spectrophotometer (Specord 40, Analytikjena, Germany) and stirred at 500 rpm (Analytikjena, 
Germany). The crystal seed slurry (50 μL) was added to induce growth. OD214nm was recorded 
every second for a period of 15 minutes.  
 
The following experimental systems were investigated: (1) SU, (2) SU dosed with plant extracts, 
(3) filtered human urine, and (4) filtered human urine dosed with plant extracts.  
 
For experiments in SU, the ratio used was, 1600 μL metastable CaOx solution: 400 μL urine 
(SU): 50 μL COM slurry. For real urine samples, the ratio used in order to get detectable crystals 
was 1990 μL metastable CaOx solution: 10 μL urine (SU): 50 μL COM slurry (Hess et al. 1989). 






























vs time (seconds) and calculating the slope of the linear decreasing region and using the formula 
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Inhibition of growth (IG) = [(AC – AT)/AC] x 100 
 
AC = Δabsorbance/Δtime (of the control) 















2.9 Mixed suspension mixed product removal (MSMPR) crystallizer 
 
Renal stone formation is a result of a series of crystallization processes which occur within the 
kidney. A continuous flow of supersaturated urine passes through the renal system. In 
nephrolithiasis research, the MSMPR crystallizer is used to model the continuous flow system of 
the kidney. All experiments were carried out at 37 ºC in a constant temperature chamber, and 
therefore can be considered a biological analog of the renal system (Miller et al. 1977, Nishio et 
al. 1991, Kavanagh 1992, Bretherton and Rodgers 1998).  
 
A simple schematic of the MSMPR system is shown in Figure 2.6. It consists of a peristaltic 
pump (Watson Marlow, 205U) that was used to control the flows of the feed and effluent 
streams. The temperature was maintained constant by circulating thermostatic water through the 
corresponding external water bath of the MSMPR chambers.  
 
In order to induce crystallization in the MSMPR, the following solutions were continuously fed 
through the system: SU, 150 mM calcium chloride (CaCl2) and 30 mM sodium oxalate 
(Na2C2O4). The SU, with ion components corresponding to urine in the distal part of the 
collecting duct, was prepared according to Walton et al. as described in section 2.2. A constant 
volume of 20 mL was maintained in the MSMPR chamber. This was achieved by feeding the 
system with SU at a flow rate of 2.3 mL/minute and CaCl2 and Na2C2O4 at flow rates of 0.1 
mL/min. The effluent stream rate was 2.5 mL/min which equalled the feed rate (2.3 mL/min + 
0.1 mL/min + 0.1 mL/min). The composition of the feed stream was 92 % AU, 4 % CaCl2 and 4 














Figure 2.6: A schematic of the MSMPR system based on the design of the crystallizer used in this 
experiment 
 
Calcium oxalate crystallization kinetics were measured after the crystallizer had been allowed to 
run 6-8 residence times (volume/flow rate) and had achieved steady state (dynamic equilibrium) 
(Rodgers and Garside 1981). Prior to steady state, the effluent from the MSMPR chamber was 
diverted to a waste tank. Two assumptions are made in this system namely that all crystals grow 
at the same rate and that aggregation occurs at a negligible rate. At steady state, CaOx crystals 
were taken from the product stream and the number of particles and particle size distribution 
































































At steady state, the crystal size distribution in the MSMPR crystallizer can be represented by the 





        n = population density at steady state,  
 L = crystal size (μm),  





 G = growth rate (μm.min
-1
),  
τ = mean residence time (minute) 
 




The residence time (τ) which is the average time that crystals remain in the crystallizer, can be 
represented as:  
 
 
where V = volume of the chamber and Q = total flow rate.  
 
By rearranging equation 2: Ln (n) = – L/Gτ + Ln (B0τ), it can be represented in the form:            
y = mx + c. Therefore plotting the graph of Ln n (the number of crystals) vs. L (the crystal size) 
can facilitate the calculation of the growth rate (G) and nucleation rate (B0). The growth rate (G) 
can be derived from the slope and nucleation rate (B0) from the y-intercept. The y-intercept = Ln 
(B0τ), therefore B0 = anti Ln (τ). The slope = -1/ Gτ, therefore G = -1/slope τ. An example of a 
graph of Ln n vs. L is shown in Figure 2.7.  
 
              n = B0τ e
 (- L/Gτ) 
   (1) 
 
                  Ln (n) = Ln (B0τ) – L/(Gτ)  (2) 
 

































Figure 2.7:  A typical plot of Ln of number of particles vs. particle size for the determination of 
nucleation (B0) and growth (G) rates 
 
Using the growth and nucleation rates, it is possible to calculate suspension density (Mτ, in 
mg.L
-1








Studying crystallization using the MSMPR system has advantages over other methods of 
measurements, as nucleation and growth rates are measured at the same time but independently 
of each other. It models the renal environment better than other crystallization techniques 
because it reaches steady state with a constant supersaturation and operates with a continuous 
flow. This allows individual crystals to transit the system quickly which is similar to the kidney 
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2.10 Bonn risk index (BRI) 
 
The BRI is an experimentally determined ratio of the concentration of free ionized calcium 
(mmol/L) to the concentration of ammonium oxalate (mol/100 mL) required to induce 
spontaneous crystallization of CaOx in the urine under study.  It can be used as a diagnostic 





Urine samples with a BRI value < 1 are not at risk for kidney stone formation whereas BRI 
values > 1 indicate risk (Laube et al. 2004). 
 
The initial concentration of free calcium in urine was determined by an ion selective electrode 
(Photometer, Metrohm, Swiss). Crystallization propensity was monitored in a 200 mL aliquot of 
urine by the step-wise addition of 0.4 M ammonium oxalate (0.5 mL per step and 1.5 ml/min). 
During the experiment, urine samples were maintained at 37 ᵒC and continuously agitated. The 
onset of crystallization was detected in situ by a laser-probe crystal system analyzer (Basic 
Titrino, Metrohm, Swiss). This device determines the number of suspended particles in vitro and 
simultaneously estimates particle size in the detection range of 0.5-250 µm. The onset of 
crystallization is accompanied by a dramatic change in particle-size distribution, and therefore 
can be easily determined (Laube et al. 2000, Laube et al. 2004).  
 
2.11 Urinary relative supersaturations  
 
The urinary relative supersaturations (RS) of CaOx, brushite and uric acid were calculated using 
a modified version of EQUIL 2 by J. Asplin (Litholink, Chicago, USA) (Werness et al. 1985), a 
speciation programme which computes the equilibrium concentrations of complexes of primary 
cations and anions present in urine.  Data from urine composition analysis were statistically 
analyzed by Instat and the results were reported statistically significant if p ≤ 0.05. Average 
values were calculated and are reported with their standard error (SE).  
[Ca
2+
]               free ionized calcium (mmol/L) 
          ------------    =    ------------------------------------------------------------ 
[Ox
2-















2.12 Tiselius risk index (TRI)  
 
The TRI is a ratio that indicates the biochemical risk of CaOx formation (Tiselius 1982). It is a 






where Ca, Ox, Mg and Cit are the urinary concentrations (mmol/24 hour) of calcium, oxalate, 
magnesium and citrate respectively. Cr is the urinary concentration (mol/24 hour) of creatinine. 
Typical values for normal urine lie in the range of 366 ± 14 while stone-formers’ urine lie in the 
range 527 ± 17 (Tiselius 1982). However, this index is used more appropriately on a relative 











































The effect of Folium pyrrosiae, Desmodium styracifolium, Hylocerus trigonus, Phyllanthus 
niruri, Orthosiphon stamineus and Cystone® on calcium oxalate crystallization in synthetic 
urine and real urine from black and white South African males 
 
3.1 Introduction  
 
In vitro CaOx crystallization experiments are of fundamental importance to urolithiasis research 
as the assessment of crystallization propensity in urine is considered an evaluation of risk (Hess 
et al. 2001). Different methods (either quantitative or qualitative) have been developed to imitate 
components of the renal system or aspects of the crystallization processes such as nucleation, 
aggregation and growth (Kavanagh 2006). Successful experiments are designed by matching the 
objective to the procedure (Hess et al. 1996). Experiments vary and are limited to the degree to 
which they mimic physiological conditions e.g. simple experiments performed in inorganic 
aqueous media to experiments carried out in real human urine which model features of urine 
flow dynamics (Kavanagh 1992, Hess et al. 2001).   
 
As stated previously, crystallization is the process which drives the phase change from solution 
to solid. This process is governed by supersaturation i.e. a measure of the chemical potential 
between the 2 phases which directs all aspects of crystallization (Finlayson 1978, Hess and Kok 
1996). As a reaction approaches equilibrium, the supersaturation decreases which impacts kinetic 
behaviour (Kavanagh 2006). Stone formation has been described as a result of an imbalance 
between 2 opposing influences i.e. urinary supersaturation and urinary inhibitors (Robertson et 
al. 1978a).  
 
Human urine is a complex medium containing ions and macromolecules that can bind or 
complex with calcium and oxalate thereby modulating crystallization (Kok 1997, Hess et al. 
2001). Therefore urinary saturation not only depends on calcium and oxalate but also on the 
presence of ions such as citrate and magnesium, as well as macromolecules such as 
glycoaminoglycans (Hess et al. 2001, Khan 2006). 
 














3.2 Materials and methods  
 
3.2.1 Preparation of plant extract stock solutions 
 
Separate stock solutions (50 mL) of each herb were prepared by dissolving the dried powdered 
material in distilled water at 20 times the recommended dosage concentrations and used to dose 
urines at 5% (v/v) in order to achieve concentrations used in other studies or as recommended by 
the manufacturer. Folium pyrrosiae and Desmodium styracifolium were prepared at a 
concentration of 1.5 g/25 mL (Gohel et al. 2006). Hylocerus trigonus was prepared at a 
concentration of 20 g/25 mL (directions from supplier). Phyllanthus niruri was prepared at a 
concentration of 3.75 g/25 mL (Freitas et al. 2002) and Orthosiphon stamineus at a concentration 
of 2.5 g/25 mL (Arafat et al. 2008). Cystone® was prepared by dissolving 2 tablets in 25 mL 
distilled water (directions from supplier). 
 
Only water extracts of the plant material were investigated. Experiments were performed in 
aqueous media. As such, organic extracts would have been insoluble. The plant material was 
weighed into conical flasks into which distilled water was added. Gentle heating with stirring 
(Labcon, Johannesburg) for 30 minutes was applied to facilitate decoction/dissolution. All stock 
solutions were microfiltered (0.22 μm) to remove insoluble material and stored in the refrigerator 
(7 ˚C) for up to 4 days.  
 
3.2.2 Study design 
 
Synthetic urine study 
SU for this study was prepared as described in chapter 2.2. Experiments were carried out in SU 
alone, which served as a control, and SU dosed with the plant stock solution (5% (v/v)). The 
CaOx MSL and PSD of each urine were measured and crystals were examined by SEM.  
 
Crystallization and inhibition kinetics were monitored by determining rates of nucleation, 
aggregation and growth of CaOx crystals are described in chapter 2. Data were statistically 














Real urine study  
Twenty-four hour urine samples were collected in plastic bottles from participants; exclusion 
criteria and details on how urine was processed are provided in chapter 2.3.  
 
Investigation of the inhibitory properties of Folium pyrrosiae and Desmodium styracifolium on 
CaOx crystallization were performed using individual urine samples from black (n=7) and white 
(n=7) subjects. Crystallization parameters were measured in each urine sample and average 
values were determined.  
 
Pooled urines from healthy black and white subjects were used to investigate the inhibitory 
properties of Phyllanthus niruri, Orthosiphon stamineus and Cystone® on CaOx crystallization. 
This change in study design, i.e. individual to pooled urines, was implemented to eliminate intra-
racial urinary differences (such as urine chemistry and crystallization parameters) which were 
detected when analyzing individual urine samples. Each pooled urine per race group was 
constituted up by taking equal volumes (200 mL) of 24 hour urine sample from 5 subjects. Two 
urine pools were constituted for each race group whereby the same 5 subjects of each race group 
provided 24 hour urine samples on 2 occasions (black pooled urines: BUP1 and BUP2; white 
pooled urines: WUP1 and WUP2). Crystallization experiments were carried out on all 4 pooled 
urines. Data are reported separately. Hylocerus trigonus was excluded from the real urine studies 
due to solubility difficulties with the plant material at the required concentrations. 
 
Experiments were carried out in urine alone, which served as a control, and urine dosed with the 
plant stock solution (5% (v/v)). Due to kinetic experiments being performed on different days the 
control values differed, therefore relative comparisons were made, meaning that an experimental 
value was compared with the control measured on that particular day. Raw data and plots of all 
experiments are presented in Appendix 1.   
 
The CaOx MSL and PSD of each urine were measured and crystals were examined by SEM. 
Crystallization was monitored by determining rates and inhibition of nucleation, aggregation and 
growth of CaOx crystals. Crystal deposition rate and BRI were measured in urine samples. These 














Experiments were repeated a minimum of three times; average values and standard error (SE) are 
reported. Error bars have been omitted from graphs for the sake of clarity. Data were statistically 
analyzed by Graphpad Instat and p<0.05 were regarded as significant. The following symbols 
were used to denote p<0.05: 
 
 * when comparing control (urine) versus experimental (urine dosed with plant extract) and 
















3.3.1 Results of crystallization studies in synthetic urine  
 
CaOx MSL 
The mean MSL of undosed SU and SU dosed with Folium pyrrosiae, Desmodium styracifolium, 
Hylocerus trigonus, Phyllanthus niruri, Orthosiphon stamineus and Cystone® are presented in 
Table 3.1. No statistically significant changes to the MSL were detected in the presence of the 
plant extracts (PE).  
 










The mean particle size of CaOx in undosed SU and SU dosed with plant extracts are presented in 
Table 3.2. Desmodium styracifolium, Orthosiphon stamineus and Cystone® caused a decrease 
(p<0.05) in average particle size.  
 










MSL of CaOx  
(µmol/l) 
SU SU + PE 
Folium pyrrosiae 105 (0) 
 
120 (0) 
Desmodium styracifolium 120 (0) 
Hylocerus trigonus 98 (2.58) 125 (0) 
Phyllanthus niruri 75 (0) 
 
75 (0) 
Orthosiphon stamineus 105 (0) 




Particle size mode 
(µm) 
SU SU + PE 
Folium pyrrosiae 15.7 (0.53) 
 
12.7 (0.70) 
Desmodium styracifolium 12.3 (0.24) *  
Hylocerus trigonus 18.5 (1.03)  
Phyllanthus niruri 11.5 (0.38) 11.6 (0.67)  
Orthosiphon stamineus  9.20 (0.60) * 
Cystone®   7.95 (0.22) * 















Scanning electron micrographs were captured of CaOx crystals deposited in SU in the presence 
and absence of all plant extracts. Only those with apparent differences to undosed SU are 
presented in Figure 3.1. The total surface-area of each stub was examined and micrographs were 
recorded of typical deposits with respect to crystal size and morphology.  
 
In SU alone (Figure 3.1a), mostly COM crystals are observed and some aggregates. In SU dosed 
with Folium pyrrosiae, larger crystals are observed than in undosed SU. Aggregates and smaller 
COM crystals are precipitated in the presence of Folium pyrrosiae (Figure 3.1b) and Desmodium 
styracifolium (Figure 3.1c). In the presence of Hylocerus trigonus (Figure 3.1d), an increase in 
nucleation is depicted by the large number of COM crystals observed and a decrease in crystal 
size was also noted. The most noteworthy change was induced by Phyllanthus niruri where 
mostly COD crystals precipitated in its presence (Figure 3.1e). No characteristic changes were 




























































Figure 3.1: Electron micrographs of CaOx crystals deposited in SU alone and SU dosed with Folium 
pyrrosiae, Desmodium styracifolium, Hylocerus trigonus and Phyllanthus niruri. Micrographs are at 5000 
x magnification unless otherwise stated 
  a: SU  (x 2000)                                      b: SU and Folium pyrrosiae                                                   
 
 
c: SU and Desmodium styracifolium                          d: SU and Hylocerus trigonus (x 10 000) 
 
 


















% Inhibition of  
GROWTH 
  SU SU + PE 
Folium pyrrosiae 35.1 (2.7) 
 
31.8 (4.2) 
Desmodium styracifolium 56.1 (3.8) * 
Hylocerus trigonus 43.4 (12.0) 46.1 (12.6) 
Phyllanthus niruri -56.9 (67.2) 23.5 (33.9) * 
Orthosiphon stamineus 15.2 (36.6) * 




%  Inhibition of 
NUCLEATION 
%  Inhibition of 
AGGREGATION 
SU SU + PE SU SU + PE 
Folium pyrrosiae 31.8 (21.2) 40.8 (18.5) -37.6 (9.82) -37.3 (14.6) 
Desmodium styracifolium 38.9 (19.1) -23.7 (7.17) 
Hylocerus trigonus 22.9 (15.2) 22.1 (14.0) -34.8 (4.38) -12.9 (5.8) * 
Phyllanthus niruri 23.9 (39.5) 41.3 (30.4) -32.3 (2.67) 3.01 (1.94) 
Orthosiphon stamineus 19.3 (29.4) 23.7 (36.6) * 
Cystone® -35.5 (46.1) * -71.0 (3.29) 
 
Simultaneous measurement of CaOx crystal nucleation and aggregation kinetics 
The percentage inhibitions of CaOx crystal nucleation and aggregation in the presence and 
absence of plant extracts are presented in Table 3.3. A negative percentage indicates promotion. 
The general trend noted is that SU inhibits nucleation and promotes aggregation. Of all the plant 
extracts, only Cystone® induced a statistically significant increase in the promotion of nucleation 
(p<0.05). With respect to crystal aggregation, the presence of Hylocerus trigonus and 
Orthosiphon stamineus caused a decrease in the inhibition this mechanism (p<0.05).  
 
Table 3.3: Percentage inhibitions (SE) of CaOx nucleation and aggregation in SU in the presence and 
absence of plant extracts  
 
CaOx crystal growth kinetics 
The percentage inhibition of CaOx crystal growth in the presence and absence of plant extracts 
are presented in Table 3.4; a negative percentage indicates promotion. Desmodium styracifolium, 
Phyllanthus niruri, Orthosiphon stamineus and Cystone® induced statistically significant 
increases in the inhibition of growth of CaOx crystals in SU (p<0.05). 
 
























Measurement of CaOx crystal nucleation and growth rates by the MSMPR crystallizer 
Nucleation and growth rates of CaOx crystals which were measured by means of an MSMPR 
crystallizer are presented in Figures 3.2 and 3.3 respectively. Phyllanthus niruri, Orthosiphon 
stamineus and Cystone® caused statistically significant increases in the rate of nucleation 





























Figure 3.3: Rate of CaOx growth in SU in the presence and absence of the plant extracts 
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3.2.2 Results of crystallization studies in real urine  
 
Data for the inhibitory studies of Folium pyrrosiae and Desmodium styracifolium on CaOx 
crystallization are reported as the mean values (n=7) obtained from the analysis of 24 hour urine 
obtained from healthy black (BU) and white (WU) subjects. Inhibitory activity of Phyllanthus 
niruri, Orthosiphon stamineus and Cystone® on CaOx crystallization was determined on pooled 
urines. As mentioned previously, two urine pools were constituted for each race group and data 
are reported separately. (Black pooled urines: BUP1 and BUP2; White pooled urines: WUP1 
and WUP2).  
 
CaOx MSL 
The mean CaOx MSL of BU and WU are reported in Table 3.5. The presence of the plant 
extracts caused no significant changes. However, the MSL of black urine is significantly higher 
(p<0.05) than that of whites in pooled and individually measured samples.  
 











p<0.05: * when comparing control (urine) versus experimental (urine dosed with plant extract) 
              ‡ ϯ when comparing black and white control urines 
 
  
MSL of CaOx 
 (µmol/l)     




105 (6.6) ‡ 107 (6.9) 
 
71 (12.9) ‡ 64 (7.8)     
Desmodium 
styracifolium 107 (8.3) 62 (6.9)     
  
                              MSL of CaOx 
                                    (µmol/l) 




120 (0) ‡ 115 (0) 
 
75 (0) ϯ 75 (0) 
 
45 (0) ‡ϯ 45 (0) 
 
45 (0 ) ‡ϯ 60 (0) 
Orthosiphon 
stamineus 105 (0) 60 (0) 45 (0) 45 (0) 
 


















The average particle size of CaOx crystals in BU and WU, in the presence and absence of 
Folium pyrrosiae, Desmodium styracifolium, Hylocerus trigonus, Phyllanthus niruri, 
Orthosiphon stamineus and Cystone® are reported in Table 3.6. No significant changes in 
particle size were induced by the plant extracts. There were also no significant differences in the 
average particle size of CaOx crystals precipitated from the urine of the two race groups i.e. in 
undosed BU and WU.  
 











Particle size mode 
 (µm)     
BU  BUP1 + PE WU WUP1 + PE     
Folium pyrrosiae 10.9 (1.6) 10.1 (0.6) 11.6 (0.5) 11.1 (0.5)     
Desmodium styracifolium 10.6 (1.3) 11.7 (0.7)     
  
Particle size mode  
(µm) 
BUP2 BUP2 + PE WUP2 WUP2 + PE     
Phyllanthus niruri 9.3 (1.1) 9.7 (0.8) 10.7 (1.2) 7.4 (0.6)         
Orthosiphon stamineus 7.8 (0.8) 7.7 (0.5)         









































Scanning electron micrographs were recorded of CaOx crystals deposited in SU in the presence 
and absence of all plant extracts. Only those with apparent differences to undosed SU are 
presented. The total surface-area of each stub was examined and micrographs were recorded of 
typical deposits with respect to crystal size and morphology 
 
Figure 3.4 shows the scanning electron micrographs of CaOx crystals deposited in BU and BU 
dosed with Phyllanthus niruri, Orthosiphon stamineus and Cystone®. A large number of crystals 
and mostly COM precipitate in the BU control (Figure 3.4a). In the presence of these plant 
extracts, a large number of crystals of seemingly smaller size are observed. Upon the addition of 
Phyllanthus niruri more COD crystals are detected (Figure 3.4b).  
  
 

























  a: WU 5000X                            b: WU  
 
 
           
 c: WU and Orthosiphon stamineus                              d: WU and Cystone® 
 
    
   
Figure 3.5a and b shows the scanning electron micrographs of CaOx crystals deposited in WU.  
Fewer but seemingly larger crystals precipitate in WU compared to BU and a mixture of COM 
and COD are observed. In the presence of Orthosiphon stamineus (Figure 3.5c) and Cystone 
(Figure 3.5d), only COD crystals can be viewed which are smaller than those in undosed WU.  
 
 


















Figure 3.5: Electron micrographs of CaOx crystals deposited in WU. Micrographs are at 10 000X 
















Simultaneous measurement of CaOx crystal nucleation and aggregation kinetics 
The inhibition of CaOx crystal nucleation and aggregation has been calculated and presented in 
Tables 3.7a and b respectively. Results of the pooled urine studies are reported separately. 
 
Folium pyrrosiae and Desmodium styracifolium showed no effect on crystal nucleation and 
aggregation in either race group.  In BU, the only significant change detected in BUP2 where 
Orthosiphon stamineus induced an increase in the inhibition of aggregation (p<0.05), Table 3.7b. 
In WU, no significant changes were detected in WUP1 however in WUP2 Orthosiphon 
stamineus caused a decrease in the promotion of nucleation (p<0.05) and Cystone® caused a 
decrease in inhibition of aggregation (p<0.05).  
 
Comparison of BU and WU controls shows that inhibition of crystal aggregation is greater WU 
(p<0.05). This result was consistent in both pools.  
  












p<0.05: * when comparing control (urine) versus experimental (urine dosed with plant extract) 






% Inhibition of  
NUCLEATION     




-66.6 (40.9)  -45.5 (37.3) 
 
-2.01 (43.7) 
  13.7 (44.9)     
Desmodium 
styracifolium  -44.8 (39.9)  21.1 (43.5)     
  
                            % Inhibition of  
                           NUCLEATION 




-18.9 (14.3)  -80.2 (31.4) 
 
-9.6 (34.4) 
  18.1 (12.1) 
 
-39.9 (3.3) 
 -41.1 (5.5) 
 
-32.4 (3.3) 
 -7.27 (2.2) 
Orthosiphon 
stamineus  -38.3 (15.7)  4.92 (13.7)  -57.5 (6.8) -17.5 (4.3) * 
 



















Table 3.7b: Percentage inhibitions (SE) of CaOx aggregation in BU and WU in presence and absence of 


















p<0.05: * when comparing control (urine) versus experimental (urine dosed with plant extract) 
              ‡ ϯ when comparing black and white control urines 
  
% Inhibition of  
AGGREGATION     





  -0.79 (46.3) 
 
39.0 (33.5) 
 50.2 (40.2)      
Desmodium 
styracifolium  -31.8 (44.4) 9.98 (37.8)      
  
                             % Inhibition of  
                           AGGREGATION 




-16.8 (0.63) ‡ 
 
 -61.6 (1.3) 
 
17.3 (0.9) ϯ 
 
 
 50.0 (0.4) 
 
41.2 (28.5) ‡ϯ 
 
 
40.9 (0.4)  
 
41.8 (0.4) ‡ϯ 41.7 (0.6)  
Orthosiphon 
stamineus -56.7 (0.8) 65.9 (0.5) * 14.9 (0.3) 24.3 (0.2) 
 





















C]-oxalate deposition experiments 
Precipitated [
14
C]-oxalate as a function of time in BU and WU are presented in Figure 3.6. All 
samples [BU (n=3) & WU (n=3); BUP2 and WUP2] were determined in triplicate and at the end 
of each experiment, the precipitated [
14
C]-oxalate was determined in duplicate using a 
scintillation counter. Hence each data point presented in the respective graphs is the average of 6 
measurements (except for BUP2 + PN where each data point is an average of 2 measurements as 
the other data points were omitted due to experimental error).  
 
The rate of precipitation is represented by the gradient of the linear portion of each curve. In 
undosed BU (Figure 3.6a and b) there is an increase in the precipitation of CaOx overall, 
however initially there is an increasing rate followed by a plateau from 60 – 90 minutes, and then 
a slight increase in the rate again from 90 – 120 minutes. In BU, statistical comparisons of the 
slopes between 0 – 60 minutes showed that the addition of Desmodium styracifolium and 
Orthosiphon stamineus significantly decreased the rate of precipitated CaOx (p<0.05). None of 
the other plant extracts demonstrated any significant effect over the course of the experiment.   
 
In undosed WU (Figure 3.6a and d), there is a continuous increase in the precipitation of CaOx, 
and the rate gradually decreased over the 2 hour period as depicted by the shape of the graph i.e. 
decreasing concavity. In WU, the presence of Phyllanthus niruri induced an increase (p<0.05) in 
the rate of precipitation between 0 – 30 minutes and the presence Cystone® induced an increase 
(p<0.05) in the rate of precipitation between 0 – 60 minutes. No significant effect on CaOx 
precipitation was exhibited by any of the other plant extracts in WU. 
 
Comparison of the BU and WU controls in Figure 3.6 shows that at the end of the experimental 







































Figure 3.6a-d: Rate of [
14
C]-oxalate deposition in individual and pooled BU and WU in the presence and 




Mean BRI values for both race groups are given in Table 3.8. The addition of Folium pyrrosiae 
and Desmodium styracifolium to BU and WU did not cause any significant change in the BRI. It 
is noted that BRI of urine from the black group is lower than that of the white group and in both 
race groups the BRI is less than 1.  
 






BU  BU + PE WU WU + PE 
Folium pyrrosiae 0.553 (0.086) 0.450 (0.050) 0.787 (0.273) 0.706 (0.239) 




































Synthetic urine study 
The value of MSL is a measure of crystallization propensity in a solution. None of the plant 
extracts had an effect on this property. However once crystallization was initiated, the plant 
extracts had an effect on the mechanisms of crystallization. These effects are summarized in 
Table 3.8.  
 
Desmodium styracifolium, Orthosiphon stamineus and Cystone® caused a decrease in the 
average particle-size of CaOx crystals (revealed by the particle size-volume distribution), which 
can arise as a result of inhibition of crystal growth. Only Cystone® triggered a promotion of 
crystal nucleation whereas Hylocerus trigonus and Orthosiphon stamineus induced a decrease in 
crystal aggregation as revealed in the simultaneous nucleation and aggregation assay. An 
increase in nucleation is considered prophylactic as it rapidly reduces supersaturation when 
crystal size is simultaneously reduced (Kavanagh 1992).  
 
Supplementary evidence, to the particle-size data presented above, of the inhibitory effects of 
Desmodium styracifolium, Orthosiphon stamineus and Cystone® on crystal growth was provided 
by the growth assay. This experiment also implicated Phyllanthus niruri as an inhibitor of crystal 
growth.  
 
Results of kinetic studies performed in the MSMPR crystallizer revealed that Phyllanthus niruri, 
Orthosiphon stamineus and Cystone® induced an increase in nucleation rate and all the plant 
extracts under investigation instigated a decrease in crystal growth rate. Some of the plant 
extracts did not exhibit any effect on crystal nucleation and growth when investigated by 
spectroscopic assays but the MSMPR system is considered to be the most credible method of 
measuring in vitro crystallization (Hess et al. 2001). Therefore these are all highly favourable 
outcomes in the context of urolithiasis as each represents a reduced risk of stone formation.  
 
It was observed in scanning electron micrographs that the presence of Phyllanthus niruri in SU 














a lower affinity for adhesion to renal epithelial cells (Wesson et al. 1998) hence minimizing the 
risk of stone formation. In addition, the higher positive charge on COD results in greater 
repulsive forces between crystals and therefore favors disaggregation (Webber et al. 2003). 
Therefore, the formation of COD crystals in the present study is another highly favourable 
outcome.  
 
Real urine study 
Interesting trends have been noted upon comparison of urine collected from the two race groups. 
In both sets of pooled urines (BUP1, BUP2 and WUP1, WUP2), the CaOx MSL was found to be 
higher in black subjects indicating that crystallization is initiated less easily in this race group – a 
finding that is consistent with the rarity of stones in the black population. However, none of the 
plant extracts exhibited an effect on the MSL of urine from either race group. This is not 
uncommon as many other well-established inhibitors have also demonstrated no effect on this 
parameter e.g. citrate (Ryall et al. 1985), urinary glycosaminoglycans e.g. heparin sulphate 
(Suzuki and Ryall 1996) and proteins e.g. Tamm-Horsfall mucoprotein and prothrombin 
fragment 1 (Grover et al. 1994, Grover and Ryall 2002). 
 
The only quantifiable significant effect induced by the plant extracts in white urine was found in 
WUP2 where Orthosiphon stamineus initiated an increase in the inhibition of nucleation (Table 
3.6a). Two changes in crystallization parameters were demonstrated in black urine: Orthosiphon 
stamineus lead to increased inhibition of aggregation and Cystone® resulted in decreased 
inhibition of aggregation.  
 
Another distinction between the urinary responses in black and white subjects is a lower 
inhibition of aggregation in the former group. This finding is counter-intuitive as a lower 
inhibition of aggregation is a risk factor and would make black subjects more susceptible to 
stone formation.  
 
Crystal deposition experiments showed a larger particle volume in undosed WU (which is a 
reflection of crystal aggregation) compared to BU after a 120 minute incubation period. None of 














of deposition as determined by the [
14
C]-deposition experiment.  Desmodium styracifolium and 
Orthosiphon stamineus decreased the rate of CaOx precipitation in BU while Phyllanthus niruri 
and Cystone® induced an increase in the rate of precipitation in WU. A decrease in the rate of 
deposition is favourable as it reduces the risk of stone formation. 
 
A difference is the morphology of urinary CaOx crystals isolated from the two race groups was 
observed by SEM. A mixture of COM and COD is observed in WU whereas almost exclusively 
COM precipitates in BU. The precipitation of COD crystals in WU is likely due to white subjects 
having a higher urinary calcium concentration which as a result favours the formation of these 
crystals (Webber et al. 2002). Fewer but seemingly larger crystals precipitate in WU compared 
to BU which would suggest that the former inhibits nucleation and promotes crystal growth, 
indicating a higher risk of stone formation in that race group. Data from the particle-size 
experiment also showed that the average size of crystals in WU to be non-significantly greater 
than BU. 
 
The addition of Phyllanthus niruri to BU favours the deposition of COD (as was the case in SU). 
The clinical significance of these crystals has been mentioned earlier in this discussion. Crystal 
sizes have decreased in the presence of Orthosiphon stamineus and Cystone®. Scanning electron 
micrographs of undosed WU showed predominance of COD however upon addition of 
Orthosiphon stamineus and Cystone® exclusively COD was viewed. 
 
Although the mechanisms of crystallization i.e. nucleation, aggregation and growth are 
quantified independently in these in vitro studies, under physiological conditions these processes 
cannot be separated (Kavanagh 2006). However obtaining these data was necessary to provide a 
foundation upon which further experiments were planned. 
 
The summarized results in Table 3.8 allow for comparison of the relative strengths of the plant 
extracts. Based on the number of significant inhibitory effects demonstrated, Orthosiphon 
stamineus and Cystone® are the greatest potential inhibitors of CaOx crystallization, followed by 
(in decreasing order of inhibitory action) Hylocerus trigonus, Desmodium styracifolium, 














The in vitro inhibitory activity of Folium pyrrosiae, Desmodium styracifolium and Phyllanthus 
niruri in SU observed in this study is consistent with what has previously been reported 
(Hirayama et al. 1993, Freitas et al. 2002, Barros et al. 2003, Barros et al. 2006, Gohel et al. 
2006). To date, data on the effects of Hylocerus trigonus, Orthosiphon stamineus and Cystone® 
on in vitro CaOx crystallization have not been published. 
 
Fewer effects were observed in crystallization parameters when moving from synthetic to real 
urine suggesting caution when extrapolating these results to physiological conditions. However 
Orthosiphon stamineus and Cystone® again demonstrated the strongest inhibitory action in real 
urine. Different physico-chemical responses were induced by the plant extracts in urines from the 
two South African population groups (evident in Table 3.8) indicating that urine chemistries in 
the two groups elicit different reactions. This confirms what has been reported previously in the 
literature (mentioned in section 1.5). 
 
However a promising result of the activity of the plant extracts, which was demonstrated in both 
real and synthetic urine, is their ability to favour the crystallization of COD crystals (over COM). 
These crystals are well-known for decreased binding affinity to renal epithelial cells. Therefore 
studies on crystal-cell binding, testing the effect of the plant extracts were warranted. 
Additionally, in view of the empirically observed differences in the crystallization processes in 
the urines from black and white subjects, the aforementioned study involving crystal binding 






















The effect of traditional herbs: Folium pyrrosiae, Desmodium styracifolium, Hylocerus 
trigonus, Phyllanthus niruri, Orthosiphon stamineus and Cystone on calcium oxalate crystal 
binding to MDCK-I cells 
 
4.1     Introduction 
 
The study of intracellular crystals and crystal-cell binding in vivo is limited. Histological 
examination of renal tissue from stone patients is challenging as calcium deposits upset cellular 
architecture (Lieske et al. 1996a), therefore cultured renal epithelial cell lines have become a 
powerful tool in investigating the mechanisms of crystal-cell binding (Hackett et al. 1994, Lieske 
et al. 1994, Goswami et al. 1995, Verkoelen et al. 1995, Lee et al. 1996, Verkoelen et al. 1999, 
Rabinovich et al. 2006).  
 
Cultured epithelial cells fall into three categories namely primary, secondary and continuous cell 
cultures. Primary cell cultures are derived directly from the tissue under investigation. Secondary 
or ‘semi-continuous’ cell cultures can grow and divide for a limited time in culture, whereas 
continuous or ‘immortalized’ cell cultures can grow indefinitely in culture (Price et al. 1994, 
Bigelow et al. 1998).   
 
Previous studies have shown that immortalization of a cell line can induce changes in cell 
morphology and gene expression (Brezden and Rauth 1994, Verkoelen et al. 1997). There is also 
variation in COM crystal binding affinity for the different cell lines (Bigelow et al. 1998, 
Verkoelen et al. 1999). COM crystals show the greatest binding affinity for continuous Madin-
Darby canine kidney (MDCK) type I cells. In addition, there is no significant change in the 
crystal-cell binding after their continuous culture for 9 days (Bigelow et al. 1998). The advantage 
of semi-continuous and continuous cell lines over primary cell lines is that they are convenient to 
work with and they can be stored frozen and additional experiments can be carried out later with 
the same material (Verkoelen et al. 1997). Therefore MDCK-I cells are considered suitable for 
investigating the mechanisms of crystal-cell binding (also referred to as attachment) and various 
studies have been reported (for example: Lee et al. 1996, Thamiselvan et al. 2000, Schepers et 














As mentioned in Chapter 1, the pathogenesis of renal stones involves the combination of two 
processes, namely nucleation of crystals and their retention within the kidney which allows for 
further growth and/or aggregation to occur. Urine in the distal region of the nephron is 
supersaturated with calcium and oxalate ions and spontaneous nucleation of crystals follows 
(Finlayson et al. 1978a, Verkoelen et al. 1997, Kumar et al. 2003, Grover et al. 2008).  
 
The ‘free particle’ and ‘fixed particle’ theories have been proposed to explain stone formation 
within the renal system. Although both theories are credible, this thesis supports the fixed 
particle mechanism (Finlayson et al. 1978a, Fleisch 1978, Hess and Kok 1996). Previously 
reported rates of urine flow and crystal growth indicate that it is not possible for a single crystal 
(i.e. ‘free’ particle) to grow large enough to obstruct the flow of urine through the nephron (Kok 
et al. 1986, Kok et al. 1990a, Kok and Khan 1994). Therefore crystals require an attachment site 
within the kidney (Finlayson et al. 1978a, Coe and Parks 1988, Kumar et al. 2003, Tiselius 
2011). Studies have shown that COM crystals can bind irreversibly to the surface of renal 
epithelial cells and this is considered to be a critical process in the growth of renal calculi 
(Finlayson et al. 1978a, Lieske et al. 1992a, Lieske et al. 1992b, Ebisuno et al. 1995, Verkoelen 
et al. 1996, Verkoelen et al. 2000). The latter finding prompted a series of investigations into 
factors affecting the interaction between COM crystals and renal epithelial cells and the 
following has been reported.  
 
The most prominent morphology of CaOx that occurs in human stones is COM. These crystals 
are highly membranolytic and irreversibly bind to renal epithelial cells (Lieske et al. 1999). 
Binding occurs very rapidly, is concentration dependent and is significantly greater than that of 
other calcium-containing crystals (Lieske et al. 1999, Lieske and Toback 2000, Grover et al. 
2008). Furthermore it has been reported that following cell binding, CaOx crystals undergo 
internalization and subsequent dissolution (Lieske et al. 1999).  
 
Once crystals attach to the surface of cells, some are taken up by the cells (Lieske and Toback 
1993, Lieske et al. 1994, Verkoelen et al. 1995). The fate of the endocytosed crystals has not 
been established with certainty. It has been hypothesized that this could represent the initial 














represent a protective mechanism to remove potential growth sites from the cell surface (Lieske 
et al. 1992b, Lieske and Toback 1993). Ultrastructural studies of MCDK cells revealed that 
initially endocytosed crystals had disappeared within 72 hours and it has been suggested that 
crystals undergo dissolution intracellularly due to the presence of lysosomes (Goswami et al. 
1995). In studies of hyperoxaluric patients, CaOx crystals were found in tubular lumen as well as 
in the renal interstitium which could be a result of translocation of luminal crystals to the 
interstitial space (Morgenroth et al. 1968, Saxon et al. 1974, Wharton et al. 1990, Lieske et al. 
1992a, Tiselius 2011). However these processes of dissolution and translocation take extended 
periods to occur (hours up to days) (Lieske and Toback 1993, Lieske et al. 1994) whereas their 
binding to cellular surfaces has been shown to occur within seconds (Lieske et al. 1995).   
 
Crystals adhere to anionic sites on cell surfaces (Bigelow et al. 1998, Grover et al. 2008). This 
process is influenced by many factors pertaining to (1) the cells, (2) the crystals and (3) the 
binding milieu. These are discussed below. The adhesive properties of cells can be affected by 
factors such as cell type, the presence of membrane receptor molecules such as hyaluronan 
(Zimmerman et al. 1999, Asselman et al. 2003) and osteopontin (Asselman et al. 2003, Verhulst 
et al. 2003), cell polarity (Riese et al. 1992, Wiessner et al. 2001) and cellular integrity 
(Wiessner et al. 2001, Asselman et al. 2003, Verhulst et al. 2003), membrane fluidity (Bigelow 
et al. 1997a), the chemical composition and pH of ambient medium (Kasemo and Lausmaa 
1994), cell surface electric charge (Lieske et al. 1996b), phosphatidyl serine groups (Bigelow et 
al. 1997b, Wiessner et al. 2001) and proximity of mineral substance that can alter the 3-
dimensional configuration of a cellular protein (Ghosh et al. 2007).  
 
Furthermore, the conformation of proteins on crystal surfaces is known to influence the binding 
affinity of the latter. For example, the binding of UPTF1 to CaOx depends on the presence of γ-
carboxyglutamic acid residues near its N-terminus (Doyle et al. 1991) whereas binding of 
osteopontin to hydroxyapatite relies on its component glutamic acid and aspartic acid residues 
















Ionic composition of the surrounding medium can alter conformation of proteins and therefore 
their binding potential. For example ambient calcium concentration affects the binding of UPTF1 
to COM (Ryall et al. 2005), osteopontin to COD (Ryall et al. 2005, Thurgood et al. 2008) and 
matrix Gla protein to hydroxyapatite (Roy and Nishimoto 2002) .  
 
Other factors that influence the binding process are: collagen IV, osteopontin and urinary 
proteins containing sialic acid (Lieske et al. 1995, Yasui et al. 2002), whereas urinary anions 
such as glycosaminoglycans (e.g. chondroitin sulphate A and B, heparin sulphate and hyaluronic 
acid), glycoproteins (e.g. bikunin, THF and nephrocalcin) and citrate can oppose the binding of 
crystals to cells (Lieske et al. 1995, Ebisuno et al. 1999a, Kumar et al. 2003).  
 
These aforementioned macromolecules have shown their inhibitory effect by altering the 
macromolecular composition of the binding medium in which crystal attachment is investigated 
(Lieske and Toback 1993, Ebisuno et al. 1999a) or by inducing macromolecular changes to the 
anionic sites on the cell surface (Verkoelen et al. 2000, Yasui et al. 2002). However a crucial 
factor that limits the physiological relevance of these aforementioned studies is the use of 
inorganic COM (iCOM) crystals which differ in size and morphology from urinary CaOx 
(uCaOx) crystals. Furthermore urinary COM crystals contain surface-bound and intracrystalline 
proteins, which iCOM do not, and these proteins affect the adhesion of these crystals (Grover et 
al. 2007, Grover et al. 2009). Another limitation of many reported studies is the use of simple 
aqueous binding media such as PBS, synthetic urine or Tris-HCl, rather than human urine 
(Lieske and Toback 1993, Lieske et al. 1995, Verkoelen et al. 2000, Kumar et al. 2005). Human 
urine is a far more complex medium as it contains proteins and other macromolecules and these 
have been shown to influence crystal-cell adhesion (Grover et al. 2007).  
 
Therefore investigations mimicking physiological conditions are warranted. The aim of this 
investigation was to study and quantify the effect of Folium pyrrosiae, Desmodium 
styracifolium, Hylocerus trigonus, Phyllanthus niruri, Orthosiphon stamineus and Cystone® on 
















4.2.1 Preparation of plant extract stock solutions 
 
Stock solutions of Folium pyrrosiae, Desmodium styracifolium, Hylocerus trigonus, Phyllanthus 
niruri, Orthosiphon stamineus and Cystone were prepared at twice the concentration 
recommended in chapter 3.2.1. These stock solutions were used in two ways: (1) to precoat 
CaOx crystals prior to the binding assay and (2) to precoat MDCK-I cells prior to the binding 
assay. Stock solutions of herbal extracts were prepared at four times the recommended 
concentration in chapter 3 where the plant extract was present in the medium itself during the 
binding assay. The stock solution concentrations were chosen to keep the final concentration of 
plant extracts constant in the respective experiments. These treatment steps will be explained in 
greater detail in section 4.2.6.  
 
4.2.2 Preparation of CaOx crystals 
 
Two types of CaOx crystals were used in this investigation, namely iCOM and uCaOx.  iCOM 
was commercially obtained (Sigma Aldrich, Germany) and its composition was confirmed using 
XRD (data presented in Appendix 2). uCaOx crystals were prepared from individual twenty-four 
hour urines of three groups of South African subjects, i.e. healthy black (n=5) and healthy white 
(n=5) males and white recurrent CaOx male stone formers (n=5). Urines were collected in plastic 
bottles without preservative. Owing to the rarity of renal calculi in the black population, it was 
not possible to recruit black stone formers. Creatinine concentrations were measured in all urine 
samples to ensure their integrity. Urine collections that tested positive for the presence of 
haematuria or nitrites using urinalysis test strips (Boehringer Mannheim, Germany) were 
excluded from this study. Urine was pre-filtered through a 0.75 m filter followed by 0.45 m 
nitrocellulose filter paper before use. 
 
In order to harvest uCaOx crystals, the MSL of each twenty-four urine sample was measured as 
described in chapter 2.3. Thereafter, a 500 mL aliquot was allowed to equilibrate at 37 ˚C in a 














with 5 mL Na2Ox at a concentration of 30 mM above the previously determined MSL at 0 
minutes and again at 1 hour. After a 2 hour incubation period, crystals were filtered (0.22 μm) 
and washed thoroughly with large quantities of distilled water and allowed to dry overnight at 
room temperature. XRD was used to confirm the composition of CaOx.  Crystals from urine of 
each of the three groups were pooled respectively for the crystal binding assay to eliminate intra-
racial differences and provide sufficient material for the respective experiments. 
 
4.2.3 Cell culture  
 
Cells were cultured according to the method described by Lieske et al. (1992b) under sterile 
conditions in a laminar flow hood. The working area of the hood was sterilized using 70% 
ethanol and by exposure to ultra-violet (UV) light for 20 minutes prior to experimental work. 
Solutions required for cell culture work were made up as follows using sterile water (distilled 
water filtered through a 0.22 μm membrane). 
 
PBS (phosphate buffered saline) was prepared by adding 11.5 g Na2HPO4 (sodium hydrogen 
phosphate), 2.28g NaH2PO4 (sodium phosphate) and 43.84 NaCl (sodium chloride). The pH was 
adjusted to 7.5 using 1 M HCl and the volume was made up to 5 L with sterile water. 
 
Trypsin-EDTA (ethylenediaminetetraacetic acid) was constituted from 0.18 g trypsin (0.09%) 
and 0.08 g EDTA (0.5%) in 200 mL PBS. The pH was adjusted to 7.5 using sodium hydroxide 
(NaOH) and filter sterilized (0.22 μm).  
 
HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) solution (1 M) was made up by 
adding 59.58 g of the salt to 250 mL sterile water. The pH was adjusted to 7.5 using 5M NaOH 
and the solution was autoclaved.  
 
Live MDCK-I cells were generously supplied by Dr John Lieske (Department of Medicine, 
Mayo Clinic, Rochester, USA). Cells were grown in Dulbecco-Vogt modified Eagle’s medium 
(DMEM) containing 10% fetal calf serum (FCS), 2% HEPES and 1% penicillin-streptomycin 














given concentrations will be referred to henceforth as 10% DMEM. The culture medium was 
sterilized using a 0.22 μm filter unit (VacuCap 90 PF, Roseville, Michigan, USA) under vacuum. 
 
Upon arrival in the laboratory, the confluent cells were subcultured to prepare stock supplies. 
Medium was aspirated from the T-225 tissue culture flask (Nunclon, Denmark) using a Pasteur 
pipette and 5 mL PBS was added to the flask. The entire surface was rinsed by rocking the 
culture plate gently. PBS was aspirated from the culture plate using a Pasteur pipette and this 
rinsing step was repeated.  A minimum volume (2 – 5 mL) of trypsin-EDTA solution was used to 
cover all of the cells and the flask was placed in a 5% CO2 incubator (United Scientific, Oregon, 
United States) at 37 ˚C. After 5 minutes, it was removed from the incubator and the flask was 
tapped repeatedly underneath to facilitate cell detachment (this was necessary as the cells were 
highly adherent) which was monitored using a light microscope (ID02, Ziess, Germany). The 
detached cells were transferred in the trypsin-EDTA solution into a sterile 15 mL reaction tube 
containing 10% DMEM and centrifuged (Centrifuge, Damon, USA) at 2000 rpm for 5 minutes. 
Thereafter the supernatant was discarded and the cell pellet was resuspended in 1 mL of 10% 
DMEM and vortex-mixed (Vortex-2 Genie, New York). The 1 mL cell suspension was pipetted 
into a vial containing 1 mL dimethyl sulphoxide (DMSO) in 8 mL of 10% DMEM. Aliquots (0.5 
mL) of the DMSO cell suspension were pipetted into 2 mL cryogenic vials and stored in liquid 
nitrogen (- 174˚C) until later use in crystal binding experiments. 
 
To prepare cells for the binding assay, two vials of frozen cells were removed from liquid 
nitrogen and thawed at room temperature. The cells were transferred immediately into a sterile 
15 mL reaction tube containing 1 mL DMEM and centrifuged (Centrifuge, Damon, USA) at 2000 
rpm for 5 minutes. The supernatant was discarded and the cell pellet was resuspended in 1 mL of 
10% DMEM and vortex-mixed (Vortex-2 Genie, New York). This washing step was repeated. 
Thereafter, the cell pellet was resuspended in 1 mL of 10% DMEM. The cell suspension was 
added to a 100 mm sterile plastic culture plate (Nunclon, Denmark) containing 9 mL 10% 
DMEM. The culture plate was swirled gently to distribute cells evenly and the cells were 
allowed to grow at 37 ˚C in a 5% CO2 incubator (Shel Lab, United Scientific, Oregon, United 
States). Cell growth was monitored daily by examination of cell morphology under a light 














differentiation and form junctional complexes, i.e. pack closely together. Fresh 10% DMEM was 
added every 2 – 3 days and confluence was achieved in approximately 5 days. 
 
Once confluent, cells were lifted from a 100 mm plate (as described previously) and split into 
fifteen 35 mm plates each containing 2 mL DMEM constituted from 5% fetal calf serum (FCS), 
2% HEPES and 1% penicillin-streptomycin (BioWhittaker, Walkersville, USA). DMEM 
containing the aforementioned constituents at the given concentrations will be referred 
henceforth to as 5% DMEM. The 35 mm plates were allowed to grow at 37 ˚C in a 5% CO2 
incubator (United Scientific, Oregon, United States) and confluence was usually achieved in 2 
days.  
 
4.2.4 Crystal-cell binding assay 
 
Inorganic and urinary crystals were sonicated (Bandelin Sonorex, Germany) for 30 minutes to 
ensure that the crystalline material contained particles of a uniform size. Crystals were added to 
either sterile water or urine, depending on the experiment, in a 100 mL soda-lime glass flask 
containing a magnetic stirrer bar (3 cm).  This glassware was chosen as it reduces the sticking of 
crystals to the sides of the flask. Crystal slurries were prepared at a concentration of 4.285 
mg/mL and the slurries were allowed to stir overnight at room temperature on a magnetic stirrer 
(VELP Scientifica, Europe) prior to the binding assay. This extended period of stirring ensured 
that all crystals were in suspension so that the concentration of CaOx used for each experiment 
remained uniform.  
 
The following solutions were required for the crystal-cell binding assay were made up as 
follows. 
 
6M HCl (hydrochloric acid) was made up by adding 136 mL concentrated HCl (32%) to 64 mL 
sterile water to give a total volume of 200 mL. 
 
100 mM PMSF (phenylmethanesulfonylfluoride) was made up by dissolving 0.871 g of the 














Triton (polyethylene glycol p-(1,1,3,3-tetramethylbutyl)-phenyl ether) lysis buffer was 
constituted from 29.5 mL sterile water, 2.5 mL 1 M HEPES, 12.5 mL 2M NaCl, 0.5 mL Triton    
X-100 and 0.5 mL 100 mM PMSF to make up to a final volume of 50 mL. The solution was 
stored at 4 ˚C.  
 
For the binding assay, the medium was aspirated from the 35 mm plates and the cells were 
washed with 1 mL PBS or urine, depending on the experiment to be performed (see section 
4.2.6). An aliquot (1.05 mL) of the same medium used to wash the cells was then added to each 
culture plate. All subsequent steps were performed under non-sterile conditions. 
 
The crystal slurry (950 μL) was added dropwise (so as to not disturb the cells) to each culture 
plate to achieve a final CaOx concentration of 2 mg/mL. The plate was agitated gently for 10 
seconds and crystals were left in contact with cells for an additional 2 minutes to allow binding 
to occur. After the 2 minute binding period, unattached crystals and medium were removed. 
Further washing with PBS was achieved by using a total of 10 mL PBS in a 10 mL plastic 
pipette which was fitted with a pipette aid to control the flow rate. The culture plate was swirled 
gently to allow the PBS to wash the surface of the cells and thereafter the PBS was poured off.  
 
Crystal binding was measured by determining the amount of calcium (from the calcium oxalate) 
that bound to cells. In order to achieve this, cells were lysed overnight by the addition of 600 μL 
6 M HCl to each culture plate. Thereafter the lysates were transferred to 15 mL centrifuge tubes. 
The culture plate was washed with a further 400 μL 6 M HCl followed by two aliquots of 500 μL 
sterile water. The combined washings were added to the centrifuge tube and the total cell lysate 
(~2 mL) was centrifuged (Centrifuge, Damon, USA) at 2000 rpm for 5 minutes. The supernatant 
was analysed using an atomic absorption spectrometer (Varian, SpectAA5, Germany) to 
determine the total amount of calcium (bound and endogenous cellular calcium). The pellet was 
retained for total protein determination.  
 
Total protein in each culture plate was assayed by the Bradford method (Bradford 1976) using 
bovine serum albumin as the standard (BSA standards, 1 – 10 µg/ml; Bio-Rad, Germany). The 














used: 3 μL cell lysate, 157 μL sterile water and 40 μL Bio-Rad protein assay dye reagent 
concentrate (Bio-Rad Lab, Munich). Absorbance was measured at 595 nm using a spectrometric 
plate reader (Anthos 2001, Labtec, Germany). Each sample was measured in duplicate.  
 
4.2.5 Determination of optimal binding conditions 
 
The concentration of crystal slurry (2 mg/mL) was chosen based on previous work carried out by 
members of the Kidney Stone Research Laboratory (KSRL) at the University of Cape Town 
(unpublished data, 2007). In most of the studies investigating crystal-cell binding (referenced in 
section 4.1), measurements of total calcium bound to cells were made using radio-labelled [
14
C] 
CaOx crystals which were counted on a scintillation counter. However, in studies carried out at 
the KSRL, calcium was determined using an atomic absorption spectrometer. This technique is a 
less sensitive than the scintillation counter. As such, a greater concentration of calcium was 
required in binding assays.  
 
Confluent 35 mm cell culture plates contain between 0.8 – 1.0 x 10
6
 cells (Kumar et al. 2003, 
Atmani et al. 2004). In binding assays, a crystal-cell ratio of 1:1 is considered acceptable 
(personal communication: Dr John Lieske, Department of Medicine, Mayo Clinic, Rochester, 
USA). In order to determine the number of crystals present in slurry of concentration 2 mg/mL, 
an aliquot was countered on the Coulter Multisizer II (Coulter Electronics Ltd., England) fitted 
with a 140 μm orifice (2.8 – 90.0 μm particle size range). The number of crystals counted was 
3.2 x 10
5
. However the coulter counter does not recognize aggregates and even though the slurry 
was stirred overnight (not sonicated), this number was an underestimate due to the presence of 
crystal aggregates. Even if this number is doubled, a concentration of 2 mg/mL crystals is still 
acceptable based on the crystal-cell ratio given above.  
 
In a crystal-cell binding experiment involving crystal slurries of concentration 0.2, 0.4 and 0.8 
mg/mL, a linear increase in adhesion was measured (R
2
= 0.999). A further increase in the crystal 
binding was detected when using slurry of 2 mg/mL. However, crystal slurry of concentration 
3.8 mg/mL induced a decrease in binding relative to the 2 mg/mL concentration which could be 














was considered the ideal slurry concentration for binding experiments as satisfies the crystal-cell 
ratio in 35 mm cell culture plates and provides sufficiently high calcium levels which can be 
detected by atomic absorption spectrometry. In experiments involving MDCK-I cells, a 2 minute 
period was considered a standard short  time to assess crystal attachment which occurs rapidly 
(Kumar et al. 2003, Atmani et al. 2004, Lee et al. 2009). 
 
4.2.6 Modifications to the binding assay 
 
In order to test the inhibitory properties of the plant extracts, the crystal-cell binding assay was 
modified in 3 ways which were adapted from studies where the inhibitory activitiy of different 
macromolecules on crystal-cell binding were investigated. Plant extracts were used to either pre-
incubate CaOx crystals (Schepers et al. 2002. Kumar et al. 2003, Grover et al. 2007), precoat 
MDCK-I cells (Ebisuno et al. 1995, Kumar et al. 2003, Grover et al. 2007) or to be present in the 
binding medium (Atmani et al. 2004). In addition, conditions were chosen to mimic those which 
occur physiologically. This was achieved by using real urine instead of PBS as the binding 
medium (Ebisuno 1999b, Grover et al. 2007) and also by substituting iCOM for CaOx crystals 
precipitated from real urine (Grover et al. 2009).  The details of the various experiments are 



























Table 4.1:  Design of crystal-cell binding experiments to investigate the effect of different plant 
extracts 
         
            Crystals:     iCOM                             iCOM                           uCaOx 
            Binding medium:      PBS             Pooled urine                       PBS 
        To precoat   To precoat    In binding   To precoat    To precoat   In binding    To precoat   To precoat   In binding 
 Plant extract used:       crystals         cells           medium         crystals         cells          medium         crystals          cells           medium 
 
Folium pyrrosiae       √      √      √      √      √      √        -      √        -  
 Desmodium styracifolium      √      √      √      √      √      √        -      √        -       
 Hylocerus trigonus      √      √      √      √      √      √        -      √        -  
Phyllanthus niruri      √      √      √      √      √      √        -       -        -  
Orthosiphon stamineus      √      √      √      √      √      √        -       -        - 
Cystone®       √      √      √      √      √      √        -       -        - 
 
Notation: √ denotes that the experiment was carried out,  
                - denotes that the experiment was not carried out due to insufficient quantity of CaOx crystals 
 
 
(i) Precoating of CaOx crystals with plant extracts  
 
iCOM crystals were precoated with plant extract prior to the assay as follows. A 2.5 mL aliquot 
of plant extract and 2.5 mL binding medium (either PBS or urine) were added to 21.4 mg iCOM, 
and the mixture was stirred rapidly (VELP Scientifica, Europe) for 15 minutes. Thereafter the 
slurry was transferred to a 15 mL centrifuge tube and centrifuged (Centrifuge, Damon, USA) at 
2000 rpm for 5 minutes. The supernatant was discarded and the crystals were washed with 3 mL 
medium. After centrifugation, the supernatant was discarded again. The crystals were 
resuspended in 3 mL medium and the slurry was set-up and the assay was carried out the 
following day as described in section 4.2.4. 
 
(ii) Precoating of MDCK-I cells with plant extracts   
 
MDCK-I cells were precoated with plant extract prior to the assay as follows. Cells, which were 
cultured as described in section 4.2.2, were washed with 1 mL medium on the day of the binding 
assay. Thereafter 1 mL plant extract and 1 mL 5% DMEM were added to each culture plate and 














aspirated. Cells were washed with an aliquot of medium (1 mL) and a further aliquot of the same 
medium (1.05 mL) was added to each plate. The assay continued as described in section 4.2.4.  
 
(iii) Addition of plant extracts to the binding medium  
 
Cells were cultured as described in section 4.2.4. An aliquot (0.5 mL) of the four times 
concentrated plant extract (prepared as described in section 4.2.1) and 0.55 mL medium were 
added to each cell culture plate. The combined medium and plant extract was used to bathe cells 
and crystals during crystal binding. The assay continued as described in section 4.2.4. 
 
(iv) Human urine as the binding medium  
 
Binding assays were carried out in which pooled urine from black and white males was used as 
the medium in which cells and crystals were bathed. Twenty-four urines were collected from 
healthy black (n=5) and white (n=5) males. Urine exclusion criteria were described earlier in 
section 4.2.2. Pooled urines for each race group, constituted from 200 mL aliquots from each 
male, were pre-filtered through a 0.75 m filter followed by 0.45 m nitrocellulose filter paper 
before use.  
 
(v) Urinary CaOx crystals instead of iCOM  
 
In these binding assays, PBS was used as the medium in which cells and crystals were saturated. 
Crystal slurries were made up of urinary CaOx crystals in PBS as described in section 4.2.4.  
These crystals were precipitated from the urine of healthy black and white males and white 
CaOx stone formers as described in section 4.2.2. Owing to a limited quantity of urinary crystals, 
it was not possible to apply all modifications to the binding assay described in section 4.2.10 thus 
only pre-coating of cells was carried out. Three plant extracts were selected for investigation 
namely Folium pyrrosiae (the principal plant of interest in this thesis purported to be effective in 
the treatment of urolithiasis), Desmodium styracifolium (another traditional Chinese remedy that 
demonstrated strong inhibitory activity in in vitro studies) and Hylocerus trigonus (a plant for 














4.2.7 Statistical analysis  
 
Experiments were carried out in triplicate and average values are reported. Data were statistically 

















All investigations summarized in Table 4.1 were carried in triplicate and at the end of each 
binding experiment and the total amount of calcium in each cell lysate in each plate was 
determined in duplicate. Hence each result presented in the respective graph is the average of 6 
measurements. Endogenous cellular calcium was measured in confluent 35 mm cell culture 
plates (blank reading: cells incubated in water alone) and this concentration was subtracted from 
total calcium assayed (calcium from cells and bound crystals) in order to obtain the net amount 
of calcium from the bound crystals. This value measured in the control i.e. iCOM binding to 
MDCK-1 cells in PBS in the absence of plant extracts, was set at 100%. All other 
measurements of bound calcium are presented relative to the control. This was done for the 
sake of clarity and to allow relative comparisons i.e. between modified experiments.  
 
The following colour scheme was employed when presenting data of experiments carried out in 
different binding media i.e. PBS, BU and WU by blue, black and white bar graphs respectively.   
Protein measurements were carried out in each culture plate to reflect the number of cells 















4.3.1 Crystal-cell binding of iCOM in PBS 
 
The binding of iCOM crystals to MDCK-I cells in PBS and the effect of the plant extracts on this 
process are illustrated in Figures 4.1a-c. The results are presented relative to the PBS control 
which has been set to a 100%. When plant extracts where used to precoat crystals, there was a 
significant decrease (p<0.05) in crystal-cell binding (Figure 4.1a). A similar effect i.e. a 
significant decrease in crystal-cell binding was bought about when plant extracts were used to 
pre-coat cells (Figure 4.1b). Plant extracts present in the PBS binding medium significantly 
decreased (p<0.05) the crystal-cell binding (Figure 4.1c).  
 
Phyllanthus niruri proved to be the strongest inhibitor overall statistically (based on p values) 
and superior inhibitory activity in PBS was also demonstrated by Desmodium styracifolium and 
Orthosiphon stamineus, compared to the other plant extracts, when present in medium. There 
were no other statistically significant differences in the relative strengths of the plant extracts 






























































Figure 4.1: The average percentage of calcium bound to MDCK-I cells in PBS where plant extracts were 
used to (a) to precoat crystals, (b) precoat cells or when (c) present in binding medium. Asterisks indicate 


































































































* * * * * 
a: Precoated crystals  
 
b: Precoated cells  
 















4.3.2 Crystal-cell binding of iCOM in urine 
 
Studies in pooled urine from black males (BU)  
The effect of the plant extracts on iCOM crystals binding to MDCK-I cells incubated in BU are 
illustrated in Figures 4.2a-c. The data are presented relative to the PBS control (the same value as 
in Figure 4.1 to enable relative comparisons); however statistical comparisons in this section 
are presented relative to the BU control (i.e. where crystal binding was measured in the 
absence of any plant extract).  
 
All plant extracts significantly decreased (p<0.05) crystal-cell binding when used to pre-treat 
crystals except Hylocerus trigonus relative to the BU control (Figure 4.2a). The plant extracts 
showed no significant effect when used to pre-treat cells prior to binding relative to the BU 
control (Figure 4.2b). And all plant extracts, when present in the binding medium, significantly 
decreased (p<0.05) crystal-cell binding (Figure 4.2c) relative to the BU control. However there 
were no statistically significant differences in the relative strengths of the plant extracts. Raw 









































Figure 4.2: The average percentage of calcium bound to MDCK-I cells in PBS where plant extracts were 
used to (a) to precoat crystals, (b) precoat cells or when (c) present in binding medium. Asterisk indicate 




















































































* * * * * 
* * * 
* 
* * 
a: Precoated crystals  
 
     b: Precoated cells  
 















Studies in pooled urine from white males (WU) 
The effect of the plant extracts on iCOM crystals binding to MDCK-I cells in WU are illustrated 
in Figures 4.3a-c. Statistical comparisons are made relative to the WU control (i.e. crystal-
cell binding experiment in WU with no plant extract used in the experiment) but as was 
implemented in BU studies, data are presented relative to the PBS control. All plant extracts 
significantly decreased crystal binding, whether they were used to pre-treat crystals, pre-treat 
cells or when present in the binding medium (p<0.05). However there were no statistically 
significant differences in the relative strengths of the plant extracts. Raw data of all 






































































Figure 4.3: The average percentage of calcium bound to MDCK-I cells in PBS where plant extracts were 
used to (a) to precoat crystals, (b) precoat cells or when (c) present in binding medium. Asterisk indicate 


















































































* *  * 
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 *  * * 
*  * 
* * 
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  * 
a: Precoated crystals  
 
b: Precoated cells  
 















4.3.3 Binding of iCOM in different media 
 
The binding of iCOM crystals to MDCK-I cells was measured in PBS, BU and WU alone 
(Figure 4.4) in order to establish whether binding media affected this process differently. These 
data are the control values in the experiments presented earlier (Figures 4.1 – 4.3). There was no 
significant difference in crystal-cell binding in PBS and WU. However, binding in BU was 
significantly lower (p<0.05) than in both of the other two media. Raw data of all measurements 



































































4.3.4 Crystal-cell binding of urinary CaOx crystals in PBS 
 
Urinary CaOx crystals were obtained from three sources, namely black (BC) and white (WC) 
healthy subjects and white recurrent CaOx stone formers (WSF), as described earlier. It was not 
possible to recruite black stone formers for this investigation. The results are given in Figure 4.5.  
 
Data are presented relative to a control where the assay was carried out in PBS using iCOM 
crystals (same control value as in Figures 4.1 – 4.3) to allow relative comparisons to be made. 
However, statistical comparisons were made relative to the respective urinary crystal control.  
 
As was mentioned earlier, three plant extracts were selected for investigation in this section, 
namely Folium pyrrosiae (the principal plant of interest in this thesis), Desmodium styracifolium 
(another traditional Chinese remedy that demonstrated strong inhibitory activity in in vitro 
studies) and Hylocerus trigonus (a plant for which there is no published data). 
 
All three plant extracts significantly decreased (p<0.05) the attachment of urinary crystals BC 
and WC (*; compare bars of the same colour with the control of that colour). However they 
showed no effect on the binding of urinary crystals obtained from WSF.  
 
With respect to the controls, urinary crystals bind significantly less (p<0.05) to MDCK-I cells 
than iCOM. It is also noteworthy that urinary crystals from black subjects and urinary crystals 
from WSF bind significantly less (p<0.05) than urinary crystals from white subjects. There were 
no significant differences in the relative strengths of the plant extracts. Raw data of all 


































Figure 4.5: The average percentage of calcium bound (iCOM and uCaOx) to MDCK-I cells in PBS. Plant 























































4.4  Discussion 
 
The binding of a crystal to a cell is considered to be a critical step that triggers a cascade of 
processes eventually resulting in the genesis of a renal calculus. The initial stage of binding is a 
surface-controlled phenomenon. However the later stages require complex stereospecific 
interactions involving a multitude of cytoplasmic, transmembrane and extracellular proteins 
which synergistically provide a stable point of crystal attachment (Hanein et al. 1993, Hanein et 
al. 1994, Grover et al. 2009).  
 
Numerous factors influence interactions between crystals and cells, as was explained in section 
4.1. It has been suggested that an effective method of inhibition of this process is to neutralize 
potential binding sites on crystal and cell surfaces (Verkoelen et al. 1997). Other inhibitory 
agents have been found to affect endocytosis by neutralizing potential cell binding sites (i.e. an 
inhibitor competitively binds to binding sites) thereby facilitating the elimination of crystals in 
urine (Lieske et al. 1995, Verkoelen et al. 1995). Therefore inhibitory agents can act in three 
ways i.e. on the crystal surface, cell surface or by being present in the medium.  
 
In this study, after a 2 minute binding time, all plant extracts under investigation demonstrated 
inhibitory activity on crystal-cell attachment in some way. In experiments carried out in PBS 
(involving the use of iCOM), plant extracts were effective in decreasing binding (p<0.05) when 
used to either pre-treat crystals, pre-treat cells or when present in the binding medium. 
Comparison of Figures 3.1a-c shows that the greatest inhibition of binding occurred when the 
plant extract was present in the binding medium. This would suggest that the possible mode of 
inhibition of the plant extracts is competitive binding to the anionic sites on cellular surfaces. 
This mechanism of inhibition has been reported for other agents mentioned in section 4.1.  
 
In BU, when used to pre-treat crystals and when present in the binding medium, all plant extracts 
significantly decreased (p<0.05) crystal-cell binding (except Hylocerus trigonus when used to 
treat iCOM crystals). However no significant change in crystal-cell binding was demonstrated 
when plant extracts were used to pre-treat cells prior to binding assays. Similar activity of the 














effective in decreasing crystal-cell binding (p<0.05) in all assays. Plant extracts show greater 
inhibitory effect in WU compared to BU.  
 
Comparison of the controls in Figure 5.4, where iCOM binding to MDCK-I cells in three types 
of media was measured, shows that attachment in BU is significantly lower (p<0.05) relative to 
attachment measured in PBS and WU. Previous studies have demonstrated the diverse anions 
present in whole urine (as mentioned in section 5.1) can coat CaOx and inhibit their binding to 
cells (Lieske et al. 1995, Ebisuno et al. 1999a, Kumar et al. 2003). This action has been 
demonstrated here to be greater in BU compared to WU thus BU naturally inhibits the crystal-
cell binding process which is considered a risk factor in stone formation. This result is in 
consensus with the rarity of stones in black subjects. Studies conducted at the KSRL on urinary 
proteins of black and white healthy male subjects have found a significantly higher (p<0.05) total 
protein in black males (Webber, PhD thesis) and proteins are known to act as inhibitors. 
However, qualitative analysis of urinary proteins isolated from the two race groups has not yet 
been accomplished which could assist in explaining the superior inhibitory nature of BU.  
 
Upon comparison of the relative strengths of the plants extracts in sections 4.3.1 and 4.3.2, 
Phyllanthus niruri proved to be the strongest inhibitor overall statistically (based on the p-value), 
in experiments performed in PBS. Statistically superior inhibitory activity in PBS was also 
demonstrated by Desmodium styracifolium and Orthosiphon stamineus when present in medium.  
 
Even though Hylocerus trigonus did not exhibit significant inhibitory action on BU when used to 
pre-treat crystals or cells, it was the strongest (p<0.05) inhibitor of cell attachment when present 
in the binding medium (BU) compared to the other plant extracts. In all other experiments 
(sections 4.3.1 and 4.3.2) there were no significant differences in the relative potency of the plant 
extracts.  
 
Plants contain phytochemicals which are biochemically active chemical compounds (Lui 2003). 
These are generally non-essential nutrients but have been proven to provide great medicinal 
benefits. Different classes of phytochemicals have been identified namely phenolics (e.g. 














isothiocyanates, allium), indoles, protein inhibitors and organic acids (e.g. oxalic acid, phytic 
acid) (Shahidi and Naczk 1995, Lui 2003). A few examples of each class are provided here but 
more than 5 000 phytochemicals are known (Lui 2003).   
 
As mentioned in chapter 1.5.4, phenolics and terpenes are been identified in all plants under 
investigation in this study, with the exception of Hylocerus trigonus (for which there is no 
published data). Phytochemicals are known for their antioxidant and anticancer properties (Ames 
and Gold 1991, Milder et al. 2005, Thakur et al. 2011, Thoppil et al. 2011). But saponins, in 
particular, are known to affect the permeability of cellular membranes but disrupting the lipid 
bilayer (Cohen et al. 1996, Baumann et al. 1999). As mentioned above, binding is a surface-
controlled phenomenon. Hence changes to the cellular membrane caused by saponins would 
impact this process and this may be the mode of action of the different plant extracts. The actual 
mechanism by which saponins act is unclear.  
 
Comparison of the binding of iCOM and uCaOx to MDCK-1 cells in PBS is depicted in Figure 
4.5. Crystals isolated from the urine of healthy black and white males and white stone-formers 
exhibit significantly lower (p<0.05) binding affinity compared to iCOM. It is also noteworthy 
that the binding capacity of crystals decreases significantly (p<0.05) in the following sequence 
iCOM < WC < BC < WSF. Regarding the observation that uCaOx crystals bind to renal 
epithelial cells significantly less than iCOM, uCaOx differ in size and morphology from iCOM, 
uCaOx crystals contain surface bound and intracrystalline proteins. 
  
In the preparation of uCaOx, urine was filtered twice (0.75 and 0.45 m) to remove cellular 
debris and larger macromolecules, prior to crystallization being induced. Even though urinary 
protein was not quantified in this experiment, a previous study reported that centrifugation (10 
000g) and filtration of urine through a 0.22 m decreased the protein content of whole urine 
from 47.3 to 24.8 mg/mL (Grover et al. 2009). Therefore, protein was certainly present in urine 
when crystallization was induced in this experiment (as a membrane with a larger pore size was 
used in filtration) and these proteins were incorporated into urinary crystals. As mentioned in 














incubation therefore some surface bound proteins would also be present (Grover et al. 2009, 
Thurgood et al. 2012). 
 
The inclusion of proteins into crystals is known to disrupt their atomic structure and alter the 
texture of their mineral phase (Aizenberg et al. 1995). This effect could extend to the surface of 
crystals and influence its adhesive properties, by causing changes to surface charge and topology 
(Grover et al. 2009), thereby hampering the binding process. And an inverse relation has been 
reported between crystal binding and the concentration of protein in the medium from which 
they were precipitated (Aizenberg et al. 1997). Therefore urinary crystals, due to the presence of 
surface bound and intracrystalline proteins, have a decreased binding affinity for renal epithelial 
cells than iCOM (reasons given above) and this result is depicted in Figure 4.5. Urine from black 
subjects is known to have a higher concentration of proteins compared to white subjects and 
crystals isolated from black urine bind with significantly less avidity those from white urine. 
This result highlights a possible difference in renal handling between the two race groups and the 
significant role of proteins on crystal-cell binding. 
  
Decreased binding of crystals from black and white controls (BC and WC) is promising in that 
the extracts achieve exactly what would be required of them as therapeutic agents. 
Unfortunately, this prognosis was not confirmed in the crystals from WSF. It is not possible to 
explain this unexpected observation in terms of the results of the experiments described here. 
However, it can be speculated that the crystals derived from the urine of WSF have some 
property (not yet identified) which compromises the effects of the extracts. A shortcoming of the 
current study is the lack of quantitative information regarding the composition of the uCaOx. 
XRD analysis of uCaOx revealed a mixture of COM and COD; however the respective amounts 
are unknown. As reported earlier in this thesis, COD has a decreased binding affinity for renal 
cells relative to COM. The presence of a high percentage of COD could be a contributing factor 
to the decreased binding (relative to BC and WC) observed in WSF. The effect of the plant 
extracts, if any, on the binding of COD has also not been established.  
 
This study has investigated several synergistic variables in an attempt to gain insights into the 














cells. Two different CaOx crystals types were used i.e. those synthesized from a simple inorganic 
solution and those derived from human urine. In the latter case, crystals were derived from three 
different human sources namely black and white controls, and white stone formers. Three 
different possible effects on binding capacity by the herbal extracts were addressed: pre-
treatment of crystals, pre-treatment of cells and presence of the extract in the binding medium. 
Three different binding media were also used i.e. PBS and urine from black and white healthy 
male subjects.  
 
Very interesting results were obtained. Firstly, all of the plant extracts demonstrated a capacity to 
inhibit crystal-cell binding (iCOM) via all three routes in PBS and WU. In BU, no effect was 
detected by any of the plant extracts when used to pre-treat cells, and Hylocerus trigonus showed 
no effect when used to pre-treat crystals. Secondly, in the experiments involving uCaOx, all 3 
plant extracts that were tested (Folium pyrrosiae, Desmodium styracifolium, Hylocerus trigonus) 
decreases the binding of crystals from BC and WC, but had no effect on the binding of crystals 
from WSF.  
 
These results demonstrate that these herbal extracts are all potentially useful as therapeutic 
agents in the treatment of urolithiasis by virtue of their ability to inhibit crystal cell binding 
which has been identified as one of the most important step in stone formation. Further studies in 















The effect of Folium Pyrrosiae on calcium oxalate kidney stone risk factors: an in vivo 
study on healthy South African black and white males 
 
5.1 Introduction  
 
The use of herbal remedies for the treatment of urolithiasis has been practiced since long 
before the use of Western medicine (cited by: Gohel et al. 2006). Since the implementation of 
the Chinese medicine ordinance in 1999, which gave Chinese medicine practitioners 
recognition as medical professionals, there has been an emergence of TCM hospitals and an 
increase in the manufacture of TCM. This trend has extended beyond the Far East to many 
Western countries, including the United Kingdom where more than 600 TCM clinics are in 
existence (McNamara and Ke 1995).  
 
According to the principles of TCM, renal stone disease can be attributed to 3 imbalances in 
the body, i.e. “sha-lin” (strangury from urolithiasis), “shi-lin” (strangury caused by urinary 
calculus) and “xue-lin” (strangury complicated by haematuria). Herbal remedies for renal 
stone disease are specifically selected to promote the circulation of “qi”, vital energy that is 
also known as yang and induce diuresis which aids stone removal (cited by: Gohel et al. 
2006).  
 
Herbal remedies are being considered increasingly as a suitable long-term treatment for renal 
dysfunction (Atmani et al. 2000). However some greatly needed scientific backing on their 
pharmacodynamics is required. An example is Folium pyrrosiae which is used commonly in 
the Chinese medicinal system for the treatment of urolithiasis (Gohel et al. 2006). Usually, 
these herbal blends are prepared by traditional water extraction methods (Zhao 2005). Three 
independent herbalists suggest a daily dose of 1.5 g of dried herb granules to treat urinary 
stone problems and in extreme cases, 40-60 g per day can be used in infusions (Zhao 2005). 
There have been no known cases of toxicity. However mild side-effects such as dizziness, 
elevated urinary volume and increased hunger have been reported when very high doses are 

















The primary objective of the study described in this chapter was to investigate the effects of 
Folium pyrrosiae on the physicochemical risk factors for CaOx kidney stone formation. A 
secondary objective was to determine whether any effects (if they did indeed occur), were 
different in subjects from South Africa‟s black and white population. Finally, it was 
anticipated that the study would provide an opportunity to compare baseline parameters in the 
two race groups, albeit that this was not the main motivation for undertaking the investigation 















5.2  Materials and methods 
 
5.2.1 Study design 
 
A double-blind, 7 day randomized, placebo-controlled, cross-over design study was 
conducted with a 1 week washout period observed between protocols. Subjects were 
recruited during the period May – July 2009. The cross-over study extended over 5 weeks.  
Folium pyrrosiae was purchased in granular form (Nong’s Powder). Starch powder (White 
Wings plain wheat flour made in Australia) was used as the placebo and was purchased from 
a supermarket in Hong Kong by Dr Mayur Danny Gohel (Department of Health Technology 
and Informatics, Hong Kong Polytechnic University). These products were encapsulated by a 
pharmaceutical company upon instruction of Dr Mayur Danny Gohel and sent via courier to 
the University of Cape Town.   
 
Healthy black (n=9) and white (n=9) male subjects were recruited from the student cohort at 
the University of Cape Town. The sample size required to achieve a statistical power of 70% 
was calculated at a significance level of 0.05 using the computer program Graphpad Statmate 
2 and was based on an average standard deviation of urinary calcium observed in the Kidney 
Stone Research Laboratory. The protocol for this investigation was approved by the Research 




South African black and white males aged between 18 and 30 years old, with no prior history 
of clinical or metabolic problems, were allowed to participate in the trial. Diabetic patients 
were excluded as the capsules enclosing the plant extract and placebo were sugar-based. Prior 
to the commencement of the study, each subject was required to fill out a questionnaire 
giving information about their social and medical history (Appendix 3). Subjects followed an 
unrestricted diet but were advised to avoid consumption of calcium and oxalate rich foods 
during the trial period. They were also required to keep a record of all food and liquids 
consumed on urine collection days.  
 
Subjects were solicited via advertisement. An information sheet was provided to them with 
instructions on how to collect 24 hour urine. They were instructed not to take any 














the traditional herbal medicine which would confound the results of the study. After a verbal 
and written explanation, they were required to sign a letter of consent. Participation was 
voluntary and subjects were able to withdraw at any time without prejudice. All information 
provided was kept confidential. This study was covered by UCT‟s no-fault liability insurance 
cover and participants could be compensated in the event of any harm being done to them; 




Subjects were administered with 3 capsules, each containing 0.5 g Folium pyrrosiae, which 
they consumed daily after breakfast for 7 days. The same subjects participated in the cross-
over study during which 3 placebo capsules containing 0.5 g starch were administered each 
morning after breakfast for 7 days. Twenty-four hour urine samples were collected on days 0 
(baseline), 7 (post treatment) and 14 (washout) of both protocols. Endogenous micronutrient 
concentration in a daily dosage of Folium pyrrosiae [Calcium = 1.38 mg, Citrate = 6.00 mg, 
Magnesium = 2.88 mg, Oxalate = 0.55 mg] and starch [Calcium = 0.54 mg, Citrate = 1.20 
mg, Magnesium = 1.15 mg, Oxalate = 0.32 mg] were determined by Gohel et al. (2006) and 
were considered too insignificant to interfere with urine chemistry.   
 
Twenty-four hour dietary information was recorded on urine collection days. Baseline 
creatinine and liver function tests were performed on all subjects on days 0 and 3, as a safety 
measure i.e. these parameters must not become elevated. Liver function was monitored by 
means of blood tests for albumin, bilirubin, international normalized ratio (INR) and 
transaminases. Blood was drawn by specialist phlebotomists and testing was performed by Dr 
Davies Pathology Laboratories, Cape Town, South Africa. Blood analyses showed no 
changes in the concentration of liver enzymes (safety-markers) and no side-effects were 















5.2.4 Experimental methods 
 
Urine collection and analysis  
Twenty-hour urine samples were collected in plastic bottles without preservative. Each 
sample was tested for haematuria and nitrite using urinalysis test strips. All samples were 
assayed for the following urinary variables: pH, calcium, citrate, chloride, creatinine, 
magnesium, oxalate, potassium, phosphate, sodium and urate as described in Chapter 2.3.  
 
The TRI was determined using standard urinary variables and specific gravity was measured 
using a densitometer (DMA 3S, Digital Densitymeter, Austria). Relative urinary 
supersaturations of CaOx, brushite and uric acid were calculated using EQUIL 2.5. All raw 
data is presented in Appendix 4.  
  
Crystallization experiments  
The CaOx MSL, PSD, rates and inhibition of CaOx crystal nucleation and aggregation as 
well as [
14
C]-oxalate deposition were measured in all urine samples both pre- and post-
treatment. These methods have been described fully in Chapter 2. All raw data is presented in 
Appendix 4.  
 
Compliance test 
A compliance test was carried out where subjects were instructed to consume a daily dosage 
of Folium pyrrosiae capsules in the presence of the investigator and the corresponding 
twenty-four urine was collected in 3 aliquots (i.e. at 2 hours, 4 hours and 24 hours after 
consumption). The samples were assayed for standard urinary variables and their ratios 
compared as a function of creatinine. 
 
Statistical analysis 
Data were analyzed by using GraphPad Instat and p<0.05 was regarded as significant. 
Average values and standard error (SE) have been reported. Error bars have been omitted in 

















5.3.1 Dietary analysis 
 
The nutrient intake of the two race groups was derived from the analysis of dietary 
questionnaires which subjects were required to complete on each urine collection day. These 
were analysed for macro- and micronutrients using the computer program Foodfinder
TM
 2 
(Wolmarans et al. 2001). The values presented in Table 5.1 are an average of each nutrient on 
collection days 0 and 7 of the two protocols. There were no significant differences in nutrient 
intake between the two race groups thereby ruling out the possibility of any confounding 
dietary factors.  
 
 






























  Blacks Whites  
Moisture (g) 610 (57) 517 (47) 
Total protein (g/day) 55.6 (7.7) 40.5 (7.4) 
Total fat (g/day) 47.4 (7.4) 43.1 (9.0) 
Total sugar (g/day) 15.4 (3.9) 8.71 (1.34) 
Carbohydrate (g/day) 155 (19) 104 (11) 
Fibre (g/day) 11.6 (1.8) 7.35 (1.31) 
Oxalate (mg/day) 50.5 (33.4) 41.1 (26.9) 
Calcium (mg/day) 303 (51) 321 (67) 
Magnesium (mg/day) 181 (26) 121 (19) 
Phosphorus (mg/day) 723 (96) 640 (142) 
Potassium (mg/day) 1412 (175) 1015 (150) 
Sodium (mg/day) 1267 (234) 1147 (321) 
Vitamin A (RE/day) 221 (44) 297 (70) 
Vitamin B6 (mg/day) 1.24 (0.3) 0.78 (0.15) 
Vitamin C (mg/day) 119 (31) 41.3 (20.1) 
Vitamin D (μg/day) 3.11 (0.9) 1.52 (0.51) 















5.3.2 Urine composition 
 
No changes were detected in urinary variables in the compliance test which confirmed the 
authenticity of the data from the trial and placebo protocols. Compliance test data are 
presented in Appendix 4.  
 
Urinary parameters and computed risk indices for both race groups during supplementation 
with the placebo and Folium pyrrosiae are presented in Tables 5.2a and b respectively.  
 
No significant changes were detected in any of the variables during supplementation with the 
placebo in either race group (p>0.05). However, upon comparison of baseline (and washout 
collection days), urinary calcium and urinary phosphate were found to be consistently higher 
in white subjects than in blacks (p<0.05).  
 
 
Table 5.2a: Mean urinary parameters (SE) in black and white subjects before and after 





BLACKS (n=9) WHITES (n=9) 
Baseline 
Post-
treatment Washout Baseline 
Post-
treatment Washout 
day 0 day 7 day 14 day 0 day 7 day 14 
pH 5.98 (0.21) 6.08 (0.12) 6.12 (0.16) 6.08 (0.11) 6.11 (0.09) 6.11 (0.13) 
Volume (mL/24 hr) 1573 (158) 1280 (160) 1220 (175) 1635 (236) 1297 (196) 1497 (234) 
Citrate (mmol/24 hr) 3.60 (0.46) 2.31 (0.24) 2.45 (0.36) 3.86 (0.80) 1.99 (0.31) 3.13 (0.57) 
Oxalate (mmol/24 hr) 0.25 (0.03) 0.26 (0.04) 0.23 (0.02) 0.29 (0.05) 0.29 (0.04) 0.27 (0.02) 
Calcium (mmol/24 hr) 1.68 (0.24) 1.89 (0.31) 1.47 (0.20) 2.92 (0.47) 2.78 (0.53) 3.02 (0.39) 
Magnesium (mmol/24 hr) 0.88 (0.17) 1.39 (0.35) 1.38 (0.23) 1.48 (0.28) 2.18 (0.52) 2.62 (0.72) 
Sodium (mmol/24 hr) 172 (27) 165 (28) 133 (24) 166 (40) 179 (30) 144 (26) 
Potassium (mmol/24 hr) 49.5 (7.4) 35.6 (4.1) 37.6 (7.5) 47.4 (12.3) 36.1 (5.8) 41.0 (9.3) 
Urate (mmol/24 hr) 3.02 (0.42) 2.82 (0.34) 2.53 (0.28) 3.97 (0.77) 3.79 (0.45) 3.97 (0.53) 
Creatinine (mmol/24 hr) 15.5 (1.1) 15.0 (1.2) 12.5 (0.9) 17.9 (1.2) 17.3 (1.1) 16.4 (1.7) 
Phosphate (mmol/24 hr) 24.1 (0.86) 24.2 (3.5) 20.4 (2.7) 35.3 (6.16) 32.9 (2.6) 32.6 (2.9) 
Chloride (mmol/24 hr) 157 (17.6) 142 (20) 133 (20) 126 (18) 162 (28) 129 (17) 
Specific gravity (g.cm-3) 1.01 (0.1) 1.01 (0.1) 1.01 (0.1) 1.01 (0.1) 1.01 (0.1) 1.01 (0.1) 
RS CaOx 1.60 (0.34) 2.92 (0.90) 2.46 (0.60) 3.28 (0.76) 3.92 (0.68) 4.04 (0.81) 
RS Brushite (exp-09) 0.24 (0.10) 0.61 (0.27) 0.52 (0.17) 0.75 (0.20) 1.13 (0.23) 1.05 (0.32) 
RS Uric acid 1.59 (0.54) 1.50 (0.33) 1.20 (0.31) 1.93 (0.56) 1.98 (0.42) 1.91 (0.51) 















There were no significant changes in any of the variables upon consumption of Folium 
pyrrosiae in either race group (day 0 vs day 7). However, as was detected in the placebo 
protocol, urinary calcium and urinary phosphate was found to be significantly higher 
(p<0.05) in white subjects than in blacks on day 14 of the protocol.   
 
 
Table 5.2b: Mean urinary parameters (SE) in black and white subjects before and after 





BLACKS (n=9) WHITES (n=9) 
Baseline 
Post-
treatment Washout Baseline 
Post-
treatment Washout 
day 0 day 7 day 14 day 0 day 7 day 14 
pH 5.77 (0.15) 6.03 (0.16) 5.98 (0.21) 6.06 (1.04) 6.04 (0.17) 6.08 (0.11) 
Volume (mL/24 hr) 1371 (90.7) 1298 (230) 1573 (158) 1430 (165) 1251 (137) 1635 (236) 
Citrate (mmol/24 hr) 2.48 (1.06) 2.28 (0.29) 3.60 (0.46) 2.51 (0.34) 2.00 (0.28) 3.86 (0.80) 
Oxalate (mmol/24 hr) 0.25 (0.02) 0.21 (0.02) 0.25 (0.03) 0.30 (0.03) 0.26 (0.03) 0.30 (0.05) 
Calcium (mmol/24 hr) 1.77 (0.31) 1.55 (0.20) 1.68 (0.24) 2.32 (0.43) 2.45 (0.32) 2.92 (0.47) 
Magnesium (mmol/24 hr) 1.20 (0.22) 1.71 (0.42) 0.88 (0.17) 2.31 (0.46) 2.07 (0.33) 1.48 (0.28) 
Sodium (mmol/24 hr) 186 (24) 179 (23) 172 (27) 155 (17) 141 (17) 166 (40) 
Potassium (mmol/24 hr) 50.2 (7.3) 38.7 (6.9) 49.5 (7.4) 40.3 (4.1) 38.1 (3.8) 47.4 (12.3) 
Urate (mmol/24 hr) 2.50 (0.42) 3.04 (0.30) 3.02 (0.42) 3.82 (0.28) 3.80 (0.39) 3.97 (0.77) 
Creatinine (mmol/24 hr) 13.9 (1.8) 14.3 (0.9) 15.5 (1.0) 16.4 (1.1) 17.2 (1.2) 17.9 (1.2) 
Phosphate (mmol/24 hr) 25.3 (3.4) 22.6 (1.6) 24.1 (0.86) 29.0 (3.1) 29.8 (1.8) 35.3 (6.2) 
Chloride (mmol/24 hr) 157 (17) 146 (17) 157 (17.6) 162 (16) 121 (10) 126 (18) 
Specific gravity (g.cm
-3
) 1.02 (0.1) 1.01 (0.1) 1.01 (0.1) 1.01 (0) 1.01 (0.1) 1.01 (0) 
RS CaOx 2.36 (0.57) 2.92 (0.90) 1.60 (0.34) 3.45 (0.62) 4.10 (0.68) 3.28 (0.76) 
RS Brushite  0.29 (0.09) 0.61 (0.27) 0.24 (0.10) 0.83 (0.27) 1.07 (0.28) 0.75 (0.20) 
RS Uric acid 2.70 (0.91) 1.50 (0.33) 1.59 (0.54) 2.01 (0.57) 2.55 (0.88) 1.93 (0.50) 















5.3.3  Crystallization parameters 
 
MSL, PSD, CaOx crystal nucleation and aggregation 
Results of the urinary CaOx crystallization parameters are presented in Tables 5.3a,b and 
Figures 5.1a,b.  
 
There was no significant change in any of the crystallization parameters post supplementation 
in both protocols. However, upon intergroup comparisons of baseline and washout data 
between the groups, the following differences were noted. In black subjects, MSL values 
were higher while the average CaOx PSD and aggregation inhibition were lower than in 
white subjects.   
 
Table 5.3 a: Mean urinary parameters (SE) in black and white subjects before and after 
supplementation with starch placebo and post protocol 
 
Table 5.3 b: Mean crystallization parameters (SE) in black and white subjects before and after 
supplementation with Folium pyrrosiae and post protocol 
  
Variables 
BLACKS (n=9) WHITES (n=9) 
Baseline 
Post-
treatment Washout Baseline 
Post-
treatment Washout 
day 0 day 7 day 14 day 0 day 7 day 14 
MSL (µmol/L) 78.3 (9.9) 85.0 (12.5) 88.3 (9.5) 40.0 (5.6) 33.3 (7.0) 61.7 (10.4) 
PSD (µm) 8.38 (1.28) 6.78 (1.34) 5.83 (0.43) 10.6 (1.6) 10.9 (1.0) 9.55 (0.69) 
% Inhibition of nucleation -102 (16) -256 (45) -167 (44) -122 (19) -236 (15) -140 (19.5) 
% Inhibition of aggregation -178 (74) -103 (35) -78.2 (73.4) -84 (43) -85 (26) 10.9 (28.8) 
 
Variables 
BLACKS (n=9) WHITES (n=9) 
Baseline 
Post-
treatment Washout Baseline 
Post-
treatment Washout 
day 0 day 7 day 14 day 0 day 7 day 14 
MSL (µmol/L) 96.7 (12.8) 101.7 (15.8) 76.7 (10.1) 56.7 (7.8) 61.7 (16.7) 40.0 (5.6) 
PSD (µm) 5.83 (0.43) 7.19 (1.10) 8.80 (1.11) 9.55 (0.69) 8.32 (1.33) 8.38 (0.84) 
% Inhibition of nucleation   -122 (52) -72.6 (15.0) -102 (16) -173 (69) -46.6 (13.6) -122 (19) 

















C]-oxalate deposition experiments   
The average precipitated [
14
C]-oxalate in the urine of black (n=5) and white (n=5) subjects as 
a function of time is presented in Figures 5.1a and b, respectively. Experiments were 
performed pre- and post-treatment for both protocols (days 0 and 7). Precipitated [
14
C]-
oxalate at each time point of the 2 hour incubation period was determined in duplicate by a 
scintillation counter. Hence each data point presented in the respective graphs represents the 
average of 10 measurements.  
 
There are three parameters of interest which can be derived from these plots: 
 Gradient of the linear section which equals the rate of crystallization, 
 Total percentage precipitation, and 
 Time for crystallization to reach completion. 
 
There were no statistically significant differences in the parameters of interest between the 
protocols in each group. However, intergroup comparisons (Figure 5.1a and b) revealed that 
in the urine of black subjects, precipitation continues for the entire duration of the experiment 
(120 minutes). While in white subjects it reaches completion at about 90 minutes (plateau in 
graphs), thereby suggesting that inhibition of crystallization occurs to a great extent in the 




































































Figure 5.1a: Rate of [
14
C]-oxalate deposition in the urine of black subjects pre-and post-treatment 
with Folium pyrrosiae (FP) and placebo (P)  
 
 
Figure 5.1b: Rate of [
14
C]-oxalate deposition in the urine of white subjects pre-and post-treatment 






































Clinical trials on Chinese Medicines are generally difficult to conduct in China due to a lack 
of willing participants. Traditional methods of preparation by decoction (i.e. boiling plant 
material in water) have proven unpopular as most medicines taste bitter and it is impossible 
to standardise the technique of preparation (Zhao 2005). Therefore administering the plant 
extract in the form of a commercially produced capsule, the approach adopted in the present 
study, is a superior and more convenient technique for an in vivo study. Furthermore it 
facilitated the blinded-effect of the study as the plant extract was brown in colour and starch 
was white.  
 
The influence of diet on urine chemistry is well-known and was discussed in detailed in 
chapter 1.1.4. Hence this investigation commenced with an inter-racial dietary analysis by 
means of evaluation of food questionnaires. Previous analysis of the typical diet of black and 
white subjects showed that whites have a significantly higher intake of total protein, vitamin 
C, vitamin B6, fat, added sugar, calcium and magnesium whereas blacks have a higher intake 
of dietary oxalate (Lewandowski et al. 2005). However none the afore-mentioned dietary 
parameters or any others were significantly different between the groups in the present study 
thereby eliminating the possibility of any c nfounding dietary factors in the two cohorts of 
subjects used. 
 
There were no significant changes in any urinary parameters in the placebo trial either. Starch 
served this purpose well as it was readily available, non-toxic and caused no interference to 
the variables of interest in this trial. There were also no significant changes in the relative 
supersaturations of the various stone-forming salts and TRI post treatment in either protocol. 
In a previous study using early morning urines derived from people of Chinese origin, 
significant changes in urinary parameters were also not observed (Ching 2007).  
 
Although there were some fluctuations in urinary parameters following supplementation with 
Folium pyrrosiae (pH, volume, citrate, oxalate, calcium, magnesium, sodium, potassium, 
urate, creatinine, phosphate and chloride) none of these changes were statistically significant 
in either race group. However, attention is drawn to the decrease in oxalate concentration 
(Table 5.2 a) from 0.25 ± 0.03 to 0.21 ± 0.04 mmol/24 hr in blacks and from 0.30 ± 0.05 to 














Despite there being no significant changes in urinary parameters post supplementation in this 
trial, calcium and phosphate was found to be statistically higher (p<0.05) in white males at 
baseline (day 0) and after the washout period (day 14) days in agreement with previously 
published urinary data (Lewandowski et al. 2001).  
 
Folium pyrrosiae is purported to induce diuresis (Zhao 2005, Gohel et al. 2006). Specific 
gravity, which was determined in this study, is a measure of osmolality (i.e. the concentration 
of solute in solution) which is an indicator of the hydration state of the body. A superior 
method of evaluating the diuretic effect is by comparison of the change in the total 24 hour 
urinary volume. Neither of these parameters changed significantly after ingestion of Folium 
pyrrosiae indicating the absence of a diuretic effect.   
 
Folium pyrrosiae demonstrated no effect on CaOx crystallization i.e. on MSL, PSD, crystal 
nucleation and aggregation. However comparison of these factors at baseline showed 
significant differences between the two race groups. The MSL of urine from blacks subjects 
was consistently higher (p<0.05) than that of white subjects (also reported for the in vitro 
studies in Chapter 3). The average CaOx PSD, which is an indication of crystal growth, was 
found to be greater in the urine of white subjects than in black subjects. These results 
correlate with the lower risk of stone formation in the black population group. However, the 
counter-intuitive finding here was the greater (p<0.05) inhibition of aggregation (which is 
associated with lower risk) in the urine of white subjects. [
14
C]-oxalate deposition 
experiments demonstrated no significant differences in the rates of aggregation between the 
two race groups.  
 
Traditional medicinal preparations and Western medicine have different principles of 
pathology and diagnosis. In Western medicine, a disease is viewed as an outcome of a 
pathogenic factor. However in traditional healing, a disease is diagnosed based on a multi-
component system, i.e. an imbalance in the body and an outcome of a pathogenic factor (Lu 
et al. 1994, Mok 2006). A disease is referred to as a „pattern of maladjustment‟ (zheng in 
Chinese, which can also be translated as syndrome). There are 4 such diagnostic states (1) 
heat which is characterised by fever, (2) an intolerance of cold in the body, (3) an excess 
accumulation of metabolic waste, and (4) a deficiency of nutrients; and there are 5 locations 
where these maladjustments can occur namely kidney, liver, heart, spleen and lung (Jiang 














imbalance at the target organ. Traditional herbs have unique synergistic and sometimes 
antagonistic interactions with other constituent substances, with Western medicine and even 
some foods (Koide et al. 1995, Ikegami et al. 2003, Ikegami et al. 2004). A trained 
practitioner is able to administer the herbal formula with the correct balance.   
 
Clearly, the system used in traditional medicinal systems for the evaluation of herbal 
preparations is very different to that used and accepted by Western practitioners as it lacks a 
sound scientific approach. Further evidence in support of this statement was revealed in a 
recent in vivo study involving Cystone® where no short (6 weeks) or long term effects (52 
weeks) of the plant extract on urine chemistry of stone formers was detected (Erickson et al. 
2011). In another recent in vivo study investigating the effect of Cystone® of cystine kidney 
stone patients, no favourable inhibitory effect was reported on stone burden either (Erickson 
et al. 2011a).  
 
The purpose of this study was to provide greatly needed scientific backing on the 
pharmacodynamics of this widely used Chinese herbal preparation. Results of this study do 
not support the previously mooted suggestion that Folium pyrrosiae might be a therapeutic 
agent in the management of urolithiasis as no significant effects were detected on urine 
chemistry, MSL, RS, TRI, PSD, CaOx deposition and inhibition of nucleation and 
aggregation. However, urine from these subjects could be useful in future experiments in 
determining whether concentrations of herbal extracts used in the earlier in vitro experiments 





















In the previous chapters of this thesis, the inhibitory activity of Folium pyrrosiae on CaOx risk 
factors (crystallization and crystal-cell binding) in in vitro and in vivo experiments has been 
described. It was shown that this herb decreased CaOx crystal growth (as determined by SEM 
and MSMPR experiments, Table 3.8) and inhibited crystal-cell binding when used to either pre-
coat crystals or cells, or when present in the binding medium (chapter 4). Once the inhibitory 
effects of an agent have been established, it is of interest to identify and determine the structure 
of its constituent bioactive compounds to determine the mechanisms by which the compounds 
act. The present chapter describes the elucidation of the structures isolated from Folium 
pyrrosiae.   
 
In an analytical study carried out by Li and Tong (1992) on Folium pyrrosiae, 3 well-known 
phytochemicals were identified. These workers employed high-performance liquid 
chromatography to analyse a methanol extract of the dried plant material and reported the 
presence of mangiferin and isomangiferin (two xanthone derivatives) as well as chlorogenic acid 
(a polyphenol). In fact, the study included compositional analysis of 7 species of this particular 
genus which was isolated from 17 districts in China. The 3 aforementioned constituents were 
detected in varying concentrations between species and in the same species obtained from the 




one) has well-known immunotherapeutic effects. It has demonstrated strong anti-oxidant, anti-
lipid peroxidation and anti-diabetic activities. In addition, it can promote wound healing and may 
play a role in preventing cancer, autoimmune disorders, atherosclerosis and coronary heart 
disease (Zheng and Lu 1990, Yoshimi et al. 2001, Leiro et al. 2003, Muruganandan et al. 2005, 














(hydroxymethyl)oxan-2-yl]xanthen-9-one), an isomer of mangiferin, is known to act as an 
antiviral (Zheng and Lu 1990). Chlorogenic acid (3-[(E)-3-(3,4-dihydroxyphenyl)prop-2-
enoyl]oxy-1,4,5-trihydroxy-cyclohexane-1-carboxylic acid) has reported anti-oxidant and anti-
carcinogenic properties, and plays a role in the homeostatic regulation of blood glucose 

























This chapter describes an attempt to identify and characterize other molecules in Folium 

















In order to characterize phytochemicals in Folium pyrrosiae, these compounds were isolated 
from the dried plant material and purified prior to analysis. An aqueous extract of Folium 
pyrrosiae was subjected to sequential liquid-liquid extractions with organic solvents ethyl acetate 
(EtOAc) and butanol (BuOH). These extracts were subsequently purified by column-
chromatography and thin-layer chromatography (TLC). Further analysis was performed by 
means of NMR spectroscopy and mass spectrometry (MS). This experimental procedure was 
designed in collaboration with Professor Thozamile Mabusela (Herbal Science and Medicine 
Institute, University of the Western Cape, South Africa). A schematic is presented in Figure 6.2 






























Figure 6.2: A flow diagram summarizing the isolation and purification of bioactive molecules in Folium 
pyrrosiae  
 
 100 g Folium pyrrosiae + 300 mL distilled H2O  
(Dissolution at 50 ᵒC, 30 minutes, filtration through 0.22 μm) 
 
 
                                                   
                                           Insoluble material discarded                        
 
 
Water extract + 300 mL EtOAc (x3) 
(Liquid/liquid extraction) 
 
                                                                
                                                                                  
                                                                      EtOAc extract  
                                                                                                  (Column chromatography, TLC, NMR, MS) 
 
 




                                                                                 BuOH extract 



















Liquid-liquid extraction is a method that is used to separate compounds based on their relative 
solubilities into 2 immiscible liquids (Zubick 1992). Folium pyrrosiae (100 g) was weighed into 
a conical flask into which distilled water was added (300 mL). Gentle heating with stirring 
(Labcon, Johannesburg, South Africa) was applied for 30 minutes to facilitate dissolution. The 
solution was microfiltered (0.22 μm) to remove insoluble material. This water-soluble extract (~ 
290 mL) was subjected to extraction by EtOAc (Sigma-Aldrich, Cape Town, South Africa) as 
described below. 
 
EtOAc (300 mL) was added to the water-soluble extract of Folium pyrrosiae which was placed 
in a separating funnel. The separating funnel was secured at both ends (rubber stopper on the top 
and tap at the bottom) and the liquid mixture was shaken vigorously. During the first 2 minutes, 
the tap of the separating funnel was opened at 5 second intervals to release built-up pressure. The 
liquids were shaken for a period of 10 minutes in total. Thereafter the separating funnel was 
clamped to a retort stand and allowed to stand for 2 hours to enable separation of the aqueous 
and organic layers. The EtOAc (lower) layer was decanted and the extraction process was 
repeated twice, each time using a further 300 mL of EtOAc. The organic extracts were pooled 
and set aside for further analysis at a later stage and the aqueous extract remained in the 
separating funnel.  
 
An aliquot of 300 mL BuOH (Kimix, Cape Town, South Africa) was added to the water extract of 
Folium pyrrosiae in the separating funnel. The extraction procedure was repeated, i.e. the 
separating funnel was secured at both ends, the liquid mixture was shaken vigorously and the 
pressure inside the flask was released intermittently. Shaking continued for 10 minutes after 
which the separating funnel was clamped to a retort stand and allowed to stand overnight to 
allow separation of the 2 layers. This longer time period (than the 2 hours above) was allowed 
due to the formation of an emulsion at the liquid-liquid interface; however, after a sufficient 
standing period undisturbed, a clear definition between the aqueous and organic layers was 
apparent. The lower organic layer was carefully decanted and the extraction process was 














The organic extracts (EtOAc and BuOH) were analyzed individually. Anhydrous magnesium 
sulphate (MgSO4) was used as a drying agent, i.e. to remove residual water in the organic 
extracts. Drying agent was added to the organic extracts until MgSO4 granules were free-
flowing, an indication that all moisture has been absorbed (Zubick 1992). MgSO4 was incubated 
firstly in an oven at 100 ᵒC for 1 hour to ensure that it was free of moisture as the anhydrous 
form is hygroscopic.  
 
The water-free organic extracts were evaporated to dryness on a rotorary evaporator (Rotovap 
A201, Switzerland). At this stage, ~ 3 g of dried material was yielded in each case which was 




Column chromatography is widely used in organic and inorganic chemistry to separate and 
purify compounds. This technique is based on the distribution of components in a mixture 
between a mobile phase (solvent or eluent) and an inert stationary phase (column packing) which 
arises as a result of differences in polarity. In order to prepare a column, the stationary phase is 
made into a slurry with the eluent and poured into the column and allowed to settle (Vogel 1989, 
Zubick 1992). Care is taken to ensure that no air bubbles are trapped in the stationary phase. 
Should such bubbles occur, then the side of the column is tapped gently to facilitate removal of 
these air bubbles. 
 
The dried liquid extract to be separated is dissolved in 2 mL eluent and loaded onto the column. 
Thereafter more solvent is added to the column and compounds are separated as they travel 
down the column (or elute) at different rates based on their affinity for the mobile phase. At the 
bottom end of the column, the solvent is collected in portions called fractions (Vogel 1989, 
Zubick 1992).  
 
Polar components adhere strongly to the stationary phase and elute much slower than less polar 
compounds. Ideally a mixture will separate into discrete bands and elution is continued until all 














to move compounds in a mixture through a column. Therefore a gradient elution is performed 
where the polarity of the solvent is gradually increased (Vogel 1989, Zubick 1992).  
 
A slower solvent flow-rate enables better separation. When compounds are coloured, they are 
easily identified; however, colourless compounds require the use of other techniques (e.g. TLC) 
for identification. After identification, the appropriate fractions are pooled and evaporated to 
dryness to yield a pure product.  
 
In order to separate the EtOAc and BuOH extracts into their constituent compounds, columns 
were set up separately and the following conditions were applied:  
 
Column dimensions: 70 x 1.5 cm 
Stationary phase:  200 g Sephadex G-100 (Sigma-Aldrich, South Africa) 
Eluents:  hexane (Kimix, Cape Town, South Africa), toluene (Kimix, Cape Town, 
South Africa) and methanol (Kimix, Cape Town, South Africa) 
Elution gradients:   
 100 mL aliquots of hexane : toluene, in the order (100:0, 90:10, 80:20, 
70:30, 60:40, 50:50, 40:60, 30:70, 20:80, 10:90, 0:100) 
 100 mL aliquots of toluene : methanol, in the order (100:0, 90:10, 
80:20, 70:30, 60:40, 50:50, 40:60, 30:70, 20:80, 10:90, 0:100) 
 100 mL water 
 
These solvents were selected as they covered the spectrum of polarity, from non-polar (hexane) 
to polar (methanol). Fractions were collected in 10 mL aliquots using an automated fraction 
collector (Bio-Rad 2110, Germany). Each aliquot was analyzed by TLC in order to detect the 


















TLC  is a technique used to detect the presence of organic materials. It is based on the same 
principles of column chromatography, namely that compounds distribute themselves between the 
mobile and stationary phases due to differences in polarity. However, in the case of TLC, the 
solid phase (usually alumina or silica) is attached to a flat plate in a thin layer and the mobile 
phase carrying the compounds washes over the plate. These plates can be made of glass or metal 
(Vogel 1989, Zubick 1992). A schematic of a TLC plate is given in Figure 6.3.  
 
 
Figure 6.3: A schematic of a TLC plate showing the solvent front and migration of sample 
 
When perfoming TLC, a small amount of sample is dissolved in an eluent. Using a caplillary 
dropper, the sample is loaded onto the plate 1 cm from the bottom and allowed to dry. This step 
is repeated a few times to ensure that sufficient amount of material is present for detection.  Once 
the sample is loaded, the plate is placed in a covered glass container (a beaker and coverslip may 
be used) containing the eluent. Care is taken to ensure that the eluent level is below where the 
sample is loaded, i.e. less than 1 cm from the bottom of the plate. This precaution is taken to 
prevent sample from moving down the plate and washing into the eluent. The solvent will slowly 
rise up the plate and carry the componds at different rates. When the solvent front is 
approximately 1cm from the top of the plate, the plate is removed from the glass chamber and 
the position of the solvent is marked with a pencil. Thereafter the plate is viewed under ultra-
violet light and the position of the spots (compounds) are marked (Vogel 1989, Zubick 1992). 
Solvent front 
Sample is spotted 1 cm from the bottom of TLC plate 














Following column chromatography, all fractions collected (approximately 230 for each column) 
were analyzed by TLC (Merck, South Africa, South Africa). A combination of hexane, toluene 
and methanol at a ratio of 1:1:1 was used as the eluent. Post TLC analysis, plates were examined 
under ultra-violet light (ʎ = 254 nm, Lamag Instruments) and the presence of compounds was 
detected by the appearance of yellow/brown dots which migrated up the TLC plate. Furthermore, 
the distribution of the spots on the plates (as shown in Figure 6.3) indicates the start and 
completion of elution of a compound (Vogel 1989). 
 
TLC data showed two distinct peaks in the EtOAc extract and five in the BuOH extract. The 
respective fractions were pooled and the solvents were evaporated. Sometimes further 
purification is needed. However due to the slow elution times that the columns were subjected to 
(which allows better separation) and that fractions were collected in small volumes (in aliquots 
of 10 mL), it was deemed unnecessary in this case. The separated compounds from the EtOAc 
were named ET1 and ET2, and those isolated from the BuOH extract were named BU1, BU2, 
BU3, BU4 and BU5 respectively. These supposedly pure compounds were analyzed by NMR 
spectroscopy and mass spectrometry for confirmation thereof. 
 
Nuclear magnetic resonance spectroscopy 
 
Nuclear magnetic resonance (NMR) was discovered in 1946 independently by Edward Purcell 
and Felix Bloch. It is a powerful and complex analytical technique used in elucidation of 
molecular structures of liquid and solid organic materials. A great advantage of this method is 
that it is non-destructive and samples can be recovered after analysis without any modification 
(Fox and Whitesell 1997, Laidler and Meiser 1999).
  
 




C) whose spin depends 
on the surrounding structural environment. Proton (
1
H) and carbon (
13
C) spectra provide 
fingerprint data which can be used to determine the identity and purity of an unknown sample. 
Confirmation and unambiguous determination of molecular structures follows from the use of 

















H NMR forms the starting point in structural analysis and requires the least amount of sample. 
The chemical shift of a proton is the frequency reported in parts per million (ppm) that is 
expressed relative to tetramethylsilane (TMS), a standard reference compound. Proton signals 
range between 0 and ~12 ppm. The chemical shift depends on the surrounding electronic 
environment and can be regarded as a distribution of protons according to their electron density. 
Peaks of a lower frequency are ‘downfield’ and arise from protons of low electron density, 
whereas peaks ‘upfield’ are due to electron-rich protons. The splitting of the peaks results from 
spin-spin coupling with neighbouring protons and under optimal conditions, the relative 
intensities of the signals may be correlated with the amount of nuclei producing these signals. 
However, in both 
1
H NMR and 
13
C NMR studies, the chemical shift values of compounds are 




C NMR spectra are often much simpler spectra than 
1
H NMR and provide two basic 
pieces of information: (1) the number of distinct signals which correspond to the number of 
different types of carbon atoms in the structure, and (2) the chemical shifts of the 
13
C NMR 
signals which are relatively characteristic and more amenable to assignment by inspection than 
those of protons (Fox and Whitesell 1997). DEPT (Distortionless Enhancement by Polarization 
Transfer) 
13
C spectrum is a very useful method to differentiate between CH, CH2, CH3 and 
quaternary carbons. 
 
The chemical shifts of 
13
C are also recorded relative to TMS and carbon signals range between 0 
and 250 ppm. There are three main distinguishable regions: (1) carboxyl and carbonyl groups 
(~170 ppm), (2) anomeric carbons (110-90 ppm), and (3) the remaining ring carbon atoms (80-
65 ppm) and primary alcohols (65-60 ppm) (Jarrell et al. 1979, Williams and Fleming 1995). 
 




C assignments, 2D NMR experiments are employed, such 
as proton-proton chemical shift correlation spectroscopy (COSY) and proton-carbon 
heteronuclear chemical shift correlation spectroscopy (HETCOR). The 2D pulse sequences are 
made up of single or multiple pulses and delays prior to the final observation of the signal. The 














connected by scalar coupling (homo- or heteronuclear) and give chemical shift information 
(Williams and Fleming 1995).  
 
COSY spectra consist of a complex diagonal with pairs of off-diagonal peaks which arise from 
each pair of scalar coupled protons. The coupling can be worked out starting from a single 
unambiguous assignment. Multiple relay COSY can be used to resolve ambiguities arising from 
proton spectra (Williams and Fleming 1995). 
 
HETCOR maps contain 
1
H chemical shifts along one axis and 
13
C chemical shifts along the other 
axis. The peaks on the map arise due to connections between a 
13
C nucleus and a proton. 
HETCOR can be used to investigate various types of connectivity, e.g. one-bond coupling, long-
range couplings or relayed correlation (Williams and Fleming 1995). There are basically two 
types of experiments in this category: those that utilize multiple quantum transitions during the 
evolution time (e.g. HMBC) and those using single quantum transitions during the evolution 
time (e.g. HSQC). HSQC experiments correlate protons with their directly attached heteronuclei 
(Williams and Fleming 1995).
 
 
The purified compounds of the EtOAc and BuOH extracts were dissolved in acetone and NMR 
spectra, as described above, were recorded at 400 MHz at 30 ˚C. NMR spectra were processed 




MS is an analytical technique to characterize molecules based on the measurement of molecular 
mass. The three essential components that make up a Mass Spectrometer are the ion source, the 
mass analyzer and the detector. The ion source ionizes the sample usually by the loss of an 
electron to form a cation. The main function of the mass analyzer is to separate ions according to 
their mass-to-charge (m/z) ratio. The detector monitors the ion current and a signal is recorded in 
the form of a mass spectrum. The m/z values of the ions are plotted against their intensities to 
show the number of species present in the sample, the molecular mass of each component and 














corresponding to the loss of specific fragments in a molecule, hence imparting structural 
information (Siuzdak 1996, Cole 1997).  
 
 The purified compounds of the EtOAc extract was analyzed on an electrospray ionization mass 
spectrometer (Waters API Q-TOF Ultima, Massachusetts, USA) under the following operating 
conditions: capillary voltage – 3.5kV; source temperature – 120 ºC; desolvation temperature –

















6.3 Results and discussion 
 
Compounds ET1 and ET2 were white and yellow amorphous powdery material, respectively. 
Compounds BU1, BU2, BU3, BU4 and BU5 were brown, liquid-like substances. Following 
analysis by NMR, ET1 and ET2 provided decipherable spectra. However, all compounds 
isolated from the butanol extract had not maintained integrity during the purification process 
hence structure elucidation was not possible. All spectral data are presented in Appendix 5.  
  
ET2 was isolated in greater abundance than ET1 therefore identification of this compound was 
given priority. Structural elucidation of a natural product is undoubted a challenging task. 
Various experiments were performed and data were analyzed concurrently. Based on these 
findings and consultation with previously published data, the structure of ET2 was proposed to 
be 5-(3-(5,5-dihydroxy-3-oxopentyl)phenoxy)-2-hydroxy-5H-indene-6-carboxylic acid. The 


































Table 6.1: NMR assignments of 5-(3-(5,5-dihydroxy-3-oxopentyl)phenoxy)-2-hydroxy-5H-
indene-6-carboxylic acid 
Assignments δC (ppm) δH (ppm) Comments 
1 40.1 3.33 DEPT indicates CH2; COSY to H at 3.04 ppm.  
2 31.1 3.04 DEPT indicates CH2; COSY to H at 3.33 ppm. 
3 195.4 - Assignment based on literature values
1
 of a C=O; 
HMBC shows correlation to H’s at 2.85 and 3.04 
ppm. 
4 43.8 2.85; 3.16 DEPT indicates CH2; HSQC confirms attachment of 
both protons to the respective carbon; COSY to H 
5.59 ppm. 
5 80.1 5.59; 
OH – 12.14 
DEPT indicates CH; COSY to H’s at 2.85 and 5.59 
ppm. OH assignment was based on literature values
1,2
. 
1’ 139.2 - Quaternary carbon. 
2’ 127.4 7.58 Aromatic carbon and proton assignments were based 
on DEPT and HSQC results as well as literature 
comparisons for signals in this chemical shift 
range
1,3,4
. Cross peaks also detected in COSY.  
3’ 141.2 - 
4’ 127.4  
5’ 129.5 7.45 














1’’ 97.1 5.98 DEPT indicates CH; HMBC shows correlations to H 
at 6.02 ppm; COSY indicates no H’s on adjacent 
carbons hence double bond proposed between 1’’ and 
1’’a. 
  1’’a 164.4 - DEPT indicates quaternary C; HMBC shows coupling 
to H’s at 1’’, 3’’, 5’’ and 4’’.  
2’’ 166.3 OH – 9.55 Assignment based on literature value
5
 of a C-OH in a 
5 membered carbon cyclic motif. 
3’’ 96.0 6.02 DEPT indicates CH; HMBC shows correlations to H 
at 5.98 ppm; COSY indicates no H’s on adjacent 
carbons; 1’’ and 3’’ are proposed to be opposite each 
other. 
  3’’a 163.1 - DEPT indicates quaternary C; HMBC shows coupling 
to H’s at 3’’, 4’’ and 5’’. 
4’’ 108.9 6.43 DEPT indicates CH; COSY shows correlation to H at 
7.8 ppm and no other protons hence double bond 
proposed between 3’’a and 4’’. 
5’’ 133.8 7.85 DEPT indicates CH; COSY shows correlation to H at 
6.43; long range coupling to 1’’a and 3’’a shown in 
HMBC 
6’’ 112.0 - DEPT indicates quaternary C hence the double bond 
proposed between 6’’ and 7’’; long range coupling to 
H’s at 4’’ and 7’’ ppm shown in HMBC 
7’’ 103.7 6.34 DEPT indicates CH; HMBC shows a small coupling 
to 1’’a and 3’’a. 




1Nagem et al. 1997; 2Corse and Lundin 1970; 3Sun et al. 2006; 4Chen et al. 2007; 5Schweiger et al. 2010; 6Berrigi et al. 2003; 
7Kim et al. 2006 
δC (ppm) – chemical shift of C atom in spectrum 
















Further extensive structural confirmation can be achieved by running the 
1
H NMR spectrum in 
deuterium oxide (D2O). This solvent freely interchanges the hydroxyl protons hence all OH 
signals will disappear from the 
1
H spectrum thereby confirming their presence. In addition to 
this, methylation and acetylation of the compound (to the carboxyl and hydroxyl groups) may be 
performed to obtain further structural validation (Faizi et al. 2006).  
 
The melting point range of a compound (a single small range) is an indicator of its purity. The 
melting point of ET2, determined using a hot stage microscope (Reichert-Jung Thermovar, 
Germany), was found to be 56-59 ᵒC. 
 
The molecular weight of the proposed structure of ET2 (Figure 6.4) is 384 g.mol
-1
 and its 
elemental composition is C = 65.6%, H = 5.2% and O = 29.1%. Microanalysis of ET2 (service 
provided by the Department of Chemistry, University of Cape Town) provided the following 
elemental composition: C = 66%, H = 5% and O = 29%, which is in close agreement with that of 




















The fragmentation pattern in the MS of ET2 is presented in Figure 6.5. The major peak at 352 
g.mol
-1
 is likely due to the loss of the hydroxyl groups on C5 (indicated by the blue bar). The 
second most abundant peak at 257 g.mol
-1
 is attributed to fragmentation (indicated by the red 
bar) via the McLafferty rearrangement reaction (McLafferty 1959) which can occur in a 
molecule containing a keto-group that undergoes β-cleavage accompanied by the gain of the γ-
hydrogen atom.  
 
 





































The protocol implemented in the isolation of compounds from Folium pyrrosiae proved to be 
successful in obtaining two pure compounds from the EtOAc extract (ET1 and ET2). ET2 was 
extracted in abundance compared to ET1 therefore the challenging task of structural elucidation 
of this compound was attempted.   
 
The experimental data presented in this chapter strongly supports the structure of ET2 to be       
5-(3-(5,5-dihydroxy-3-oxopentyl)phenoxy)-2-hydroxy-5H-indene-6-carboxylic acid. This 
phytochemical is believed to be a novel compound as there has been no characterization studies 
reported in literature previously. Further investigations of its bioactive properties are highly 
warranted in order to determine if it has similar biological activity to the other compounds 















Concluding remarks  
 
In concluding this thesis, it is appropriate to assess the extent to which the objectives have been 
achieved. This project was based on the well-established observation that stone patients are very 
likely to have recurrent episodes, and despite years of research, there is still no ideal drug to cure 
the disease. Patients are usually administered with the same contemporary Western medicines over 
long periods of time and unpleasant side-effects have been reported. In recent years, herbal 
remedies have emerged to be useful with fewer known side-effects and are therefore being 
considered suitable for long-term treatment. 
 
The primary focus of this project was directed towards developing and establishing models for in 
vitro and in vivo investigations of herbal remedies purported to be effective in the treatment of 
urolithiasis. Six such preparations (Folium pyrrosiae, Desmodium styracifolium, Hylocerus 
trigonus, Phyllanthus niruri, Orthosiphon stamineus and Cystone®) were utilized in this 
development process. The secondary objective was to investigate the renal response of subjects 
from South Africa’s black and white population groups to the administration of one of these 
remedies (Folium pyrrosiae), with a view to gaining insights into why the stone incidence in the 
former group is extremely rare.  
 
Intensive literature reviews have revealed two major mechanisms by which stone formation may be 
inhibited, namely by inhibition of the crystallization processes of stone-forming salts (free-particle 
theory) and inhibition of crystal-cell adhesion (free-particle theory).  
 
The in vitro effects of the plant extracts on crystallization processes (i.e. nucleation, growth and 
aggregation) are reported. All plant extracts inhibited one or more of these processes in SU. These 
favourable results gave impetus for further in vitro studies in real urine collected from healthy 
South African black and white males. However, fewer statistically significant effects on 
crystallization were observed in real urine. Since human urine contains urinary proteins and other 
macromolecules which SU does not, this finding drew attention to the need to introduce 














Different urinary responses were induced by the plant extracts in the two population groups, 
suggesting that renal handling differences exist between the races. This confirms previous literature 
reports. 
 
The most noteworthy result from the in vitro study was the ability of the plant extracts to favour the 
crystallization of COD over COM since the former has a lesser binding affinity for renal epithelial 
cells. This outcome prompted the exploration of another facet of urolithiasis research, namely 
crystal-cell binding which has been identified as a critical step in the genesis of a kidney stone.  
 
A basic crystal-cell binding assay was performed. Various modifications were introduced to 
investigate possible mechanisms by which the plant extracts operate and to mimic physiological 
conditions. The potency of the six plant extracts under investigation was demonstrated by their 
ability to significantly decrease binding of CaOx crystals (inorganic and urinary) to renal epithelial 
cells in both aqueous media and real urine.  
 
Despite all the promising results mentioned earlier, Folium pyrrosiae demonstrated no effect on 
urine chemistry and crystallization properties in vivo. Hence no scientific support for its use as a 
therapeutic agent for kidney stone disease. This finding also demonstrates that the system used to 
evaluate herbal remedies in traditional medicinal systems is different to that used and accepted by 
Western practitioners and lacks a sound scientific approach. As mentioned previously, the 
diagnosis (and subsequent treatment) of diseases in the traditional medicinal system significantly 
varies to that of modern day medicine.  
 
In the present project, a successful protocol was established to purify and characterize potentially 
bioactive molecules. This was implemented in the analysis of Folium pyrrosiae. A novel 
compound, 5-(3-(5,5-dihydroxy-3-oxopentyl)phenoxy)-2-hydroxy-5H-indene-6-carboxylic acid, 
was identified. It would be of great interest to determine the immunological activity of this 
molecule.  
 
With respect to understanding the rarity of stone incidence in black South Africans, this thesis 
provided no new information but confirmed previous findings which were mentioned above. In 














to those of white subjects. Qualitative analysis of urinary proteins contained in these crystals from 
the two race groups would be another avenue of interest in future studies.   
 
The key contribution of this thesis to the pool of knowledge about kidney stone disease has been to 
demonstrate that herbal preparations have the potential for becoming therapeutic and prophylactic 
agents in the treatment and management of this condition. Further scientific and clinical 
investigations are needed before such regimens are implemented. Ultimately, the efficacy question 
can probably only be answered with randomised placebo-controlled studies in patients, using stone 
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1.1) MSL of SU and SU+Shi Wei and SU+JQC (in triplicate) 1.2) MSL of SU and S
no. of particles reported is the average of 2 readings taken no. of particles reported is the
No. of particles No. of parti
[Na2Ox] SU 1 SU 2 SU 3 SU+SW 1 SU+SW 2 SU+SW 3 SU+JQC 1 SU+JQC 2 SU+JQC 3 [Na2Ox] SU 1
0 2080 1714 1698 2547 2547 1195 2175 3510 112 15 1398
15 3796 2233 1846 3626 30 2380
30 1924 2204 1638 2325 45 3089
45 2048 1047 2768 3049 3374 3232 3095 2697 3773 60 3865
60 2073 1067 1958 3255 1985 3790 2129 3303 5534 75 3645
75 2500 1287 2632 5194 4326 5846 4211 3152 5311 90 3759
90 2845 1468 2071 4092 1391 6321 6638 3770 3953 105 3732
105 2085 1095 9742 4983 7722 6171 9865 5859 3014 120 11926
120 22071 11096 7322 15783 23104 12709 6441 12869 7618 135 23613
135 25078 12607 8625 29380 21532 14829 20637 5731 4759 150 19553
150 28967 14559 32276 27014 41334 40439 31012 36656 23617 165
165 43907 22036 9824 33663 38452 36229 24112 32647 19935
180 42562 43392 38653 14699 42105 25308
195 43177 43049 44267 44973 32975
AU 1 AU 2 AU 3 PN 1 PN 2 PN 3 JT 1 JT 2 JT 3 CYS 1 CYS 2 CYS 3
0 362 367 360 927 1093 700 420 454 356 1211 1782 2551
30 1002 1351 1785 1129 1494 1056 1366 837 589 1411 2121 2678
45 1464 3382 1807 2053 945 2027 494 238 1151 1511 2273 2230
60 811 1556 478 2197 892 1884 2051 610 1226 2566 794 2791
75 2173 2529 897 2774 1325 2995 547 736 480 2260 938 4053
90 22774 5125 3091 5526 5602 5515 789 465 1559 2571 1431 3573
105 19982 29906 5235 6344 6656 6521 4660 1948 2994 4782 6360 8744












U+Odyvato (in triplicate) 1.4) MSL of SU, SU+PN, SU+OS and SU+CYS (in triplicate)
e average of 2 readings taken no. of particles reported is the average of 2 readings taken
cles No. of particles
SU 2 SU 3 SU+ODY 1 SU+ODY 2 SU+ODY 3 [Na2Ox] SU 1 SU 2 SU 3 SU+PN 1 SU+PN 2 SU+PN 3 SU+OS 1 SU+OS 2 SU+OS 3
1402 0 362 367 360 1093 700 925 420 454 356
2290 2335 2456 1543 2188 30 1002 1351 1785 1494 1366 837
4135 3612 1556 2324 2053 45 1464 3382 1807 945 2027 1332 494 238 1151
2893 3379 800 4310 1248 60 811 1556 478 892 1884 1296 2051 610 1226
3811 3728 4996 2383 1525 75 2173 2529 897 1325 2995 1554 547 736 480
3700 3729 1652 4989 2348 90 18889 5125 3091 5602 5515 1066 789 465 1559
16355 10043 5060 7364 2506 105 19982 29906 5235 6656 6521 4080 4660 1948 2994
14950 13438 8381 3378 5102 120 27030 11980 6006 17434 10749 13749 11559
43256 33434 6837 10276 35974 135 17926































blank 0.000 0.000 0.000 0.000 60.853
0.001 0.001 0.002 0.001 average 324.313
0.003 0.004 0.004 0.004 0.002 109.536
minus blank ug/ml
control  0.284 0.285 0.285 0.285 0.283 2.715338
0.391 0.394 0.399 0.395 0.393 3.772014
0.292 0.293 0.295 0.293 0.291 2.798591 3.095314
treated crystals ug/ml
SW 59a 0.131 0.132 0.133 0.132 0.130 1.248799
59b 0.097 0.103 0.101 0.100 0.098 0.944605
59c 0.118 0.119 0.115 0.117 0.115 1.107909 1.100438
JQC 39a 0.046 0.047 0.049 0.047 0.045 0.435479
39b 0.018 0.019 0.020 0.019 0.017 0.163305
39c 0.030 0.030 0.031 0.030 0.028 0.272174 0.290319
ODY 40a 0.019 0.019 0.020 0.019 0.017 0.166507
40b 0.014 0.014 0.015 0.014 0.012 0.118476
40c 0.018 0.018 0.018 0.018 0.016 0.153698 0.146227
PN 41a 0.085 0.085 0.086 0.085 0.083 0.800512
41b 0.089 0.093 0.093 0.092 0.090 0.861351
41c 0.087 0.088 0.088 0.088 0.086 0.822927 0.828263
JT 42a 0.109 0.112 0.111 0.111 0.109 1.043868
42b 0.075 0.076 0.079 0.077 0.075 0.717259
42c 0.097 0.096 0.096 0.096 0.094 0.90618 0.889102
CYS 43a 0.079 0.080 0.080 0.080 0.078 0.746077
43b 0.079 0.081 0.083 0.081 0.079 0.758886
43c 0.079 0.080 0.080 0.080 0.078 0.746077 0.750347
treated cells
SW 44a 0.020 0.021 0.021 0.021 0.019 0.179315
44b 0.021 0.021 0.021 0.021 0.019 0.182517
44c 0.021 0.021 0.021 0.021 0.019 0.182517 0.181449
JQC 45a 0.035 0.035 0.036 0.035 0.033 0.320205
45b 0.046 0.048 0.048 0.047 0.045 0.435479
45c 0.041 0.041 0.042 0.041 0.039 0.377842 0.377842
ODY 46a 0.049 0.049 0.049 0.049 0.047 0.451489
46b 0.074 0.073 0.074 0.074 0.072 0.688441










PN 47a 0.047 0.047 0.046 0.047 0.045 0.429075
47b 0.047 0.046 0.047 0.047 0.045 0.429075
47c 0.047 0.047 0.046 0.047 0.045 0.429075 0.429075
JT 48a 0.095 0.096 0.096 0.096 0.094 0.899776
48b 0.068 0.071 0.072 0.070 0.068 0.65642
48c 0.083 0.083 0.081 0.082 0.080 0.771694 0.775963
CYS 49a 0.013 0.013 0.014 0.013 0.011 0.10887
49b 0.019 0.021 0.021 0.020 0.018 0.176113
49c 0.017 0.017 0.018 0.017 0.015 0.147294 0.144092
medium
SW 50a 0.019 0.019 0.019 0.019 0.017 0.163305
50b 0.020 0.021 0.022 0.021 0.019 0.182517
50c 0.020 0.021 0.020 0.020 0.018 0.176113 0.173978
JQC 51a 0.007 0.007 0.007 0.007 0.005 0.048031
51b 0.038 0.039 0.037 0.038 0.036 0.345821
51c 0.025 0.025 0.024 0.025 0.023 0.217739 0.203864
ODY 52a 0.018 0.019 0.018 0.018 0.016 0.1569
52b 0.027 0.028 0.028 0.028 0.026 0.246558
52c 0.022 0.022 0.024 0.023 0.021 0.198527 0.200662
PN 53a 0.014 0.014 0.014 0.014 0.012 0.115274
53b 0.092 0.094 0.094 0.093 0.091 0.877362
53c 0.047 0.047 0.046 0.047 0.045 0.429075 0.473903
JT 54a 0.099 0.100 0.100 0.100 0.098 0.9382
54b 0.101 0.101 0.101 0.101 0.099 0.951009
54c 0.099 0.099 0.100 0.099 0.097 0.934998 0.941402
CYS 55a 0.127 0.128 0.129 0.128 0.126 1.210375
55b 0.031 0.031 0.031 0.031 0.029 0.278578
55c 0.080 0.079 0.081 0.080 0.078 0.74928 0.746077
ppm/ug ppm
WHITE URINE WHITE URINE
crystals cells medium crystals cells medium
Control  0.02991 0.02991 0.02991 Control  3.0953 3.0953 3.0953
Shi Wei 0.02636 0.00043 0.00164 Shi Wei 1.1004 0.1814 0.1740
Jin Qian Cao 0.00311 0.01007 0.00525 Jin Qian Cao 0.2903 0.3778 0.2039
Odyvato 0.00405 0.00804 0.00233 Odyvato 0.1462 0.5742 0.2007
Phyllanthus niru 0.00407 0.00179 0.00214 Phyllanthus n 0.8283 0.4291 0.4739
Java Tea 0.00484 0.01156 0.01149 Java Tea 0.8891 0.7760 0.9414














































mg/ml per 2ml % average protein ppm/ug
0.002715 0.0054307 0.27 171.821 0.0158
0.003772 0.007544 0.38 71.592 0.0527
0.002799 0.0055972 0.28 0.31 131.7297 0.0212 0.02991
mg/ml per 2ml %
0.001249 0.0024976 0.12 46.535 0.0268
0.000945 0.0018892 0.09 75.172 0.0126
0.001108 0.0022158 0.11 0.11 27.921 0.0397 0.02636
0.000435 0.000871 0.04 318.5853 0.0014
0.000163 0.0003266 0.02 57.98969 0.0028
0.000272 0.0005443 0.03 0.03 52.97824 0.0051 0.00311
0.000167 0.000333 0.02 17.89805 0.0093
0.000118 0.000237 0.01 205.470 0.0006
0.000154 0.0003074 0.02 0.01 67.297 0.0023 0.00405
0.000801 0.001601 0.08 157.5029 0.0051
0.000861 0.0017227 0.09 202.606 0.0043
0.000823 0.0016459 0.08 0.08 285.653 0.0029 0.00407
0.001044 0.0020877 0.10 220.504 0.0047
0.000717 0.0014345 0.07 169.674 0.0042
0.000906 0.0018124 0.09 0.09 163.230 0.0056 0.00484
0.000746 0.0014922 0.07 131.0137 0.0057
0.000759 0.0015178 0.08 255.584 0.0030
0.000746 0.0014922 0.07 0.08 204.0378 0.0037 0.00411
0.000179 0.0003586 0.02 539.805 0.0003
0.000183 0.000365 0.02 365.836 0.0005
0.000183 0.000365 0.02 0.02 386.598 0.0005 0.00043
0.00032 0.0006404 0.03 40.80756 0.0078
0.000435 0.000871 0.04 81.615 0.0053
0.000378 0.0007557 0.04 0.04 22.194 0.0170 0.01007
0.000451 0.000903 0.05 32.93242 0.0137
0.000688 0.0013769 0.07 110.252 0.0062










0.000429 0.0008581 0.04 718.0699 0.0006
0.000429 0.0008581 0.04 137.457 0.0031
0.000429 0.0008581 0.04 0.04 259.880 0.0017 0.00179
0.0009 0.0017996 0.09 74.4559 0.0121
0.000656 0.0013128 0.07 65.149 0.0101
0.000772 0.0015434 0.08 0.08 61.569 0.0125 0.01156
0.000109 0.0002177 0.01 12.17068 0.0089
0.000176 0.0003522 0.02 37.944 0.0046
0.000147 0.0002946 0.01 0.01 30.78465 0.0048 0.00612
0.000163 0.0003266 0.02 47.967 0.0034
0.000183 0.000365 0.02 280.641 0.0007
0.000176 0.0003522 0.02 0.02 204.038 0.0009 0.00164
4.8E‐05 9.606E‐05 0.005 291.3803 0.0002
0.000346 0.0006916 0.03 28.637 0.0121
0.000218 0.0004355 0.02 0.02 62.285 0.0035 0.00525
0.000157 0.0003138 0.02 39.37572 0.0040
0.000247 0.0004931 0.02 143.900 0.0017
0.000199 0.0003971 0.02 0.02 153.923 0.0013 0.00233
0.000115 0.0002305 0.01 834.7652 0.0001
0.000877 0.0017547 0.09 160.367 0.0055
0.000429 0.0008581 0.04 0.05 523.339 0.0008 0.00214
0.000938 0.0018764 0.09 37.22795 0.0252
0.000951 0.001902 0.10 231.959 0.0041
0.000935 0.00187 0.09 0.09 180.412 0.0052 0.01149
0.00121 0.0024207 0.12 133.1615 0.0091
0.000279 0.0005572 0.03 254.152 0.0011




























































University of Cape Town 
Department of Chemistry 
 
Information Sheet 




Urinary stones are a frequent problem affecting many individuals. Prophylaxis and shock 
wave therapy are some common methods of treatment, but there is a high rate of 
recurrence due to no effective cure being known. Chinese herbal preparations have 
been used to treat renal stones for many years.  
 
Researchers at the University of Cape Town Kidney Stone Research Laboratory are 
interested in studying the inhibitory effects of traditional Chinese herbs on the formation 
of calcium oxalate stones in vivo. You are invited to participate in a study conducted by 
Ms Ronica Ramsout, PhD student in the Department of Chemistry under the supervision 
of Professor AL Rodgers, Head of the Department of Chemistry and Director of the 
Kidney Stone Research Laboratory. 
 
You will be required to ingest 3 capsules containing a Chinese traditional herb Shi Wei, 
after breakfast everyday for 7 consecutive days. On these days, you need to avoid 
calcium and oxalate rich foods, and you will have to provide a 24 hour urine sample for 
analysis. We shall closely monitor your health for side effects. The possible adverse 
effects of these compounds are diarrhoea, abdominal pain, vomiting and nephritis but 
none have been reported in previous studies. Baseline creatinine and liver function 
tests (monitoring of transaminases) will be performed on all subjects. Urinary creatinine 
levels will be monitored daily as a safety marker i.e. creatinine levels must not become 
elevated. Transaminase levels will be monitored on days 0, 3 and 7. Other liver function 
tests will be performed based on results of transaminase levels and urinary creatinine. 
Blood will be drawn by trained phlebotomists from the Pathcare Laboratory and analysis 












Dr Dick Barnes, a medically trained professional, is affiliated to this study and any 
symptoms can be reported to him. Dr Barnes’s contact details are: 
Dick.Barnes@uct.ac.za, 021 404 6105, Department of Urology, Ward E26, Groote 
Schuur Hospital. This study will be covered by the UCT no-fault liability insurance cover 
and participants will be compensated in the event of any injuries being done to them. 
 
Prior to analysis you are required to provide a 24 hour baseline urine sample for 
analysis. You will also need to fill out a health questionnaire and answer some general 
questions with respect to your medical history.  
 
There is no payment or reward for participating in this study, but you will be reimbursed 
for petrol costs. Urine results can be made available to you should you be interested to 
know them. You may withdraw from this study at anytime without any penalty or having 
to give a reason. We can also exclude you from this investigation if you do not comply 
with the instructions requested of you.  
 
All information related to you will remain confidential and will be identified by codes 
known only to the investigator. The results will be made available to the scientific 
community but no names will be linked to it.  
 
If you interested in being a participant in this study or would like any information, please 
contact Ms Ronica Ramsout on 021 650 2534 or 084 472 9223.  
 
If you have any queries about your rights or welfare as a research participant, please 
contact Professor Marc Blockman, Chairperson of the Research Ethics Committee in the 



















Patient Consent Sheet 
 
 
I _________________________________________ (Name and Surname), have 
carefully read and understood the Patient Information Sheet and Informed Consent. All 
my questions about the study were answered to my complete satisfaction and I can keep 
copies of the written Patient Information Sheet and Informed Consent. I was given 
enough time to decide about taking part in this study. 
 
I have been informed of the risks and benefits of this investigation. I understand that the 
information obtained from this research may be used in future research and be 
published; however my right to privacy will be maintained.  
 
By signing this Informed Consent Sheet (to be signed by parents if participant is under 
21 years of age), I declare that I take part in this study of my own free will and without 
being persuaded or pressured by any other person. I am aware that I am liberty to 
withdraw from this study at any time, without giving a reason, but I will not be reimbursed 
for travel expenses or inconveniences.  
 
I document my informed consent by signing my name below: 
 
 
------------------------------------------------           ------------------------------------------- 




I _____________________________ (Name of Researcher) have fully informed the 
above person of the procedures, aims and risks of the study and answered questions 
truthfully. 
 
------------------------------------------------           ------------------------------------------- 












Health Questionnaire  
 
Identification Code __________ 
 
General Info           
Date    _______________________________________________ 
Full Name  _______________________________________________ 
Address  _______________________________________________ 
Email   _______________________________________________ 
Date of Birth    _______________________________________________ 
Telephone No.  _______________________________________________ 
 
Nutritional/Exercise Info 
Weight  ____________kg___ 
Height  ____________m___ 
Do you follow any special diet (e.g. vegetarian)? _______________________________ 
If yes, please specify _______________________________________________  
Are you taking any vitamin/mineral supplements? ______________________________ 
 If yes, please give details (name, dose, frequency) ________________________ 
What kind of exercise do you do? ___________________________________________ 
 Hours per week ______________ 
 
Exposure to toxic substances 
Do you smoke? _________________ 
If yes, how many a day? __________________ 
Do you consume alcohol?  __________________ 
If yes, how many a week? _________________ 
(1 drink = 1 can of beer or 1 glass of wine) 
 
Medical history  
Have you had any illnesses lately?  __________________ 
If yes, please give details  
___________________________________________ 











If yes, please give details
 ____________________________________________ 
Do you take any medication?  _______________ 
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